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ABSTRACT 
At the outset of this research in the early 2000s, the application of meta-analysis in 
observational epidemiology, including occupational epidemiology was regarded as 
controversial because of the greater potential for bias in such studies compared with 
randomized controlled clinical trials.  This remains true even in 2017. 
The overall aim for this research is to identify the best approaches to the use of meta-
analysis in the occupational health setting, and to summarise through meta-analysis the 
evidence at to whether or not occupational exposure to formaldehyde is an occupational 
carcinogen. 
Chapter 2 of this thesis concluded that meta-analysis in occupational epidemiology was 
becoming increasingly popular, but that its limitations appear not to have been heeded 
in practice.  Two principal issues were identified: the heterogeneity of exposures 
estimates and the pooling of standardized mortality ratios from different study 
populations with different characteristics including length of follow-up.  By 2016, 
neither of these issues had been addressed in the literature. 
Chapter 3 contains a description of the published statistical methods available for meta-
analysis up to 2001.  Methodological developments continue within the discipline of 
randomized controlled clinical trials and recently include the advent of multivariate 
methods and network analysis.  It has been recommended that any new methods should 
be backed up by simulations. 
Chapter 4 concludes that the default approach adopted by most statistical packages 
could not deal with such studies and excluded them from any calculations.  In meta-
analyses of rare diseases, this biases the meta-relative risks upwards.  Approaches that 
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avoided exclusion of such studies are considered, in particular analyses on the original 
untransformed scale rather than the log scale. 
Chapter 5 concludes that there remains insufficient evidence for an association.  There 
was significant heterogeneity in the lung cancer results and so this is a random effects 
analysis; the analyses for nasopharyngeal and sinonasal cancer contains no such 
heterogeneity and so are fixed effect analyses. 
The final chapter concludes that, when studies with zero cases are not excluded, there is 
insufficient evidence of an increased risk of lung cancer, nasopharyngeal cancer or 
sinonasal cancer, and that further methodological developments are still required to deal 
with the pooling of occupational epidemiological studies in relation to study 
characteristics, exposure assessments and standardised mortality ratios. 
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1 INTRODUCTION 
This chapter introduces the thesis, setting out the issues being addressed and the context 
in which they have been encountered. 
1.1 THE META-ANALYSIS CONTROVERSY 
The term meta-analysis was first coined in the mid-1970s [1].  Although the application 
of meta-analysis in the synthesis of the results of controlled clinical trials has become 
commonplace, its application in observational epidemiology remains controversial, 
because of the greater potential for biased effect estimates [2]. 
1.2 THE ENVIRONMENT OF OCCUPATIONAL REGULATORY 
RISK ASSESSMENT AND LIMIT SETTING 
In occupational regulatory risk assessment in the United Kingdom, there remains an 
ongoing need to make decisions on the basis of published knowledge about whether a 
particular workplace hazard represents a risk to those exposed to it and at what level.  
Those decisions are often based on a qualitative assessment of the evidence.  The first 
step is usually to determine whether or not the association between a workplace 
exposure and a particular disease outcome represents a causal association.  If such a 
determination is made, a second step is to try to better quantify the nature of the 
exposure-response relationship.  This usually involves characterising the risk at 
different levels of exposure.  Of particular interest in the regulatory setting for 
determining appropriate occupational exposure limits, is the size or extent of the risk at 
the levels at which such exposure is encountered in the workplace. 
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1.3 THE AIMS OF THIS THESIS 
The overall aim for this research is to identify the best approaches to the use of meta-
analysis in the occupational health setting, and to summarise through meta-analysis the 
evidence at to whether or not occupational exposure to formaldehyde is an occupational 
carcinogen. 
1.4 THE OUTLINE OF THIS THESIS 
Chapter 2 contains a review of practice in occupational epidemiology and Chapter 3 
contains a review of meta-analytical methods available for use in occupational 
epidemiology.  Chapter 4 investigates the possible methodological approaches to meta-
analysis that could be taken when there are risk estimates based on zero observed 
(observed) cases.  Chapter 5 contains substantive meta-analyses of occupational 
exposure to formaldehyde, in relation to lung cancer, nasopharyngeal cancer and 
sinonasal cancer, making use of best practice in the application of meta-analysis 
methodology and applies methods that have been specially investigated for dealing with 
studies with zero (observed) cases.  The final chapter draws the methodological and 
substantive findings together to form a view of the carcinogenicity of occupational 
exposure to formaldehyde in relation to respiratory cancers, discusses the strengths and 
limitations of the approach taken, and makes recommendations for future research. 
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2 LITERATURE REVIEW 1 – META-ANALYSIS: PAST 
PRACTICE IN OCCUPATIONAL EPIDEMIOLOGY 
The main body of work contained in this chapter was published as a paper in the peer-
reviewed scientific literature [3].  The completed cover sheet for the paper is in Section 
2.1, and section 2.2 contains a brief update of practice since. 
2.1 PUBLISHED REVIEW OF PAST PRACTICE IN 
OCCUPATIONAL EPIDEMIOLOGY 
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2.2 PAST PRACTICE IN OCCUPATIONAL EPIDEMIOLOGY: A 
BRIEF UPDATE 
A recently as 2013, it has been restated that there is a long history of debate about the 
value of meta-analysis for occupational cohort studies [4], reminding us of Shapiro’s 
argument that “meta-analysis of published non-experimental data should be 
abandoned”, in which he reasoned that relative risks of low magnitude, say less than 2, 
are virtually beyond the resolving power of the epidemiological microscope because we 
can seldom eliminate all sources of bias.  Because the pooling of studies in a meta-
 24 
analysis increases statistical power, the pooled estimate can easily become significant 
and thus incorrectly taken as an indication of causality even though the biases in the 
included studies may not have been taken into account [5].  Others have argued that the 
method of meta-analysis is important but should be applied appropriately taking into 
account the biases in the individual studies [6].  The more methodological research on 
meta-analysis in occupational epidemiological which was called for around 10 years 
ago [3] has yet to be carried out, despite that huge increase in applications of the method 
that have occurred during that time.  In particular, the meta-SMR remains a complicated 
concept, for example, because of its incorporation of standardization on completely 
different and often non-comparable populations [4]. 
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3 LITERATURE REVIEW 2 - META-ANALYSIS 
METHODS AVAILABLE FOR THE 
OCCUPATIONAL HEALTH SETTING 
3.1 INTRODUCTION: SCOPE AND STRUCTURE OF THE 
REVIEW 
The original purpose of this chapter is to describe published statistical methods for 
meta-analysis, emphasising those that are specifically relevant or important to the 
occupational health setting, or at least those that were when the search was done in 
2001.  This has been supplemented with a brief summary of some of the key 
methodological approaches that have been developed since the original review. 
After a description of the search methodology employed to identify potentially relevant 
references, this Chapter is split into methods that attempt to estimate an overall mean 
effect measure (fixed effect and random effects) and those that assess and explore 
between study heterogeneity.  Finally, the Chapter sets out some methods for the 
identification and adjustment for the effects of publication bias and other relevant 
methods. 
3.2 SEARCH METHODOLOGY 
The following on-line databases were searched from the earliest year available to Oct 
2001: OSHROM (NILOSH, HSELINE, MEDLINE OEM subset, NIOSHTIC (to Sep 
1998 only), NIOSHTIC-2);  DIALOG (Mental Health Abstracts);  DATASTAR 
(Applied Social Sciences Index and Abstracts, Excerpta Medica, Medline, Psychinfo, 
Sociological Abstracts, Social Science Citation Index) using the free text terms meta-
analys*, meta-analyt*, metaanalys* and metaanalyt* combined with method*.  In 
addition, methodological citations from the meta-analysis examples identified in 
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Chapter 2 and papers already held and their citations, together with the contents pages 
of Statistics in Medicine and Biometrics were used. 
3.3 METHODS FOR ESTIMATING MEAN MEASURE OF 
EFFECT 
Historically meta-analyses, particularly in the occupational health field, initially 
concentrated on estimating an overall average effect estimate across all the studies 
relevant to the hypothesis under question.  This Section sets out the main statistical 
measures of mean effect of relevance for the occupational health setting. 
3.3.1 Fixed effect methods 
These methods have an underlying assumption that each of the studies included in the 
meta-analysis is estimating a single true underlying “fixed” measure of effect.  This can 
be expressed mathematically as 
 ii eY    
where Yi is the observed effect from study i,   is the population effect size and ei is the 
sampling error. 
3.3.1.1 Combining generic effect measures by means of a weighted average approach 
If Y denotes the generic effect measure and w the reciprocal of its variance, then an 
estimator of an assumed common underlying effect size, for studies i = 1,…,k, is 
 , 
where 



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k
i
i
k
i
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w
Yw
Y
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1
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w  , 
and an associated approximate )%1(100   confidence interval is given by 
  [7]. 
If Yi is assumed to be a ratio (a relative risk), then by putting 
  
the mean relative risk on a log scale can be expressed as 
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In practice, because variances or standard errors of risk estimates may not be presented 
in scientific papers, an estimate of the variance of log RRi can be calculated from the 
associated )%1(100   confidence interval using 
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Thus, assuming normality of RR on the log scale, a )%1(100   confidence interval can 
be expressed as 
 )logvar(log 2/1 RRzRR   [8]. 
3.3.1.2 Combining Standardised Mortality Ratios (SMRs) 
A SMR is a measure of RR that is particularly important in the occupational health 
setting.  It is aggregated in those meta-analyses that are the combination of the results of 
cohort studies where the analyses are based on comparison with an external population. 
An overall SMR can be calculated, using 
 𝑌𝑖 = 𝑙𝑜𝑔(𝑆𝑀𝑅𝑖), 
from 
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and 
i
i
O
SMR
1
)var(log   [9]. 
An approximate )%1(100   confidence interval for the SMRlog  is given by 
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and thus for the meta-SMR1 is 
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Note that if the number of observed and expected events is available from the individual 
studies, then an alternative form of the meta-SMR can also be calculated simply by 
using 
 




k
i
i
k
i
i
E
O
SMRmeta
1
1
2
 [10], 
which is algebraically equivalent to 
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Note that meta-SMR1 and meta-SMR2 are algebraically different and meta-SMR2 is to 
be preferred when the data are available to calculate it. 
3.3.1.3 Combining Odds Ratios (ORs) 
These methods are used when the studies to be combined are all case-control studies, 
and have the advantage of being able to deal with ORs that are either zero or infinity. 
The Mantel-Haenszel Method 
The special case where no adjustment for confounding has been made for the odds 
ratios to be combined is of limited use in practice.  It has the advantage of being easy to 
calculate when some of the ai, bi, ci, or di are 0. 
For study i, the number of exposed and unexposed cases and controls are given by: 
 Case Control 
Exposed ai bi 
Unexposed ci di 
 
The pooled estimate is calculated by 
 , 
i
k
i
ii
i
k
i
ii
MH
ncb
nda
OR




1
1
 31 
where ni is the total number of subjects in the i
th
 study [11]. 
The estimate of variance most commonly used for deriving confidence intervals is 
, 
where 
 , 
 , 
 , and 
 . 
Thus a )%1(100   confidence interval for ln(ORMH) is given by 
  [12]. 
Where covariates are adjusted for, in order to eliminate (or reduce) the bias caused by 
confounding, one method of achieving this is via stratification.  Here an extended form 
of the Mantel-Haenszel odds ratio is used. 
Suppose there are S strata, then the summary odds ratio is given by 
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where aj,…,dj are equivalent to those above, but are at the stratum, rather than the study-
level.  Note that S can indicate an odds ratio from a study or statistically independent 
strata from within a study. 
The standard error of the log of the summary odds ratio is given by 
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A )%1(100  confidence interval can then be constructed analogously as above.  Note 
that ORMH(S) is a weighted average of the S stratum-specific odds ratios, given by  
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The Peto Method 
This is essentially a modification of the Mantel-Haenszel method, and also has the 
advantage of being easy to calculate when some of the ai, bi, ci or di above are 0.  
However, it has been shown to produce serious underestimates when the odds ratio for 
the exposure effect is far from unity [14]. 
 , 
where 
 
)1(
))((



ii
iiiei
ii
nn
dnnn
EV , 
with 
 ni = number of subjects in study i;  
 nei = number of exposed subjects in study i;  
 di = number of deaths in the exposed and non-exposed groups, and 
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which is the expected number of deaths in the exposed group. 
Thus a )%1(100   confidence interval is given by  
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  [15]. 
3.3.1.4 Combining correlation coefficients 
The use of correlation coefficients in the occupational health field has been exclusively 
restricted to studies of psychosocial endpoints.  Suppose there are k product moment 
correlation coefficients to be combined r1,…,rk.  The most direct approach to estimating 
the overall correlation coefficient   is to derive a linear combination of the r1,…,rk.  
This is not recommended unless the sample sizes of all m data sets of size ni are very 
large;  the method usually used is to calculate the weighted average of z-transformed 
estimates yielding 
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A )%1(100   confidence interval for   can be obtained for   from 
 , 
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where 
  [16]. 
3.3.2 Random effects methods 
This approach assumes that the studies are a random sample from a larger population of 
studies, and that there is a mean population effect size around which the underlying 
study-specific effect sizes vary.  Expressed mathematically 
 , 
where Yi is the observed effect from study i,  is the population effect size, i  is the 
deviation of the i
th
 study’s underlying effect size from  , and ei is the sampling error.  
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and when 
 , 
the model reduces to the fixed effect model. 
3.3.2.1 Combining generic effect measures (the DerSimonian and Laird method) by 
means of a weighted average approach 
The mean weights from the k studies are defined as 
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where the wi are as defined in the fixed effect approach and the variance of the weights 
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where Q is the heterogeneity statistic (see Section 3.4). 
Adjusted weights for the individual studies are given by 
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As for the fixed effect analysis, if Yi is assumed to be a ratio (relative risk), then by 
putting 
  
the mean relative risk on the log scale can be expressed as in 3.3.1.1 but with wi 
replaced by wi
*
 and the associated )%1(100   confidence interval can be expressed as 
before with 
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Thus, assuming normality of RR on the log scale, a )%1(100   confidence interval can 
be expressed as before as 
 )logvar(log 2/1 RRzRR   [8]. 
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 38 
3.3.2.2 Combining Standardised Mortality Ratios (SMRs) 
The random effects meta-SMR (meta-SMRRE) has the same formula as that given in 
Section 3.3.1.2, but the weights wi
*
 are given by 
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Thus an approximate )%1(100   confidence interval for the meta-SMRRE is given by 
 


















k
i
iw
z
SMR
1
*
2/1logexp   [9]. 
 39 
3.3.2.3 Combining other effect estimators 
Analogous risk estimates and associated )%1(100   confidence intervals can be 
computed for the Mantel-Haenszel estimator (with and without adjustment for 
confounders), for the Peto estimator and for the combined correlation coefficients. 
3.3.2.4 Maximum likelihood methods 
Likelihood approaches exist under both the fixed effect and the random effects 
assumption.  For the random effects case, with the assumption of the underlying effect 
parameter following a normal distribution, DerSimonian and Laird [18] proposed 
maximum and restricted maximum likelihood methods of parameter estimation (the 
latter being a modification to the former adjusting for the fact that the mean and the 
variance are estimated from the same data).  Likelihood and restricted maximum 
likelihood equations that can be solved by iterative numerical methods have been 
presented [19]. 
For the specific case of combining odds ratios, maximum likelihood estimates exist 
under the fixed effect assumption, although they are difficult to compute, and are only 
useful when there are a large number of odds ratios to be combined.  As well as 
unconditional estimates, estimates conditional on fixing the marginal totals in 2x2 tables 
are also available, and are superior to the Mantel-Haenszel estimate in terms of bias and 
precision [20]. 
3.3.2.5 Bayesian methods 
Bayesian methods are becoming more widely applied in meta-analyses in occupational 
epidemiology.  This is partly due to advances in computational methods.  The Bayesian 
approach provides a framework in which the data and model parameters are considered 
random quantities and the likelihood function can be thought of as defining the 
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plausibility of the data given values of the model parameters.  As the model parameters 
are unknown random quantities, prior distributions can be specified for them which may 
be based on actual evidence or on subjective a priori beliefs (which in practice can also 
be non-informative).  The joint probability density function for all the parameters is 
then combined with the likelihood function to obtain the joint posterior probability 
density function. 
Usually there are a large number of parameters in the model, but attention is usually 
restricted to a few of specific interest.  In the context of a meta-analysis in occupational 
epidemiology, this is usually the effect size,  , say.  The marginal posterior density of 
  is obtained by integrating the joint posterior density over all the other parameters;  
the more parameters the higher dimension the integral.  Thus, applied use of Bayesian 
methods has involved computationally innovative procedures for this. 
The method most popularly applied is the use of Markov Chain Monte Carlo methods 
for estimating the marginal posterior density and in particular the use of Gibbs sampling 
via the software WinBugs [21].  Caution has to be exercised to ensure that the Markov 
chain has properly converged and the sensitivity of the results to the choice of prior 
distribution and initial values is examined.  Also problematic, as with any exercise in 
statistical modelling is determining the best model in the circumstances and whether it 
represents an adequate representation of the data. 
The Bayesian framework allows for fixed effect and random effects methods to be 
pursued.  Further extensions not practised much to date include the incorporation of 
informative prior distributions, perhaps based on the evidence of a pre-existing meta-
analysis [22]. 
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3.4 METHODS FOR ASSESSING THE PRESENCE OF 
BETWEEN-STUDY HETEROGENEITY 
In meta-analyses the point estimates of effect size from the component studies are 
usually different.  Of interest, is whether these differences can be attributed to random 
variation (the studies are estimating the same overall effect estimate) or whether they 
are estimating a distribution of effect estimates (and thus differences are not solely due 
to random variation).  The strength of evidence against the underlying effects from the 
component studies being the same is conventionally assessed via a heterogeneity test, 
the null hypothesis being that there is a lack of heterogeneity.  These tests are usually 
based on the Cochran 
2  test and are acknowledged as not statistically very powerful 
[23]. 
3.4.1 Generic Cochran chi-squared test 
The generic form of the test can be expressed as 
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where k, wi, Yi and Y are defined in Section 3.3.1.1 and the null hypothesis of no 
heterogeneity would be rejected if Q exceeded the upper )%1(100   percentile of the 
2  distribution with k-1 degrees of freedom [7].  Note, however, a lack of significance 
of this test does not imply homogeneity [24]. 
For multiple studies where the effect measure can be expressed in the form of a relative 
risk, a statistical test of the homogeneity assumption on the log scale is given by 
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where 
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3.4.2 SMRs 
The statistic can be adapted for use with SMRs in an analogous way giving 
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3.4.3 Peto method 
A heterogeneity test statistic based on the Peto method [15] is given by 
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with degrees of freedom equal to k
*
-1, where k
* 
< k is the number studies with nonzero 
variances, and Vi defined as in Section 3.3.1.3. 
3.4.4 Correlation coefficients 
Where the statistics being combined are correlation coefficients, a heterogeneity test 
statistic is given by 
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where z(ri) and wi are as given in Section 3.3.1.4, and 
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3.5 METHODS FOR EXPLORING BETWEEN-STUDY 
HETEROGENEITY 
It is now generally agreed that meta-analysis can and should go further than simply 
producing overall summaries of effect [19].  Thus the main focus of meta-analyses 
should be an exploration of the reason why the different component studies within a 
meta-analysis produce different effect estimates (or at least more than can be explained 
simply by sampling variation). 
3.5.1 Graphical methods 
A graphical examination of heterogeneity is normally carried out in addition to a test 
based on the Cochran 
2  test.  A forest plot, which consists of the individual study 
effect sizes together with their associated confidence interval being plotted on the same 
graph, provides a useful informal comparison of the effect sizes from the different 
component studies, usually at the exploratory stage of a meta-analysis.  A useful feature 
is that the plotting symbol can be made proportional in size to the inverse of the 
variance of the effect estimate, to provide a visual representation of the relative weight 
of each study. 
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3.5.1.1 Plots of normalised scores 
Here the standardised residuals for each study can be calculated as 
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where Yi and Y  are as in Section 3.3.1.1, when under the null hypothesis of only 
random differences between the studies, a histogram of the z-scores would have an 
approximately normal distribution with mean 0 and variance 1.  It is therefore usual to 
superimpose on the histogram a normal distribution with mean 0 and variance 1.  Large 
absolute z-scores can signal important deviations from the average result, thus 
providing an indication of which studies are responsible for large contributions to the 
heterogeneity test statistic [15]. 
3.5.1.2 Radial plots 
These plots consist of the outcome from each study divided by the square root of its 
variance 
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The position of each study in relation to the horizontal axis provides an indication of the 
weight associated with each study (the smaller the weight the larger the standard error 
and the further it will be from the abscissa).  Deviations from the simple linear 
regression line constrained to fit through the origin indicate possible outliers 
contributing considerably to the between study heterogeneity [25].  Subgroups of 
studies may be highlighted by the use of colour. 
3.5.2 Subgroup analysis – stratification by study characteristics 
The main type of subgroup analysis possible in meta-analyses in occupational 
epidemiology is that which investigates subsets of workers defined by study 
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characteristics (e.g. country, industry, occupational group).  It is important that the 
subgroups are clearly defined (preferably defined a priori).  Regression models are 
required, however, if there are many different characteristics that need to be examined 
at the same time. 
3.5.3 Fixed effect and random effects regression models 
There are two types of regression model, the fixed effect or meta-regression model and 
the random effects regression or mixed model (so called because it includes fixed and 
random terms). 
The meta-regression model is used when all the variation, other than sampling error, is 
explainable by the covariates included in the model (usually study characteristics).  A 
mixed model is used when the covariates only partly explain the variation or 
heterogeneity and a random effects term is employed to explain the remainder.  Clearly 
in practice, not all the variation (other than sampling error) will be explained by the 
covariates and so a choice between the regression approaches will need to be made. 
A mixed model can be expressed as 
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i.e.  
 𝑌𝑖 = 𝜇 + 𝛿𝑖 + 𝑒𝑖 (see section 3.3.2) 
where: 
𝑌𝑖 = log (𝑅𝑅𝑖)  
and 
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 𝜇 = 𝛽0 + ∑ 𝛽𝑗𝑥𝑗𝑝
𝑃
𝑗=1 ; 
 And the ei are the sampling errors as in Section 3.3.1; the i  are the deviations of the i
th
 
study’s underlying effect size from   as in Section 3.3.2; the xij are the values of the 
predictor variables for the i
th
 study; and the  s are the p+1 unknown regression 
parameters to be estimated, each of which estimates the influence of a study 
characteristic on the magnitude of the outcome of interest.  As for the weighted average 
approach, if 
   0var i , 
then the model reduces to the fixed effect meta-regression  model. 
The usual standard errors for the parameter estimates from regression models can be 
computed and thus associated )%1(100   confidence intervals can also be derived.  
The explanatory variables are characteristics of the studies and the magnitude of the βs 
indicates the potential impact on the overall meta-RR.  The testing of the usual 
assumptions underlying the regression models, as well as the testing of model adequacy 
and for influential risk estimates, need to be carried out before drawing conclusions. 
3.6 PUBLICATION BIAS 
Identification of all possible epidemiological investigations is important, since 
identification of only a subset has the potential to lead to biased conclusions.  Complete 
ascertainment of all possible studies is unlikely to happen in practice, since the practice 
of writing up or submitting for publication is related to whether or not the study findings 
are positive.  In such instances the ensuing bias in the overall effect estimate caused by 
this is known as publication bias. 
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3.6.1 Funnel plots (identification of publication bias) 
Detection of publication bias can be carried out informally using a visual method based 
on a funnel plot.  A funnel plot is simply a scatter plot of the effect estimates of interest 
from individual studies against some measure of each study’s size or precision.  An 
asymmetric graph, usually caused by a lack of small studies with low relative risk or an 
exaggeration of effect sizes in small studies of low quality, suggests the presence of 
publication bias.  Funnel plots are at their most useful in the presence of studies with a 
range of sizes [26], as a spread of observations in the vertical direction will make the 
absence, for example, of small null studies easier to spot. 
Other, more formal, methods exist for identifying publication bias.  For example, a 
method exists where the association between effect estimates and their variances is 
examined via a rank correlation test [27].  The normalised test statistic is compared to 
the standardised normal distribution.  This Begg and Mazumdar test is usually carried 
out alongside the funnel plot, and is not considered powerful when dealing with a small 
number of studies.  Other methods include a linear regression test [26] in which the 
effect estimate divided by its standard error, producing a standard normal deviate, is 
regressed against the estimate’s precision (inverse of standard error), and a ‘trim and 
fill’ method [28] also exist. 
3.6.2 The file-drawer method (measurement of extent of publication bias) 
This is a method that attempts to answer the question: “how many studies have been 
conducted averaging a null result are needed to bring the overall effect estimate to not 
statistically significant?” 
The normal z-scores (Zi) associated with the p-values observed for each study can be 
combined to produce an overall z-score: 
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where k is the number of effect estimates included in the meta-analysis.  If k0 is defined 
as the number of unpublished studies with an average observed effect size of 0 that 
would be needed to make the overall z-score Z not statistically significant, then it can be 
estimated as: 
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Once calculated a judgment has to be made about whether k0 represents a realistic 
number of studies that have been “filed away”.  Further, it has been suggested that 
105  kN  should be considered a fail-safe such that if k0 is less than this level then 
one must have doubts about the validity of the meta-analysis [29]. 
3.6.3 Brief overview of other methods for dealing with publication bias 
If feasible, then efforts should be made to track down studies missing from a meta-
analysis, although this will usually mean the incorporation of results that have not been 
through the peer-review process.  In practice, this is usually too difficult.  One of the 
most straightforward methods to adjust for publication bias in a meta-analysis is to 
include only the largest studies in a meta-analysis.  This involves an arbitrary cut-off for 
deciding what constitutes a large study.  Another possibility is to carry out a cumulative 
meta-analysis in which studies are combined sequentially in order of precision.  
Approaches other than the file drawer method exist for estimating the number of 
unpublished studies [30].  The ‘trim and fill’ method mentioned in Section 3.6.1 
provides a method for adjusting for publication bias.  In addition a method has been 
k
Z
Z
k
i
i
 1
 49 
developed based on a random effects meta-analysis model via a sensitivity analysis 
approach [31]. 
3.7 OTHER META-ANALYTICAL METHODS 
This section includes details of other methodological methods not already covered that 
may be important for the occupational setting. 
3.7.1 Methods for combining dose-response data 
This is an area of meta-analysis that is very important in the occupational setting, 
particularly in the regulatory risk environment where decisions have to be made about 
whether or not an association represents a causal one and what constitutes a “safe” 
occupational exposure limit.  The following contains only a very brief introduction to 
the topic. 
Combining dose response data involves the pooling of correlated estimates to compute 
regression slopes across different occupational exposure categories.  Methods have been 
proposed that account for these correlations but only require summary estimates of the 
marginal data from the component studies.  Some of the methods can also be extended 
to allow for non-linear increases in risk with exposure [32]. 
3.7.2 Methods for assessing and adjusting for study quality 
If a general formula for the fixed effect weighted average effect size over the k studies 
is 
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then a quality adjusted weight may be defined as 
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This approach can be extended to a random effects approach by using the DerSimonian 
and Laird approach.  Note, however, that the use of quality scores in meta-analysis 
remains controversial [34] and these are discussed in section 3.8. 
3.7.3 Sensitivity analysis 
Sensitivity analyses can play an important part in determining the sensitivity of the 
findings of the results of a meta-analysis to the approach chosen.  This will be 
particularly important in the context of statistical modelling where for example 
assumptions of normality (or, more usually, normality on the log scale) for effect 
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measures and independence of studies cannot be easily tested.  Other important issues, 
such as the effect of the choice of inclusion/exclusion criteria or of the choice of quality 
scores may also be important to investigate.  It is prudent therefore to try to demonstrate 
consistency of conclusions from a variety of approaches.  A lack of consistency would 
provide a focus for areas for further investigation. 
3.8 SOME EXAMPLES OF THE CONTROVERSIAL ASPECTS 
OF THE METHOD 
Some aspects of the meta-analysis method are of central importance or specifically 
relevant in occupational epidemiology.  For example, the summary Standardised 
Mortality Ratio (SMR) or meta-SMR has been used because of its simplicity, ease of 
interpretation, its preservation of the adjustments in the original studies, and its 
resemblance to the analyses in the original studies [35].  However, it has also been 
suggested that the validity of the meta-SMR is uncertain, even though it has the virtue 
of weighting the various SMRs (from the different studies) by the number of expected 
deaths and is (therefore) of some value [36].  Furthermore, it has been forcefully stated 
that SMRs from cohorts with different age structures cannot be validly compared 
(although there may be circumstances when this is not so) and that this problem is 
generally ignored in meta-analysis in occupational epidemiology on the assumption that 
the age distributions of the cohorts to be combined are approximately equal [9].  (This 
issue also applies to subgroup analyses within cohort studies.)  Another major difficulty 
faced by the meta-analyst in the occupational health field is the differences in exposure 
measurements between studies [37].  For example, in cohort studies where exposures 
are classified by a broad definition such as a job title, not all of those workers will have 
the same exposures [38] and combining those studies with different exposures would 
tend to dilute the effects of the relevant exposures and bias the risk estimates towards 
the null [39, 40]. 
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3.9 RECENT METHODOLOGICAL DEVELOPMENTS (SINCE 
THE ORIGINAL REVIEW) 
This section briefly summarises some recent developments in meta-analysis 
methodology that are relevant for practice in occupational epidemiology. 
In their 2008 paper, Sutton and Higgins recognized that the need for research and 
practice to be based on the totality of relevant and sound evidence had been increasingly 
recognized and that the impact of meta-analysis in this had grown enormously [41].  
They outlined how emphasis has been placed on (i) heterogeneity and random-effects 
analyses; (ii) special consideration in different areas of application; (iii) assessing bias 
within and across studies; and (iv) extension of ideas to complex evidence synthesis.  
They conclude that any new method should be backed up by appropriate simulation 
work, and that non-statistical considerations can have an important role in the choice of 
meta-analysis model. 
Reitsma et al pointed out that several advances have been made in the methods used in 
performing meta-analyses of diagnostic test accuracy studies, most notably how to 
assess the methodological quality of diagnostic test accuracy studies and the paired 
measures of test accuracy (bivariate meta-regression model of sensitivity and 
specificity) [42]. 
The multivariate random effects model is a generalization of the standard univariate 
model. Multivariate meta-analysis is becoming more commonly used and the techniques 
and related computer software, although continually under development, are now in 
place.  Jackson et al have described the areas of application that multivariate meta-
analysis has found, the methods available, the difficulties typically encountered and the 
arguments for and against the multivariate methods.  They concluded that the 
multivariate methods can be useful, and in particular can provide estimates with better 
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statistical properties, but also that these benefits come at the price of making more 
assumptions which do not result in better inferences in every case.  Thus although there 
is evidence that multivariate meta-analysis has considerable potential, it must be even 
more carefully applied than its univariate counterpart in practice [43].   
Higgins in a Lancet editorial explained network meta-analysis as applied to clinical 
trials.  In the absence of a direct head-to-head comparison of two treatments, results of 
separate studies of those treatments need to be drawn on.  He explained that a naïve 
indirect comparison could be made by comparison of outcomes of people receiving one 
treatment in one study with those receiving the other treatment in a different study, but 
that this approach could easily give the wrong answer, because it doesn’t account for 
key differences between studies and loses the advantage gained by the used of 
randomization.  Network analysis combines results from all studies simultaneously, 
drawing on both direct comparisons within studies and indirect comparisons across 
studies via common reference treatments.  In a standard meta-analysis, studies need to 
be sufficiently similar to each other for the combined result to be meaningful.  In a 
network meta-analysis – see for example Siontis et al [44] – studies need to be 
sufficiently similar in ways other than the particular choice of treatments being 
compared.  The method allows estimation of both heterogeneity in the effect of any 
given treatment and inconsistency in evidence from different pairs of treatments [45].  
The method is closely related to multivariate meta-analysis and it is possible to see how 
this approach could be adapted for use in occupational epidemiology. 
Wei and Higgins published an extension of the method of Bayesian multivariate meta-
analysis to cover the situation when there are more than two outcome of interest.  Their 
approach includes marginal modelling of data, to account for the fact that not all 
relevant studies necessarily publish data on all the outcomes of interest [46].  There are 
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currently very few examples if any of multivariate meta-analyses, whether Bayesian or 
frequentist in the occupational epidemiology literature. 
An assessment of bias in randomized controlled trials indicated that there was 
heterogeneity between trials in terms of the baseline characteristics of the study 
populations to be combined and this resulted in bias being introduced into the meta-
analysis [47].  This is clearly an issue that is extremely important within the context of 
meta-analyses in occupational epidemiology and one which has yet to be fully 
addressed in examples in the literature. 
An interesting recent development has been the introduction of an inverse variance 
quasi-likelihood based alternative to the random effects model, the so called IVhet 
model [48].  The paper suggests that the IVhet model is an improved alternative to the 
random effects model for meta-analysis of heterogeneous studies.  It shows that the 
known issue of the underestimation of the statistical error and thus spuriously 
overconfident estimates with the random effects model can be resolved by use of an 
estimator under the fixed effect model assumption with a quasi-likelihood based 
variance structure.  The authors claim that extensive simulations have confirmed that 
the estimator retains a correct coverage probability and a lower observed variance than 
the random effects model estimator, regardless of the level of heterogeneity.  They 
recommended that the IVhet model be used in practice instead of the fixed effect and 
random effects models.  This is an interesting very recent development.  There are no 
examples yet where this has been utilized in the occupational epidemiology setting. 
A systematic review of simulation studies comparing the performance of different 
estimation methods for the estimate of between-study heterogeneity in random effects 
meta-analysis has recently stated that the DerSimonian and Laird method is negatively 
biased when heterogeneity is moderate to high and for most studies recommended an 
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alternative [49].  Three of the studies they reviewed recommended the Paule-Mandel 
method [50] as being simple to implement and being less biased than the DerSimonian 
and Laird method, performing well with dichotomous and continuous outcomes.  The 
authors of the review provisionally recommended this method, but cautioned that 
further simulation studies are required before firmer conclusions could be drawn [49]. 
The Cochrane collaboration has produced a tool to assess bias in randomized controlled 
trials (see 
http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.
htm).  However, a recent review of its use in practice has mainly been in a non-
recommended way and it has been recommended that its structure be improved and 
more focused guidance be produced[51]. 
A tool also now exists for assessing the quality of meta-analyses [46]. 
A recent paper has indicated that the inverse variance methods perform poorly when the 
data contain zeroes in either control or intervention arms in clinical trials and 
recommended that methods based on Poisson regression with random effects terms for 
the variance components are very flexible and offer substantial improvement [52]. 
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4 META-ANALYSIS FOR RARE DISEASE 
OUTCOMES: WHAT TO DO WHEN THERE ARE NO 
EXPOSED CASES? 
4.1 INTRODUCTION 
The issue of sparse and missing data is an issue of major concern in randomized 
controlled clinical trials.  Meta-analyses including the calculation of confidence 
intervals in statistical software e.g. Stata [53], are often carried out on the log scale as 
the distributions are more likely to be normal and their results transformed back to the 
original scale.  However those studies that have a zero relative risk are excluded from 
such analyses because log 0 is undefined.  It is clear, however, that such studies are 
potentially important because they contain important statistical information, especially 
when the disease under consideration is rare, and so should be included in the analyses. 
This chapter aims to explore possible approaches available to the meta-analyst when a 
non-trivial number of studies of a rare disease outcome have an observed relative risk 
equal to zero, and to make recommendations about the optimum approach in such 
circumstances.  Studies of formaldehyde and nasopharyngeal cancer and sinonasal 
cancer will be used as a basis for this exploration. 
4.2 SUMMARY OF THE LITERATURE ON THE META-
ANALYSIS OF SPARSE DATA SETS 
A search of the Science Direct and PubMed databases was carried out using the search 
terms ‘meta’ and ‘analysis’ combined with ‘sparse’ or ‘zero’ in order to find relevant 
papers that deal with sparse data sets.  By 2007, there were fewer than 10 papers have 
been published on this issue.  Previously authors have concentrated on issues relating to 
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the pooling of data from controlled clinical trials, and thus the pooling of odds ratios.  
These papers are summarised below. 
Sankey et al, 1996 
Sankey et al explored two possible approaches for carrying out meta-analyses of sparse 
data sets that could be expressed in the form of a 2x2 contingency table using 
simulations: a corrected method in which one half was added to each cell, and an 
uncorrected method.  These methods were compared over a range of sparse data 
situations in terms of coverage rates using three summary statistics: the Mantel-
Haenszel odds ratio and the DerSimonian and Laird approach using the odds ratio and 
the rate difference.  The uncorrected method performed better only when using the 
Mantel-Haenszel odds ratio with very little heterogeneity present.  For all other sparse 
data applications, the method with the continuity correction performed better and is the 
one recommended by authors for use in meta-analyses of similar scope [54]. 
Austin et al, 1997 
Austin et al contended that although there are a variety of procedures available for 
combining effect measures across epidemiologic studies, none of the methods provided 
an overall effect estimate when the data were sparse within studies and come from 
different study designs.  In their paper they discussed the statistical relationship between 
case-control studies and two types of follow-up studies.  Their method relies on the data 
from follow-up studies being able to be expressed in the form of a 2x2 contingency 
table.  They developed an exact methodology for combining results across study 
designs. They also derived Mantel-Haenszel-type formulae for summarising results 
across studies, and illustrated the techniques with data from studies of breast implants 
and connective tissue disease.  The authors identified the limitations of their approach in 
that: continuous data needed to be categorised;  prudence was needed in the combining 
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of results from different study designs;  discrepancies in exposures and other study 
characteristics affect comparability;  and estimates adjusted for confounders by 
stratification or regression could not be used, but that in practice adjusted and 
unadjusted estimates of effect size were often quite close [55]. 
Sutton et al, 2002 
Sutton et al examined this problem in the context of binary data that could be expressed 
in the form of a 2x2 table in the context of rare adverse event data in clinical trials.  The 
risk measures considered were: 
 The risk difference 
 The risk ratio of beneficial and harmful outcomes 
 The odds ratio 
 The numbers needed to harm (does not have properties required for meta-
analysis, but can be derived from other summary statistics) 
They stated that the choice between the different effect measures was far from 
straightforward.  The risk ratio and the odds ratio are approximately equal for rare 
events and so the choice comes down to an absolute or relative comparator.  They 
eventually concluded that they preferred the risk difference due to its direct 
interpretability and potential inclusion of studies in which zero events occurred [56]. 
Sweeting et al, 2004 
Sweeting et al compared via simulation the performance of different classical and 
Bayesian meta-analysis methods for pooling odds ratios when applied to sparse event 
data with emphasis on the use of continuity corrections [57].  The continuity corrections 
used were either a constant or two alternatives: one based on a function of the reciprocal 
of the opposite group arm size; and the other on an empirical estimate of the pooled 
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effect size from the remaining studies in the meta-analysis.  A variety of scenarios were 
simulated whilst varying the ratio of the study arm sizes.  The methods employed were: 
 Inverse-variance-weighted fixed effect model [58] 
 Mantel-Haenszel summary odds ratio [11] 
 Peto’s method for combining odds ratios [15] 
 Logistic regression using iterative weighted least squares 
 Logistic regression via a Bayesian model [22] 
Sweeting et al found that the Mantel-Haenszel summary estimates using the alternative 
continuity correction factors gave the least biased results for all group size imbalances.  
Logistic regression was unbiased for all scenarios and gave good coverage probabilities.  
The Peto method provided unbiased results for balanced treatment groups, but the bias 
increased with increasing ratio of study arm sizes.  The Bayesian fixed effect model 
provided good coverage for all group size imbalances.  The two alternative continuity 
corrections outperformed the constant correction factor in nearly all situations.  The 
inverse variance method always performed badly, irrespective of the continuity 
correction used.  They concluded that a sensitivity analysis using several methods and 
continuity correction factors is required for routine practice [57]. 
Bradburn et al, 2007 
Bradburn et al evaluated, via simulation, the performance of 12 methods, readily 
available in software, for pooling rare events and considered estimability, bias, coverage 
and statistical power [59].  Their simulations were based on data sets from three case 
studies with between five and 19 trials using baseline event rates between 0.1 and 10 
per cent and risk ratios of 1, 0.75, 0.5 and 0.2.  The methods they employed were: 
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 Odds ratios (continuity corrections of adding 0.5 to each 2x2 cell were 
made only where absolutely necessary and feasible): 
 Inverse variance - fixed effect (variance of individual trial ORs 
calculated using Woolf’s method [60]) 
 DerSimonian and Laird - random effects [18] 
 Mantel-Haenszel with and without zero-cell correction (their pooled 
variance estimators being the unconditional product binomial estimators 
[12, 13, 61]) 
 Mantel-Haenszel with continuity correction (their pooled variance 
estimators being the unconditional product binomial estimators [12, 13, 
61]) 
 The Peto ‘one-step’ method [15] 
 Exact stratified method [62] 
 Maximum likelihood from logistic regression 
 Risk differences 
 Inverse variance - fixed effect (variance of risk difference estimated 
using a Normal approximation [63]) 
 DerSimonian and Laird - random effects [18] 
 Mantel-Haenszel (their pooled variance estimators being the 
unconditional product binomial estimators [12, 13, 61] 
In addition two unstratified marginal methods were evaluated [64, 65]. 
Bradburn et al found that most of the commonly used meta-analytical methods were 
biased when data were sparse and that the bias was greatest in inverse variance and 
DerSimonian and Laird odds ratio and risk difference methods, and for the Mantel-
Haenszel odds ratio with a 0.5 continuity correction.  Risk difference meta-analytical 
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methods tended to show conservative confidence interval coverage and low statistical 
power at low event rates.  At event rates below one per cent, the Peto one-step method 
was the least biased and most powerful method, and provided the best confidence 
interval coverage, provided there was no substantial imbalance between treatment and 
control group sizes within trials, and treatment effects were not exceptionally large.  In 
other circumstances the Mantel-Haenszel odds ratio approach in the absence of use of 
continuity corrections, logistic regression and the exact method performed similarly to 
each other, and were less biased than the Peto method [59]. 
In summary, for studies that can be expressed in the form of a 2x2 table, there is no 
clear consensus on how the meta-analysis should be carried out.  There appears to be a 
difference of opinion on whether meta-analyses of odds ratios are to be preferred to 
meta-analyses of risk differences.  In meta-analyses of odds ratios, caution is advocated 
when continuous data has been categorised, a continuity correction should be used and a 
sensitivity analysis should be carried out using several approaches to examine the 
robustness of any conclusions.  None of the methods previously applied include the 
appropriate use of adjusted relative risks; it is just argued that unadjusted relative risks 
provide a good approximation to adjusted relative risks.  None of the literature deals 
specifically with methods that could be used in meta-analyses of studies used in 
occupational epidemiology. 
4.2.1 More recent methodological developments 
Friedrich et al demonstrated that inclusion of trials arms with no events in a meta-
analysis of randomized controlled trials could have a crucial impact on any inferences 
that may be drawn [66].  They used Mantel-Haenszel inverse variance methods, exact 
statistical methods, Bayesian analysis with non-informative priors and analyses of 
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additionally related outcomes to conduct alternative analyses to those that had 
previously been published. 
A random effects meta-analysis approach has been proposed in which the 
approximately normal within-study likelihood is replaced by the appropriate exact 
likelihood [67], leading to a generalized mixed model that can be fitted using standard 
statistical software.  It can also be fitted in situations where studies have zero exposed 
cases. 
Cai et al proposed a random effects model based on the Poisson distribution [68]. 
Bohning et al reminded meta-analysis practitioners that meta-analysis of rare event 
studies had recently become a topic of controversy and debate [69].  They argued and 
demonstrated that the occurrence of zero events in clinical trials or cohort studies, even 
if zeroes occur in both arms is less problematic, at least from a statistical perspective, if 
the available statistical tools are applied in an appropriate way.  In particular that 
cautioned against the exclusion of studies with zero events from meta-analyses.  They 
focused on Mantel-Haenszel techniques, mixed Poisson regression and related 
regression models. 
Bayesian estimators of the treatment effect and the heterogeneity parameter, as well as 
hypothesis testing methods based on Bayesian model selection procedures [70], have 
been compared by simulation to moment-based approaches under a random effects 
model [71].  This last method deals with zero events via a simple average estimator 
although the bias will tend to increase as the event rate gets lower and the number of 
studies with zero events gets higher. 
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4.3 SYSTEMATIC PRESENTATION OF OPTIONS 
The aim of this section is to focus on options of relevance in occupational 
epidemiology, and of cohort studies in particular.  It is rare that there will be no exposed 
cases of a rare disease in a type of study other than a cohort study.  Clearly there will be 
studies other than occupational cohort studies that will contain data of relevance and so 
a couple of alternative methods are presented to allow their inclusion.  In rare 
circumstances where there a large number of informative studies that can be included in 
the meta-analysis, an exploration of sources of heterogeneity via meta-regression might 
be undertaken. 
There are several approaches for inclusion of studies with zero relative risk in the 
estimation of an overall mean, which can be applied to cohort or PMR-type studies: 
 Carry out analyses on the log scale 
o ignoring studies with O = 0 
o by making adjustments to the data so that they will not introduce 
any important bias into the analysis, but in a way that allows the 
studies with RR= 0 to be included in an analysis on the log scale;  
this may involve adding a constant to the O and E for the studies 
with O = 0 
 Carry out the analysis on the original (unlogged) scale; and 
 Carry out analyses using transformations other than logs. 
If the analysis includes studies other than cohort or PMR-type studies, then such 
studies can be included by: 
 Deriving a pseudo expected number of cases and applying the method for 
cohort studies 
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 Analysing them separately on the log scale, with the results presented 
separately from those of the cohort studies or (if appropriate) for the end 
results of the two analyses to be combined to produce a single overall 
estimate of effect. 
If there are sufficient studies to make exploration of heterogeneity meaningful, carry out 
a meta-regression on the original scale (Poisson for fixed effect; negative binomial for 
random effects).  In the form of null models (no fitted covariates), these could be used 
as additional options to obtaining single pooled estimates of meta-relative risk.   
These options are expanded upon in the following sections. 
4.3.1 Analyses on the log scale 
As mentioned in section 4.1, analyses of relative risks in meta-analyses are often carried 
out on the log scale.  These are backed up by an observation that much of the available 
statistical software has been written for analyses on the log scale, for example, the 
‘metan’ routine for Stata [53].  The motivation for using the log scale is that it helps to 
symmetrise the distributions of random variables and thus make them more normal [9].  
Because the log of the relative risk is essentially a sum of independent random 
variables, it should converge to normality under the central limit theorem, allowing an 
approximate 95% confidence interval to be calculated [9].  However, there remains a 
problem when a non-trivial number of cohort studies involving a relatively rare event 
such as nasopharyngeal cancer or sinonasal cancer are studied, since there is a high 
probability that more than a few studies will contain no observed cases of interest and 
thus the relative risk equals zero and so the log of the relative risk is undefined.  In 
general, approaches to meta-analysing RRs involve taking logarithms and so at first 
sight are not possible here.  There remain two obvious options: ignore the studies with 
no observed cases; and finding a way to include them by adding small constants to 
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avoid having to take logs of zero.  The additional option of Poisson or negative 
binomial regression is also possible, and has been explored. 
4.3.1.1 Ignoring studies with zero observed cases 
This approach is often adopted subconsciously by meta-analysts who simply use the 
available software that performs the analyses on the log scale by excluding those studies 
with zero observed cases.  The analysis proceeds using the methods outlined in Chapter 
3.  In practice, the upward bias in meta-RR is likely to be small, unless there are an 
informative number of studies with a zero relative risk.  This can occur in occupational 
cohort studies of rare cancers. 
4.3.1.2 Adding a constant to avoid taking logs of 0 
The attempts to address this problem in the literature have almost exclusively 
concentrated on situations in which the data are from a controlled clinical trial and when 
the data from the component studies can be expressed in the form of a 2x2 contingency 
table in order to derive odds ratios.  Thus approaches to address the problem of zero 
observed (exposed) cases have centred on the use of continuity corrections to prevent 
having to take logs of zero.  The use of a continuity correction in such circumstances is 
based on the approximation of a discrete distribution by a continuous one.  It has been 
argued that the use of a continuity correction of 0.5 makes the estimate of the mean 
unbiased [72].  The use of smaller values as low as 10
-8
 have also been proposed for 
contingency tables in general [73], but none has been used in the meta-analysis context 
[57]. 
Thus, as before, if Yi is assumed to be a ratio (a relative risk), then putting 
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Thus a small constant k can be added to all the observed and all the expected values, to 
both the observed and expected values when O = 0, to the observed values only, or to 
the observed only when O = 0.  In practice, it seems intuitive, that k should be added to 
both O and E for each study and that k should be small to minimise the resultant bias in 
the logRR. 
The mean relative risk on a log scale can then be expressed in the usual way as in 
Section 3.3.1.1 as 
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Clearly, this approach assumes that the RR can be expressed as a ratio of observed to 
expected number of cases. 
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4.3.2 Analyses on the original scale 
There exist approaches that involve analyses on the original (unlogged) scale, provided 
the relative risks can be expressed in the form O/E.  They assume that the variance of 
the individual study effect sizes can be estimated.  The fixed effect weighted average 
approaches can be applied and appropriate confidence intervals can be calculated using 
exact methods.  Although a central estimate can be calculated from the random effects 
method, the calculation of appropriate confidence intervals requires assumptions of 
normality for the estimates of between and within study variance. 
If the number of observed and expected events are available from the individual cohort 
or PMR-type studies, then as outlined in Chapter 3, the meta-SMR can be calculated 
simply by using 
  (Herbold, 1993), 
(referred to previously as meta-SMR2) which is algebraically equivalent to 
, 
where 
 . 
Exact confidence intervals can be calculated via the Poisson distribution, for example 
by using its relationship with the chi-squared distribution [74]. 
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Now, 
   
A simple extension to incorporate random effects can be derived.  Here 
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This approach is outlined in a Stata technical bulletin [75]. 
For fixed effect analysis, the meta-SMR is equivalent to Poisson regression with no 
covariates.  For random effects analysis, the meta-SMR would be expected to be similar 
to random effects Poisson regression which, when the errors are distributed according to 
the gamma distribution, is equivalent to negative binomial regression.  This approach 
can be extended to studies other than cohort studies, such as case-control studies, by 
regarding the expected number of cases as though a “pseudo” expected number of cases 
from a cohort study (see section 4.3.4).  Alternatively, for non-cohort studies, better 
estimates for standard errors on the original scale (e.g. to take account of extra 
uncertainty from controls in case-control studies) may be generated from the standard 
error on the log scale using the delta method.   
Thus: 
𝑆𝐸(𝑅𝑅) = 𝑆𝐸(log 𝑅𝑅) ∗ 𝑅𝑅. 
Therefore for analyzing studies that are a mixture of cohort and non-cohort studies, 
rather than the meta-SMR, a standard meta-analysis method involving RRs and their 
SEs is required.  Meta-analyses on the original scale can, in theory, be extended as a 
form of meta-regression by including study characteristics as explanatory variables in 
the model.  
4.3.3 Transformations other than taking logarithms 
A variety of transformations are available for normalising a data set, the one most 
usually used in meta-analysis being that of taking logarithms.  In addition, a square root 
transformation can be used.  In one meta-analysis of formaldehyde and respiratory 
cancer [76], the authors made use of a square root transformation: 
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“However a number of studies had no cases of nasopharyngeal or nasal 
cancers, which precluded the logarithmic transformation typically utilized in 
meta-analyses formulae.  In these cases, we used a square-root transformation 
of the lower and upper confidence intervals to derive weights for the individual 
studies and calculated the mRR by summing the products of the study weights 
and the RRs from the individual studies.” 
It is not clear precisely how this transformation was implemented.  It can be speculated 
that the square root transformation may have been applied to all studies when there was 
at least one study with a zero SMR or only to the studies with a zero SMR.  Thus, the 
square root transformation implemented in this chapter may not be an implementation 
of the method used by Collins et al. 
For cohort studies, the variance of the square root of a Poisson random variable can be 
approximated by ¼, the approximation improving as the mean increases [77].  So 
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4.3.4 Dealing with studies other than cohort studies 
Odds ratios from case-control studies can be incorporated into analyses on the original 
scale (4.3.2), provided an associated standard error for the odds ratio can be derived.  
The standard error may be estimated directly on the original scale or from the estimated 
standard error on the log or square root scale via the delta method.  The delta method 
has the advantage that it does not require the data to be in O/E format in order for the 
study to be used in a meta-analysis.  Deriving the standard error directly on the original 
scale requires the data to be in O/E format; this can be achieved using a pseudo 
expected number of cases (pseudo E = O/OR), with the additional assumption that 
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pseudo expected values from studies with adjustment for confounding factors may be 
estimated by a pseudo expected value from an unadjusted estimate [53, 78].  Empirical 
evidence suggests that the difference between unadjusted odds ratios and confounder-
adjusted odds ratios in practice is not large.  The delta method [78] can be used to 
transform estimates from the log scale to the original scale; it is implemented in the 
Stata software [53] and so is judged a reliable approximation. 
Thus, irrespective of whether the analyses are carried out on the original, square-root or 
log scales, there are two main approaches that can be adopted.  The first is to combine 
the results from non-cohort studies with those of cohort studies to derive an overall 
estimated mean relative risk.  The second is to carry out meta-analyses separately for 
each study type and if appropriate to combine these risk estimates together to obtain an 
overall estimate of relative risk. 
4.3.5 Meta-regression 
Standard meta-regression extends fixed effect and random effects meta-analysis to 
estimate the extent to which one or more covariates with values defined for each study 
in the meta-analysis explain any observed heterogeneity in the study effect estimates.  
When the data are in the form usually found in occupational cohort studies, that is, can 
be expressed in the form O/E fixed effect and random effects meta-regression analyses 
may be undertaken even when O = 0 in some studies using a Poisson regression or 
negative binomial regression model respectively. 
4.3.5.1 Fixed effect Poisson regression 
In a model where the observed number of cases of interest are from an epidemiological 
study, it is often reasonable to assume an underlying Poisson distribution for the 
response variable and to describe the impact of explanatory variables, the study 
characteristics, on their means by some regression function. 
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To define a basic version of a Poisson regression model, suppose there are observations 
y1, y2, … , yn for the response variable Y1, Y2, … , Yn, assumed to be independently 
distributed Poisson variates with means µ1, µ2, … , µn, i.e. 
 )exp(
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The systematic component of the model is specified by some regression function η, 
depending on regression parameters β1, …, βk, with each component relating values xi1, 
… , xik of explanatory variables that are study-related to respective means, i.e. 
 ),...,;,...,()( 11 kikiiii xx   . 
Often this relationship is such that some monotone transformation g of the means is 
connected to a linear predictor of explanatory variables, 
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In this situation, g is called the link function and the model defined in this manner is an 
example of a generalised linear model. 
For 
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the familiar log-linear model, 
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When dealing with RRs that can be expressed in the form of observed divided by 
expected, the observed number of cases can be regarded as from the Poisson 
distribution and the expected number is regarded as fixed (i.e. known without error) in 
any modelling. 
This means that the expected number of cases is regarded as an offset in the model and 
thus 
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Thus applying a Poisson regression in a meta-regression involves identifying and 
coding study characteristics that might be responsible for between study heterogeneity 
in effect estimates.  Provided there are sufficient studies, examining these variables in a 
Poisson regression may provide some insight into whether there might be reasons due to 
study characteristics for differences in effect estimates. 
4.3.5.2 Random effects negative binomial regression 
Negative binomial regression is used to model the number of occurrences of an event 
when the event has extra-Poisson variation, i.e. when there is over-dispersion. 
The structure of the model is similar to that for the Poisson regression model, except 
there is an additional variable for the extra-Poisson variation that follows a gamma 
distribution with mean 1 and variance  . 
Thus 
 )(~
*
ii PoissonY  , 
 74 
where 
 







 

)(exp
1
*
k
j
iijjii
uoffsetx   
and 
 ),1(~ Gammae iu , 
which has expectation 1 and variance  .  The term   is referred to as the dispersion 
parameter and the larger  , the greater the overdispersion or between-study variability. 
When   = 0, the model corresponds to the Poisson regression model [80]. 
Note that note that null models (using the methods described) could be used as 
additional options to obtaining single pooled estimates of meta-relative risk.  
4.4 SIMULATIONS OF META-ANALYSES OF SMRS FROM 
COHORT STUDIES, WHEN EXPECTED NUMBER OF 
CASES IS SMALL 
As mentioned in 4.3.1.2, the value of k which is used to allow studies with zero relative 
risk could be 0.5 if based on precedent or alternatively as small as 10
-8
.  This section 
contains some simulations to illustrate the possible effect that different choices of k 
might have on the results of a fixed effect meta-analysis. 
Meta-analyses of SMRs in which a simple correct solution was available from the 
original untransformed scale (based on summing of observed and expected cases) were 
carried out.  The number of studies of 30 was chosen because it was similar to the 
number of effect estimates anticipated to be used in the nasopharyngeal and sinonasal 
cancer examples. 
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4.4.1 Basic approach 
SMRs were randomly generated using the Poisson random variable to generate a 
random distribution of observed cases from 30 studies.  Thus each study has the 
potential to have a different number of cases.  This was repeated for different 
underlying true SMRs of 1.0, 1.5 and 2.0.  Summary SMRs were generated by summing 
the observed and expected cases on the unlogged (original) scale.  Exact 95 percent 
confidence intervals (95% CIs) were generated .  For comparison fixed effect summary 
SMRs and 95% CIs on the log-transformed scale were also generated using the ‘metan’ 
routine in Stata and compared with the estimates derived on the original scale.  The 
results were also analysed using Poisson and negative binomial regression for the case k 
= 0.  In addition these calculations were repeated by adding 10 alternative continuity 
corrections of 10
-8
, 0.001, 0.01, 0.1 0.25, 0.5, 0.75, 1, 2 and 5 to both the observed and 
expected cases from each study. 
4.4.2 Results when true summary SMR = 1.0 
In the following table, there were 12 studies out of 30 that had zero cases randomly 
generated.  The results from the Poisson and negative binomial regression for k = 0 
were identical at 0.97 (0.67 to 1.39) and the central estimate was confirmed as being the 
same as the fixed effect summary SMR, but with a slightly different 95% confidence 
interval. 
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Table 4.1 - Comparison of results when true summary SMR = 1.0 
Fixed effect meta-analysis on 
original untransformed scale 
(exact 95% CI) 
Continuity Correction k Fixed effect SMR using Stata 
routine ‘metan’ (95% CI) and 
continuity correction 
0.97 (0.65 to 1.39) 0 (i.e. no correction) 2.04 (1.57 to 2.66) 
0.97 (0.65 to 1.39) 10
-8
 2.04 (1.57 to 2.66) 
0.97 (0.65 to 1.39) 0.001 2.04 (1.57 to 2.65) 
0.97 (0.65 to 1.39) 0.01 2.03 (1.56 to 2.64) 
0.97 (0.66 to 1.37) 0.1 1.91 (1.49 to 2.46) 
0.97 (0.68 to 1.34) 0.25 1.75 (1.39 to 2.20) 
0.98 (0.71 to 1.31) 0.5 1.54 (1.26 to 1.90) 
0.98 (0.73 to 1.29) 0.75 1.41 (1.18 to 1.69) 
0.98 (0.75 to 1.27) 1 1.32 (1.12 to 1.55) 
0.99 (0.79 to 1.22) 2 1.14 (1.02 to 1.28) 
0.99 (0.85 to 1.15) 5 1.03 (0.97 to 1.10) 
 
4.4.3 Results when true summary SMR = 1.5 
In the following table, there were 6 studies out of 30 that had zero cases randomly 
generated.  The results from Poisson and negative binomial regression were again 
identical at 1.37 (1.01 to 1.86).  As for the case when SMR = 1.0, the summary SMR is 
that same as that using the meta-SMR, with slightly different 95% confidence intervals. 
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Table 4.2 - Comparison of results when true summary SMR = 1.5 
Fixed effect meta-analysis on 
original untransformed scale 
(exact 95% CI) 
Continuity Correction k Fixed effect SMR using Stata 
routine ‘metan’ (95% CI) and 
continuity correction 
1.37 (0.98 to 1.85) 0 (i.e. no correction) 2.50 (2.04 to 3.08) 
1.37 (0.98 to 1.85) 10
-8
 2.50 (2.04 to 3.08) 
1.37 (0.98 to 1.85) 0.001 2.50 (2.04 to 3.07) 
1.36 (0.98 to 1.85) 0.01 2.49 (2.03 to 3.05) 
1.33 (0.97 to 1.79) 0.1 2.32 (1.91 to 2.83) 
1.29 (0.96 to 1.71) 0.25 2.10 (1.78 to 2.54) 
1.24 (0.94 to 1.62) 0.5 1.85 (1.57 to 2.15) 
1.20 (0.93 to 1.55) 0.75 1.68 (1.44 to 1.95) 
1.18 (0.92 to 1.49) 1 1.55 (1.35 to 1.78) 
1.12 (0.91 to 1.36) 2 1.30 (1.17 to 1.44) 
1.06 (0.92 to 1.23) 5 1.10 (1.05 to 1.17) 
 
4.4.4 Results when true summary SMR = 2.0 
In the following table, there were 4 studies out of 30 that had zero cases randomly 
generated.  The results from the Poisson and negative binomial regression were 
identical at 1.73 (1.32 to 2.27).  As for the other true summary SMR values, the meta-
SMR gave the same estimate as the Poisson and negative binomial regression, albeit 
with slightly different 95% confidence intervals. 
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Table 4.3 - Comparison of results when true summary SMR = 2 
Fixed effect meta-analysis on 
original untransformed scale 
(exact 95% CI) 
Continuity Correction k Fixed effect SMR using Stata 
routine ‘metan’ (95% CI) and 
continuity correction 
1.73 (1.29 to 2.27) 0 (i.e. no correction) 2.90 (2.45 to 3.43) 
1.73 (1.29 to 2.27) 10
-8
 2.90 (2.45 to 3.43) 
1.73 (1.29 to 2.27) 0.001 2.90 (2.45 to 3.43) 
1.72 (1.29 to 2.26) 0.01 2.88 (2.44 to 3.40) 
1.67 (1.26 to 2.17) 0.1 2.69 (2.29 to 3.17) 
1.59 (1.21 to 2.05) 0.25 2.44 (2.09 to 2.85) 
1.49 (1.15 to 1.89) 0.5 2.14 (1.86 to 2.46) 
1.42 (1.12 to 1.78) 0.75 1.93 (1.70 to 2.19) 
1.37 (1.09 to 1.70) 1 1.78 (1.58 to 2.00) 
1.24 (1.03 to 1.50) 2 1.45 (1.32 to 1.59) 
1.12 (0.97 to 1.29) 5 1.18 (1.12 to 1.24) 
4.4.5 Indications for a continuity correction from the simulations 
The simulations in the previous section were based on only a single realisation of 30 
Poisson random variables.  Thus any inferences drawn from them have to be interpreted 
cautiously.  However the following were indicated: 
Introduction of k for the analyses on the original scale simply introduces an unwanted 
bias and is therefore unnecessary. 
For µ = 1 exclusion of 12 out of 30 studies that have zero relative risk causes an upward 
bias in the estimated relative risk such that the risk is doubled and becomes statistically 
significant at the 5% level of significance.  The addition of very small and small 
constants does not appear to resolve the issue, as k = 10
-8
, 0.001 and 0.01 give very 
similar estimates of fixed effect meta-SMR.  A similar pattern is seen for µ = 1.5 and µ 
= 2. 
For µ = 1, it is only when k gets as large as 5 does the 95% confidence interval for the 
true meta-SMR include the true value of 1.  For µ = 1.5, k was at least 0.75 before the 
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95% confidence interval included 1.5 and for µ = 2, k was at least 0.5 before 2 was 
included in the 95% confidence interval.   
The optimum value of k depends on the true value of the SMR and it doesn’t seem 
possible to choose it in advance. 
These examples are illustrative only, especially with the simulations being based on a 
single realisation.  There doesn’t appear to be an optimal value of k, so if an approach is 
to be adopted the conventional k = 0.5 may as well be used. 
When k is very small or small, the results of the meta-analyses on the log scale appear 
to be the same as when k = 0.  This point can be demonstrated algebraically.  As given 
in Chapter 3, the meta-SMR on the log scale is given by: 
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Thus as k →0, 
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which only contains a contribution from those studies where Oi is not equal to zero.  
Thus when k is very small, the fixed effect analysis on the log scale which is carried out 
by adding k to O and E for those studies with zero relative risk is approximately 
equivalent to excluding those studies from the analysis. 
This suggests that adding a constant and taking logs are not reliable ways of processing.  
The results from the Poisson and negative binomial regression as give the same 
summary SMR as the meta-SMR.  Indeed both Poisson and negative binomial 
regression gave the same confidence intervals which were very similar to those obtained 
from exact Poisson probabilities for the meta-SMR. 
As well as simulating multiple realisations, extending with work to include other 
random effects models would be appropriate. 
4.5 SUMMARY OF APPROACHES 
The following meta-analyses were undertaken using the formaldehyde and 
nasopharyngeal cancer and formaldehyde and sinonasal cancer data sets: 
 Fixed effect and random effects on the log scale, excluding risk estimates 
with no observed cases 
 Fixed effect and random effects on the log scale, with k = 0.5 added to 
the observed and expected number of cases for each study 
 Fixed effect and random effects on the square root scale 
 Fixed effect and random effects on the original untransformed scale 
 Poisson and negative binomial regression 
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The analyses were undertaken for all studies combined when studies other than cohort 
studies were included by generation of pseudo expected numbers of cases and treated in 
the same way as cohort studies and analyses were undertaken for cohort studies alone. 
4.6 COMPARISON OF APPROACHES USING DATA FOR 
FORMALDEHYDE AND NASOPHARYNGEAL CANCER 
The analyses presented in this section include all of the studies included in the analysis 
in Chapter 5. 
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Table 4.4 - Headline nasopharyngeal cancer analyses – all studies 
Analysis No. of 
estimates 
Meta-RR SE (Meta-
RR) 
95% CI P-value for 
heterogeneity 
Log scale 
FE, excluding 
studies with O = 
0 
12 1.38 0.15 1.11 to 1.71 0.137 
RE, excluding 
studies with O = 
0 
12 1.41 0.21 1.06 to 1.88 0.137 
FE, adding k = 
0.5 to O & E for 
studies with O = 
0 
16 1.31 0.14 1.07 to 1.62 0.867 
RE, adding k = 
0.5 to O and E 
for studies with 
O = 0 
16 1.31 0.14 1.07 to 1,62 0.867 
Square root scale 
FE 16 1.19 0.02 1.15 to 1.23 <0.001 
RE 16 1.05 0.14 0.80 to 1.33 <0.001 
Original scale 
FE 16 1.19 0.13 0.94 to 1.44 <0.001 
RE 16 1.41 0.41 0.60 to 2.22 <0.001 
Poisson 
regression 
16 1.23 0.08 1.08 to 1.40 0.039 
Negative 
binomial 
regression 
16 1.26 0.13 1.02 to 1.56 0.039 
Abbreviations: 
FE = Fixed effect 
RE = Random effects 
Notes: 
All non-cohort studies are included in the square root and regression analyses analyses by assuming E = 
O / RR for each study. 
For the original scale analyses for cohort studies, it was assumed that SE(RR) = sqrt(E), and for non-
cohort studies, SE(RR) was generated from SE(log RR) using the delta method (see section 4.3.2). 
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The naïve analysis on the logarithmic scale in Table 4.4 excluded 4 studies and gave 
statistically significantly raised meta-RRs from both the fixed effect and random effects 
analyses.  On this scale, the between-study heterogeneity was not statistically 
significant.  Adding k = 0.5 to the observed and expected values for each study did not 
appreciably alter the findings. 
For the analysis on the square root scale, the fixed effect analysis gave a statistically 
significantly raised meta-RR, but in the presence of significant heterogeneity on this 
scale, the random effect meta-RR is preferred and was not statistically significantly 
raised. 
The analysis on the original scale, however, was not statistically significant raised in the 
fixed effect analysis and in the presence of statistically significant heterogeneity, was 
not significantly raised in the random effects analysis either.  Interestingly, although the 
Poisson and negative binomial regression effect estimates give similar meta-RRs, these 
were both marginally statistically significantly raised. 
Table 4.5 repeated the same analyses, but restricted to just the cohort studies.  On the 
logarithmic scale (excluding the studies with zero observed cases), the fixed effect 
meta-RR was significantly raised in the presence of significant between-study 
heterogeneity; however the random effects analysis was not significantly raised.  
Adding k = 0.5 to O and E gave analyses that were not statistically significantly raised 
from either the fixed effect or random effects analyses. 
Neither the fixed effect or random effects analyses on the square root scale gave meta-
RRs that were raised, nor did the weighted average on the original scale or regression 
analyses. 
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Table 4.5 - Nasopharyngeal cancer analyses – cohort studies only 
Analysis No. of 
estimates 
Meta-RR SE (Meta-
RR) 
95% CI P-value for 
heterogeneity 
Log scale 
FE, excluding 
studies with O = 
0 
5 1.75 0.45 1.06 to 2.89 0.027 
RE, excluding 
studies with O = 
0 
5 2.40 1.22 0.89 to 6.50 0.027 
FE, adding k = 
0.5 to O & E for 
studies with O = 
0 
9 1.39 0.29 0.93 to 2.08 0.715 
RE, adding k = 
0.5 to O and E 
for studies with 
O = 0 
9 1.39 0.29 0.93 to 2.08 0.715 
Square root scale 
FE 9 0.98 0.06 0.85 to 1.10 <0.001 
RE 9 0.99 0.45 0.29 to 2.06 <0.001 
Original scale 
FE 9 1.27 0.26 0.76 to 1.78 <0.001 
RE 9 2.31 1.15 0.06 to 4.57 <0.001 
Poisson 
regression 
9 1.27 0.29 0.81 to 1.99 0.479 
Negative 
binomial 
regression 
9 1.27 0.30 0.80 to 2.01 0.479 
Abbreviations: 
FE = Fixed effect 
RE = Random effects 
Notes: 
All non-cohort studies are included in the square root and regression analyses by assuming E = O / RR for 
each study. 
For the original scale analyses for cohort studies, it was assumed that SE(RR) = sqrt(E), and for non-
cohort studies, SE(RR) was generated from SE(log RR) using the delta method (see section 4.3.2). 
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4.7 COMPARISON OF APPROACHES USING DATA FOR 
FORMALDEHYDE AND SINONASAL CANCER 
Table 4.6 - Headline sinonasal cancer analyses – all studies 
Analysis No. of 
estimates 
Meta-RR SE (Meta-
RR) 
95% CI P-value for 
heterogeneity 
Log scale 
FE, excluding 
studies with O = 
0 
20 1.31 0.10 1.13 to 1.52 0.009 
RE, excluding 
studies with O = 
0 
20 1.34 0.16 1.06 to 1.69 0.009 
FE, adding k = 
0.5 to O & E for 
studies with O = 
0 
28 1.25 0.09 1.08 to 1.45 0.207 
RE, adding k = 
0.5 to O and E 
for studies with 
O = 0 
28 1.25 0.11 1.05 to 1.50 0.207 
Square root scale 
FE 28 1.22 0.02 1.18 to 1.25 <0.001 
RE 28 0.89 0.13 0.66 to 1.16 <0.001 
Original scale 
FE 28 1.01 0.08 0.85 to 1.17 0.388 
RE 28 1.01 0.09 0.83 to 1.18 0.388 
Poisson 
regression 
28 1.32 0.07 1.19 to 1.47 <0.001 
Negative 
binomial 
regression 
28 1.29 0.17 1.00 to 1.67 <0.001 
Abbreviations: 
FE = Fixed effect 
RE = Random effects 
Notes: 
All non-cohort studies are included in the square root and regression analyses by assuming E = O / RR for 
each study. 
For the original scale analyses for cohort studies, it was assumed that SE(RR) = sqrt(E), and for non-
cohort studies, SE(RR) was generated from SE(log RR) using the delta method (see section 4.3.2). 
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The naïve analysis for sinonasal cancer on the logarithmic scale (Table 4.6), excluded 
eight effect estimates and was statistically significantly raised for both the fixed effect 
and random effects analysis.  As for the nasopharyngeal cancer analyses, adding k = 0.5 
to the observed and expected values for each study did not materially alter the findings 
from these analyses.  The meta-RR from the fixed effect analysis on the square root 
scale was statistically significantly raised, but in the presence of highly statistically 
significant between-study heterogeneity, was not significantly raised in the random 
effects analysis.  The meta-RR from both the fixed effect and random effects analysis 
on the original scale were not statistically significantly raised, but as for the 
nasopharyngeal cancer findings, were both marginally statistically significantly raised 
from the Poisson and negative binomial regression analyses.   Restricting the sinonasal 
cancer analyses to cohort studies only (Table 4.7) did not produce any statistically 
significant findings, regardless of the scale or whether the analysis was fixed effect or 
random effects. 
Table 4.7 - Sinonasal cancer analyses – cohort studies only 
Analysis No. of 
estimates 
Meta-RR SE (Meta-
RR) 
95% CI P-value for 
heterogeneity 
Log scale 
FE, excluding 
studies with O = 
0 
3 1.06 0.26 0.65 to 1.70 0.835 
RE, excluding 
studies with O = 
0 
3 1.06 0.26 0.65 to 1.70 0.835 
FE, adding k = 
0.5 to O & E for 
studies with O = 
0 
10 0.94 0.19 0.64 to 1.39 0.981 
RE, adding k = 
0.5 to O and E 
for studies with 
O = 0 
10 0.94 0.19 0.64 to 1.39 0.981 
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Square root scale 
FE 10 0.72 0.04 0.64 to 0.71 <0.001 
RE 10 0.10 0.10 0.00 to 0.40 <0.001 
Original scale 
FE 10 0.86 0.20 0.47 to 1.26 0.914 
RE 10 0.86 0.20 0.47 to 1.26 0.914 
Poisson 
regression 
10 0.86 0.19 0.56 to 1.32 1.000 
Negative 
binomial 
regression 
10 0.86 0.19 0.56 to 1.32 1.000 
Abbreviations: 
FE = Fixed effect 
RE = Random effects 
Notes: 
All non-cohort studies are included in the square root and regression analyses by assuming E = O / RR for 
each study. 
For the original scale analyses for cohort studies, it was assumed that SE(RR) = sqrt(E), and for non-
cohort studies, SE(RR) was generated from SE(log RR) using the delta method (see section 4.3.2). 
 
When the analyses are restricted to the cohort studies only, the fixed effect analysis on 
the original scale is not statistically significant and there is no significant heterogeneity.  
None of the results on the log or square root scales provide any statistically significant 
mean relative risks. 
4.8 DISCUSSION AND CONCLUSIONS 
This chapter began with a review of the approaches that have been employed in the 
literature to date for meta-analyses of rare health outcomes.  The methods produced 
have essentially been in the context of the meta-analyses of controlled clinical trials.  
No clear conclusions are drawn about which is the optimum approach and none of the 
approaches deal with meta-analyses in occupational epidemiology. 
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For meta-analyses in occupational epidemiology three methods have been examined in 
the context of meta-analyses of occupational exposure to formaldehyde and risks of 
nasopharyngeal cancer and sinonasal cancer.  Cohort studies have been examined in 
isolation as well as in combination with other study designs. 
  When the true SMR equals one, k = 5 provided the least biased effect estimate when 
the analysis was carried out on the logarithmic scale.  Clearly is does not make sense to 
use such a large value of k in practice.  When the true SMR equals 1.5, the optimum 
value of k appears to be k = 1 and for SMR – 2, k = 0.75 appears to give the least biased 
estimate of effect.  Given that these simulations were based on a single realization it is 
difficult to generalize the findings.  However, what is clear is that analysis on the 
logarithmic scale is not appropriate for rare diseases, especially when plausible 
alternative analytical approaches exist on the original untransformed scale.The findings 
for both nasopharyngeal cancer and sinonasal cancer both gave meta-RRs that were 
statistically significantly raised when the analysis was carried out on the logarithmic 
scale.  However, analyses on the original scale using ‘metan’ in Stata or using Poisson 
or negative binomial regression suggest that the findings of an excess meta-RR are not 
robust and that determination of a causal association is not yet strongly supported.  
Analyses on the log scale causing the exclusion of studies with no observed cases are 
clearly biased and when the disease is rare has significant potential to produce 
misleading results.  Analyses on the original scale or Poisson and negative binomial 
regression are to be preferred.  Any meta-analysis or a rare disease should also include a 
good sensitivity analysis as a check on the robustness of any findings and therefore 
before any inferences are drawn. 
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5 REVIEW AND META-ANALYSIS OF THE 
EPIDEMIOLOGICAL EVIDENCE FOR THE 
CARCINOGENICITY OF FORMALDEHYDE IN 
RELATION TO LUNG CANCER, 
NASOPHARYNGEAL CANCER AND SINONASAL 
CANCER 
5.1 INTRODUCTION 
An earlier analysis of the National Cancer Institute (NCI) cohort [82] suggested that the 
association between nasopharyngeal cancer and formaldehyde exposure might be 
causal.  An assessment of robustness with respect to alternative methods of data 
analysis, including categorisations of formaldehyde exposure, was subsequently 
undertaken and concluded that the nasopharyngeal excess was centred on one plant, 
which had been separately analysed and no excess found [83], and that overall there was 
considerable uncertainty over whether or not the association was causal [84].  The NCI 
cohort analysis probably prompted the International Agency for Research on Cancer 
(IARC) to update their evaluation of formaldehyde and resulted in a determination for 
the first time of the carcinogenicity of formaldehyde in relation to nasopharyngeal 
cancer [85].  The IARC evaluation was apparently heavily dependent on the NCI 
cohort, which had previously been criticized as not being robust and this prompted 
Marsh et al to look again at the NCI cohort, this time looking at the model specification 
and the degree of instability in the risk estimates.  Marsh et al reiterated their earlier 
claim that the NCI cohort did not support the determination of a causal association for 
occupational exposure to formaldehyde and nasopharyngeal cancer [86].  Marsh et al 
subsequently carried out further analyses to determine whether the association at the 
plant with the large nasopharyngeal excess could have been due to factors other than 
formaldehyde exposure and concluded that the association might be due to silver 
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smithing and other metal work [86].  It was subsequently admitted by the NCI that there 
may have been incomplete follow-up of their cohort which may have affected the 
subsequent re-analyses by Marsh et al [87]. 
The most recent of IARC evaluation was published in 2012 [88].  In relation to the 
evidence for carcinogenicity in humans, IARC concluded that there was sufficient 
evidence for the carcinogenicity in relation to nasopharyngeal cancer, that a positive 
association was found for sinonasal cancer, and that several studies showed statistically 
significant positive associations for lung cancer.  This and a further follow-up of the 
NCI cohort [89], prompted Marsh et al to reiterate all of their earlier concerns [90].  
They subsequently published an updated re-analysis and again reiterated their earlier 
concerns about the analysis and interpretation of the NCI cohort [91]. 
This series of publications highlights the question as to what evidence exists, aside from 
the NCI cohort, for the association between occupational exposure to formaldehyde and 
the risk of nasopharyngeal.  Further examination of the epidemiological evidence in 
relation to sinonasal cancer and lung cancer is also warranted.  For the two rarer 
cancers, the impact of the exclusion of studies with no exposed cases on the totality of 
the evidence is also examined for its potential impact on any inferences drawn. 
5.1.1 Distribution of absorption of formaldehyde in the human body 
Formaldehyde is produced endogenously in the body and is an essential metabolic 
intermediate in all human cells [92].  Formaldehyde is also a skin irritant and can cause 
allergic contact dermatitis [92].  The production of DNA-protein cross-links induced by 
a single six hour exposure to formaldehyde has been compared in several regions of the 
upper respiratory tract of F-344 rats and rhesus monkeys.  Concentrations of the cross-
links in the nasal mucosa were significantly lower in the monkeys than in the rats.  
Cross-links were also detected in the nasopharynx and trachea of the monkeys, but not 
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in the nasal sinus, proximal lung or the bone marrow [93].  It is possible, however, for 
formaldehyde to reach the lung when adsorbed to particulates [92].  The distance from 
the nostrils to the nasopharynx is usually proportional to head and snout length, which 
varies widely in rodents, in which atrioturbinates in the nasal vestibule, a structure 
which is lacking in humans, act as baffles which deflect large volumes of air away from 
the nasopharynx [94].  The site-specific flux of formaldehyde into tissue is heavily 
dependent on the proportion and concentration of the inhaled formaldehyde coming into 
contact with the tissue [95].  Thus, it is reasonable to conclude that any carcinogenic 
risk in humans might extend to respiratory organs beyond the nasal cavity, other than 
the nasal sinuses, but that the exact dose to a particular tissue depends on a number of 
factors including the level of formaldehyde inhaled.  There is also experimental 
evidence that formaldehyde causes nasal cancer in rats [96]. 
5.1.2 The known and suspected risk factors for nasopharyngeal cancer, sinonasal 
cancer and lung cancer 
Cancer of the nasopharynx is rare in England and Wales, with about 200 new cases per 
year in adults.  Annual incidence rates are about 0.4 per 100,000 in men and 0.2 per 
100,000 in women [97].  Nasopharyngeal cancer is believed to result from a 
combination of genetic susceptibility, infection with Epstein-Barr virus and regular 
consumption of salted fish in childhood [98].  Smoking is not regarded as a risk factor 
for nasopharyngeal cancer. 
Cancers of the nasal cavity and paranasal sinuses are uncommon.  There are about 400 
new cases per year in England and Wales, with incidence rates of 1 per 100,000 in men 
and 0.5 per 100,000 in women [97].  Wood dust and selected nickel compounds, 
especially oxides and sulphides involved in nickel refining cause cancer of the nasal 
cavities and paranasal sinuses.  Hexavalent chromium compounds and untreated and 
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mildly treated mineral oils cause cancer of the nasal sinuses according to the IARC 
classification [99].  Smoking is not regarded as a risk factor for cancers of the nasal 
cavity or paranasal sinuses. 
Lung cancer is the most common cancer in men in England and Wales, accounting for 
about one in four cancers (25,000 cases per year), and the third most common in women 
(1 in 9; 12,000 cases per year).  Lung cancer accounts for 6% of deaths from all causes.  
Incidence rates are typically for developed countries, about 100 per 100,000 per year for 
men and 45 per 100,000 for women [97].  Aside from tobacco smoking, IARC has 
classified many exposures as definitely causing lung cancer: ionising radiation 
including X-rays, gamma-rays, neutrons and radon gas;  asbestos;  crystalline silica;  
talc containing asbestiform fibres;  arsenic and arsenical compounds;  beryllium;  
cadmium and cadmium compounds;  selected nickel compounds including 
combinations of oxides and sulphides involved in nickel refining;  coal and tar pitches;  
untreated and mildly treated mineral oils;  soots;  bis(chloromethyl) ether and technical 
grade chloromethyl ether;  2,3,7,8-tetrachlorodibenzo para-dioxin;  passive smoking;  
mustard gas;  and strong acid mists containing sulphuric acid [99].  Also classified as 
probably lung carcinogens are: benz[a]anthracene;  benz[a]pyrene;  
dibenz[a,h]antracene;  diesel engine exhaust;  alpha-chlorinated toluenes;  
epichlorohydrin;  and nonarsenical insecticides [99]. 
5.1.3 Formaldehyde and its industrial use 
Formaldehyde has the molecular formula CH2O.  At room temperature it is a colourless 
gas with a pungent odour.  In 1992, about 12 million tonnes were produced worldwide.  
Formaldehyde is produced by catalytic vapour phase oxidation of methanol, and is most 
commonly commercially available as an aqueous solution commonly referred to as 
‘formalin’.  The widest use of formaldehyde is in the production of resins with urea, 
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phenol and melamine and, to a small extent, their derivatives.  Formaldehyde-based 
resins are used in adhesives and impregnating resins in the manufacture of particle-
board, plywood, furniture and other wood products.  The resins are also used in the 
production of curable moulding materials and as raw materials for surface coatings and 
controlled-release nitrogen fertilisers.  They are also used in the textile, leather, rubber 
and cement industries.  Further uses are as binders for foundry sand, stonewool and 
glasswool mats in insulating materials, abrasive paper and brake linings.  Formaldehyde 
itself is used for preservation and for disinfection, for example it is used in human and 
vetinary drugs and biological materials, for disinfecting hospital wards and for 
preserving and embalming biological specimens.  It is used as an antimicrobial agent in 
many cosmetic products.  It is also used directly to inhibit corrosion, in mirror finishing, 
electroplating, in the electrodisposition of printed circuits, and in photographic film 
development [92].  Formaldehyde is also present in tobacco smoke [100]. 
5.1.4 Formaldehyde exposure in different occupational circumstances 
This section contains a brief overview of the formaldehyde exposures encountered in a 
range of occupational circumstances that have been the subject of epidemiological 
investigations.  Table 5.1 sets out the results of a selection of the results of hygiene 
surveys that have been carried out in relation to exposure to formaldehyde in the 
workplace.  It is presented for illustration purposes only and is not meant to be a full 
review, but rather a brief overview. 
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Table 5.1 - Brief overview of formaldehyde exposures in workplaces 
Occupational 
circumstances 
Exposure 
range (ppm) 
Arithmetic mean exposure level (ppm) Personal (P) or Area 
(A) sample 
Reference 
Formaldehyde 
manufacture 
ND
(1)
-4.78  P Stewart et al, 1987[101] 
Funeral homes 0.09-5.26 
0.12-5.64 
0.11-4.12 
0.05-8.37 
0.18-0.43 
0.00-2.11 
0.31-8.72 
0.23-7.52 
0.28-8.15 
0.25-1.39 (range across 6 funeral homes) 
0.78 
0.80 
0.61 
0.27 
0.88 
2.58 
2.03 
2.16 
A 
P 
P 
A 
P 
P 
P 
A 
P 
Kerfoot & Mooney, 1975 [102] 
Korczynski, 1994 [103] 
 
 
Williams et al, 1984[104] 
 
Stewart et al, 1992 [105] 
Anatomy 
laboratories 
0.30-2.63 
0.07-2.94 
0.24-5.87 
0.31-6.77 
0.18-1.29 
1.25
(2) 
1.24 
1.69 
1.53 
0.50 
P 
P 
P 
P 
A 
Skisak, 1983 [106] 
Akbar-Khanzedah et al, 1994 [107] 
Perkins & Kimbrough, 1985 [108] 
Pathology 
laboratories 
<0.10-13.57 
2.2-7.9 
 P 
A 
Coldiron et al, 1983[109] 
Bernstein et al, 1984[110] 
Garment factory 0.46-1.13 
0.43-1.30 
0.42-1.40 
0.82 
0.92 
1.05 
P 
A 
A 
Luker & Van Houten, 1990 [111] 
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Occupational 
circumstances 
Exposure 
range (ppm) 
Arithmetic mean exposure level (ppm) Personal (P) or Area 
(A) sample 
Reference 
Fertilizer 
production 
0.2-1.9  A Bernstein et al, 1984 [110] 
Dyestuffs 
manufacture 
<0.1-5.8  A Bernstein et al, 1984 [110] 
Resins manufacture <0.1-5.5 
ND-43.2 
 A 
P 
Bernstein et al, 1984 [110] 
Stewart et al, 1987[101] 
Iron foundry 0.12-0.8  A Bernstein et al, 1984 [110] 
Treated paper 0.14-0.99  A Bernstein et al, 1984 [110] 
Plywood 
manufacture 
1.0-2.5  A Bernstein et al, 1984 [110] 
Furniture 
manufacture 
<0.1-6.1 1.16 
0.06 
A 
P 
Priha et al, 1986 [112] 
Sass-Kortsak et al, 1986 [113] 
Woodworking  0.10 P Partanen et al, 1985 [114] 
Urea-formaldehyde 
foam application 
<0.08-2.4  A Bernstein et al, 1984[110] 
Molding compound 
manufacture 
ND-79.5  P Stewart et al, 1987 [101] 
Molded plastic 
products 
manufacture 
ND-44.5  P Stewart et al, 1987 [101] 
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Occupational 
circumstances 
Exposure 
range (ppm) 
Arithmetic mean exposure level (ppm) Personal (P) or Area 
(A) sample 
Reference 
Decorative 
laminates 
manufacture 
ND-13.46  P Stewart et al, 1987 [101] 
Plywood panelling 
manufacture 
ND-2.01  P Stewart et al, 1987 [101] 
Photographic film 
manufacture 
ND-4.49  P Stewart et al, 1987 [101] 
(1) ND = Not detectable 
(2) Estimated from presented summary of data 
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Since non-occupational exposure to formaldehyde is ubiquitous, all work contributes to 
total human exposure.  The mean concentrations of formaldehyde measured in the 
1980s during the manufacture of formaldehyde and formaldehyde-based resins were 
below 1 ppm.  In the wood and pulp and paper industries, the highest mean 
concentrations are usually in gluing departments and the mean levels were usually >1 
ppm before the mid-1970s, but have been below that since.  The levels of formaldehyde 
measured in particle-board mills before the mid-1970s were high – often well over 2 
ppm – but the development of glues with lower formaldehyde content and improved 
ventilation have decreased the levels to about 1 ppm or below.  Measurements of 
formaldehyde in the garment industry from the 1980s were relatively low, averaging 
0.1-0.2 ppm.  Phenol-formaldehyde resins are commonly used to bind man-made 
mineral fibre products; measurements in the 1980s showed mean concentrations of 0.1-
0.2 ppm of formaldehyde.  The mean concentrations of formaldehyde measured during 
the coating of photographic film and during the development of photographs are usually 
well below 1 ppm.  The concentration of formaldehyde in the air during embalming 
depends on the content of the embalming fluid, type of the body, ventilation and work 
practices; the mean level is about 1 ppm.  The mean concentration when used in 
hospitals for disinfection ranges from 0.1 to 0.8 ppm.  The mean formaldehyde 
concentration in histopathology laboratories is usually around 0.5 ppm [92]. 
5.1.5 Brief Summary of the toxicological evidence 
Formaldehyde has acute effects in mammals.  Inhalation of high concentrations (> 120 
mg/m
3
) of formaldehyde causes hypersalivation, acute dyspnea, vomiting, muscular 
spasms, convulsions and finally death.  Histopathological examination shows 
respiratory tract irritation, bronchioalviolar constriction and lung oedema.  
Formaldehyde is irritating to the eyes, and aqueous solutions of formaldehyde (0.1% to 
20%) are irritating to the skin of rabbits [115]. 
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In humans transient and reversible sensory irritation of the eyes and respiratory tract has 
been observed in clinical studies and epidemiological surveys.  The odour threshold for 
most people ranges between 0.5 and 1 ppm.  In general, eye irritation, the most sensitive 
endpoint, is associated with airborne concentrations beginning in the range 0.3 to 0.5 
ppm.  Formaldehyde causes skin irritation and has corrosive properties when ingested.  
Contact dermatitis can occur at concentrations as low as 30 ppm [115]. 
Formaldehyde is a highly reactive gas that is absorbed quickly at the point of contact 
and is also produced by endogenous metabolism.  It is rapidly metabolised such that 
exposure to high concentrations (up to 15 ppm in rats) does not result in increased blood 
concentrations.  Repeated formaldehyde exposure causes toxic effects only in the tissues 
of direct contact after inhalation, and oral or dermal exposure is characterised by local 
cytotoxic destruction and subsequent repair of the damage.  The typical locations of 
lesions in experimental animals were the nose after inhalation, the stomach after oral 
administration and the skin after dermal application.  The nature of the lesions depends 
on the inherent abilities of the tissues involved to respond to the noxious event and the 
local concentration of the substance [115]. 
Formaldehyde is weakly genotoxic and is able to induce chromosomal aberrations in 
mammalian cells.  DNA-protein crosslinks are a sensitive measure of DNA 
modification by formaldehyde.  However, the genotoxic effect is limited to those cells, 
which are in direct contact with formaldehyde.  Formaldehyde is therefore a direct 
acting locally effective mutagen [115]. 
Chronic inhalation of concentrations of 10 ppm and higher can lead to clear increases in 
nasal tumour incidence in rats.  Most of the nasal tumours are squamous cell 
carcinomas.  Marked non-neoplastic pathological lesions of the nasal epithelium 
accompanied them.  No increased incidence has been found in other organs after 
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inhalation and via administration routes other than inhalation does not result in local or 
systemic tumour formation.  The damage of nasal tissue plays a crucial role in the 
tumour induction process, since nasal cancer is only found at concentrations inducing 
epithelial degeneration and increased cell proliferation.  Thus the stimulation of cell 
proliferation seems to be an important pre-requisite for tumour development.  Although 
formaldehyde exhibits some genotoxic activity, the correlation between cytotoxicity, 
cell proliferation and the induction of nasal cancer in rats provides a convincing 
scientific basis for the aetiology of the carcinogenic response to be cytotoxicity driven.  
In contrast, no significant numbers of tumours have been seen in mice and Syrian 
hamsters following chronic exposures to concentrations up to 14.3 or 30 ppm, 
respectively.  These clear species differences appear to be related, in part, to the local 
dosimetry and disposition of formaldehyde in nasal tissues.  Species differences in nasal 
anatomy and respiratory physiology may have a profound effect on susceptibility to 
formaldehyde induced nasal tumours [115]. 
5.1.6 IARC reviews of the carcinogenicity of formaldehyde 
In their 1995 review, IARC classified formaldehyde as probably carcinogenic to 
humans [92].  A more recent review by the IARC working group resulted in a 
classification of formaldehyde as definitely carcinogenic to humans [116].  The latest 
IARC monograph noted that one industrial cohort study had both a strong overall 
association between exposure to formaldehyde and nasopharyngeal cancer and the most 
elevated risks were in the highest exposure category.  In addition, however, there were 
also positive associations in many of the case-control studies, particularly the larger 
ones and those with higher-quality exposure assessment.  Although there were no 
associations in the two other large industrial cohort studies, the expected number of 
cases in both of those studies was quite small.  Thus IARC concluded, given it was 
unlikely that bias or confounding could explain the observed association, that 
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occupational exposure to formaldehyde causes nasopharyngeal cancer in humans.  
IARC also noted that many case-control studies showed positive associations for 
exposure to formaldehyde and sinonasal cancer, some with evidence of an exposure-
response pattern.  However, many of the studies included co-exposure to wood dust, 
which is strongly associated with sinonasal cancer.  The industrial cohorts show no such 
association and this could be due to a lack of statistical power, or could indicate that 
uncontrolled confounding to wood dust partially explains the observed associations in 
case-control studies.  Finally in relation to lung cancer IARC noted that several studies 
identified statistically significant positive associations with formaldehyde exposure, but 
that the results were inconsistent. 
5.1.7 Previous meta-analyses of formaldehyde and respiratory cancer 
To date, eight meta-analyses have been published examining the carcinogenicity of the 
respiratory system from workplace exposures to formaldehyde (see Table 5.2 for key 
findings) [76, 117-123]. 
The first of these examined deaths among males for a variety of cancer sites, including 
the buccal cavity and pharynx, the nose and the lung from nine different studies [117].  
Analysis of mortality among workers at chemical plants gave rise to a meta-RR for 
buccal cavity and pharynx cancer of 0.74 (0.24 to 1.74), based on 5 deaths from three 
studies.  There were no deaths from nasal cancer against 1.07 expected and the meta-RR 
for lung cancer was 0.95 (0.83 to 1.09) based on 216 deaths from three studies.  For 
exposure among male pathologists, anatomists and morticians, the meta-RR for buccal 
cavity and pharynx cancer was 0.81 (0.48 to 1.29), based on 18 deaths from four 
studies.  There were no nasal cancer deaths against 1.8 expected, and the meta-RR for 
lung cancer was 0.80 (0.68 to 0.94) based on 162 deaths from six studies, and this was a 
statistically significant deficit.  The authors reported that there had been two case-
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control studies of formaldehyde that had detected no increased risk for lung cancer.  
They concluded that the data provided little evidence for the carcinogenicity of 
formaldehyde in humans at site of contact, for example the buccal cavity and pharynx 
and the nose, and that the number of deaths from lung cancer was clearly not in excess 
among formaldehyde-exposed groups [117]. 
Table 5.2 – Results of previous meta-analyses of formaldehyde in relation to 
nasopharyngeal cancer, sinonasal cancer and lung cancer 
Meta-
analysis 
number 
Meta-
analysis/Cancer 
Site 
Industrial 
Cohorts 
Meta-RR (95% 
CI) 
[No. studies, No. 
cases] 
Cohorts of 
Professionals 
(Anatomists,  
Pathologists and 
Morticians) 
Meta-RR (95% CI) 
[No. studies, No. 
cases] 
Non-nested case-
control Studies 
Meta-RR (95% 
CI) 
No. studies/No. 
exposed cases 
1 Levine et al, 1984 
[117] 
Buccal cavity & 
pharynx 
Nose 
 
Lung 
 
 
 
 
0.74 (0.24 to 1.74) 
[3, 5] 
0.00 (0.00 to 2.80) 
[3, 0] 
0.95 (0.83 to 1.09) 
[3, 216] 
 
 
 
0.81 (0.48 to 1.29) 
[4, 18] 
0.00 (0.00 to 1.66) 
[5, 0] 
0.80 (0.68 to 0.94) 
[6, 162] 
 
 
 
Two case-control 
studies detected no 
increased risk for 
lung cancer 
2 Nelson et al, 1986 
[118] 
Buccal cavity & 
pharynx 
Nose 
 
Lung 
 
 
 
1.64 (0.79 to 3.01) 
[3, 10] 
0.00 (0.00 to 3.35) 
[6, 0] 
1.09 (0.96 to 1.24) 
[6, 245] 
 
 
1.04 (0.55 to 1.35) 
[4, 21] 
0.00 (0.00 to 2.05) 
[5, 0] 
0.74 (0.64 to 0.86) 
[5, 178] 
 
 
Three case-control 
studies provide 
indications of a 
possible association 
for nasal cancer. 
Two case-control 
studies detected no 
increased risk for 
lung cancer 
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Meta-
analysis 
number 
Meta-
analysis/Cancer 
Site 
Industrial 
Cohorts 
Meta-RR (95% 
CI) 
[No. studies, No. 
cases] 
Cohorts of 
Professionals 
(Anatomists,  
Pathologists and 
Morticians) 
Meta-RR (95% CI) 
[No. studies, No. 
cases] 
Non-nested case-
control Studies 
Meta-RR (95% 
CI) 
No. studies/No. 
exposed cases 
3 Blair et al, 1990 
[119](1) 
Nasopharynx 
 
Nose 
 
Lung 
 
 
 
1.22 (0.86 to 1.73) 
[4, 36] 
1.07 (0.81 to 1.38) 
[12, 60] 
1.06 (1.02 to 1,14) 
[14, 1181] 
 
 
2.22 (0.61 to 5.69) 
[2, 4] 
0.42 (0.01 to 2.32) 
[4, 1] 
0.89 (0.80 to 0.95) 
[13, 511] 
 
 
Results presented 
for all study types 
combined 
 
4 Partanen, 1993 
[124] 
Nasopharynx 
 
Sinonasal 
 
Lung 
 
 
1.74 (1.21 to 2.41) 
[4, 36] 
1.19 (0.96 to 1.46) 
[11, 93] 
1.11 (1.03 to 1.19) 
[14, 833] 
 
 
 
2.22 (0.61 to 5.69) 
[2, 4] 
0.42 (0.01 to 2.32) 
[4, 1] 
0.88 (0.80 to 0.95) 
[13, 511] 
 
 
 
Results presented 
for all study types 
combined 
 
 
5 Collins et al, 1997 
[76] 
Nasopharynx 
 
Sinonasal 
 
Lung 
 
 
 
 
1.36 (0.50 to 2.97) 
[6, 6] 
0.6 (0.1 to 1.7) 
[6, 3] 
1.1 (1.0 to 1.2) 
[6, 757] 
 
 
0.91 (0.25 to 2.33) 
[8, 4] 
0.00 (0.0 to 1.0) 
[6, 0] 
0.77 (0.71 to 0.83) 
[8, 562] 
 
 
1.3 (0.9 to 2.1) 
[6, 445] 
1.8 (1.4 to 2.3) 
[11, 933] 
0.8 (0.7 to 1.0) 
[6, 301] 
6 Bosetti et al, 2008 
[121] 
Nasopharynx 
 
Sinonasal 
 
Lung 
 
 
 
1.33 (0.61 to 2.53) 
[3, 9] 
1.01 (0.33 to 2.35) 
[3, 5] 
1.07 (1.01 to 1.12) 
[6, 1459] 
 
 
Not presented 
 
0.00 (0.00 to 3.51) 
[7, 0] 
0.68 (0.63 to 0.74) 
[13, 703] 
 
 
Only considered 
cohort studies. 
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Meta-
analysis 
number 
Meta-
analysis/Cancer 
Site 
Industrial 
Cohorts 
Meta-RR (95% 
CI) 
[No. studies, No. 
cases] 
Cohorts of 
Professionals 
(Anatomists,  
Pathologists and 
Morticians) 
Meta-RR (95% CI) 
[No. studies, No. 
cases] 
Non-nested case-
control Studies 
Meta-RR (95% 
CI) 
No. studies/No. 
exposed cases 
7 Bachand et al, 2010 
[125] 
Nasopharynx 
(No data presented 
for sinonasal cancer 
or for lung cancer) 
 
 
0.72 (0.40 to 1.29) 
[11, 39] 
 
 
 
Not examined. 
 
 
1.22 (1.00 to 1.50) 
[7, 502] 
8 Binazzi et al, 2015 
[123] 
Sinonasal cancer  
(No data presented 
for nasopharyngeal 
cancer or for lung 
cancer) 
 
 
1.09 (0.66 to 1.79) 
[2, not presented] 
 
 
Not separately 
examined. 
 
 
1.68 (1.37 to 2.06) 
[6, not presented] 
 Notes:  
(1) For Blair et al, studies of non-occupational exposures were grouped with 
exposures to professionals. 
In addition, where confidence intervals were not presented, they have been calculated 
using exact methods. 
 
The second meta-analysis also examined mortality for a variety of cancer sites including 
cancers of the buccal cavity and pharynx, the nose and the lung from 12 different 
studies [118].  Among studies of chemical and garment industry workers, the meta-RR 
for cancer of the buccal cavity and pharynx was 1.64 (0.79 to 3.01) based on 10 deaths 
from three studies.  There were no deaths from nasal cancer, with 1.1 expected, and the 
meta-RR for lung cancer was 1.09 (0.96 to 1.24) based on 245 deaths from six studies.  
Among studies of pathologists, anatomists and morticians, the meta-RR for cancer of 
the buccal cavity and pharynx was 1.04 (0.55 to 1.35) based on 21 deaths from four 
studies.  There were no deaths from nasal cancer against 1.8 expected, and the meta-RR 
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for lung cancer was 0.74 (0.64 to 0.86), based on 178 deaths from five studies, a 
statistically significant deficit.  As in the report of the first meta-analysis [117], there 
were two case-control studies of formaldehyde exposure that detected no increased risk 
for lung cancer.  However, there were also three other case-control studies that provided 
indications of a possible association between formaldehyde exposure and nasal cancer.  
On the basis of no deaths from nasal cancer in SMR or PMR studies, but three case-
control studies suggesting the possibility of an increased risk of nasal cancer, the 
authors concluded that there was limited epidemiological evidence for the human 
carcinogenicity of formaldehyde [118]. 
The third meta-analysis also examined mortality for a variety of cancers in over 30 
discrete study populations [119].  Among industrial worker cohorts the meta-RR for 
nasopharyngeal cancer was 1.22 (0.86 to 1.73), based on 36 cases from four studies.  
The meta-RR for nasal cancer was 1.07 (0.81 to 1.38) based on 60 deaths from 11 
studies, and the meta-RR for lung cancer was 1.06 (1.02 to 1.14) based on 1181 deaths 
from 14 studies, a statistically significant excess.  Among professional and non-
occupationally exposed groups, the meta-RR for nasopharyngeal cancer was 2.22 (0.61 
to 5.69) based on four deaths from two studies.  For nasal cancer the meta-RR was 0.42 
(0.01 to 2.32), based on a single death from four studies.  The meta-RR for lung cancer 
was 0.88 (0.80 to 0.95) based on 511 deaths from 13 studies, a statistically significant 
deficit.  The risk of nasal cancer was evaluated by exposure level or duration of 
exposure to formaldehyde.  When the observed and expected numbers from the various 
studies were combined, no exposure response gradient was evident from the combined 
RR values.  In contrast, the data for nasopharyngeal cancer showed a statistically 
significantly positive trend of increased mortality risk with increased exposure.  There 
were no significant trends between level of formaldehyde exposure and risk of death 
from lung cancer.  The authors concluded that it was likely that the excesses of 
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nasopharyngeal cancer observed were caused by exposure to formaldehyde, and that an 
association with nasal cancer was plausible, but somewhat less persuasive than that for 
nasopharyngeal cancer.  They also concluded that although a role for formaldehyde in 
the excess of lung cancer could not be dismissed, inconsistencies among and within 
studies of industrial workers suggested that the association was not causal.  They went 
on to suggest that other interpretations were possible and that formaldehyde might be an 
effective carcinogen only in the presence of other exposures which were not consistent 
from study to study, or it may be a weak carcinogen whose effect was easily masked by 
the presence of lung carcinogens that varied from study to study [119]. 
In order to further clarify the findings of the third meta-analysis, a fourth meta-analysis 
has been published [124] which scrutinised the findings of the third meta-analysis [119] 
in relation to respiratory system cancers.  The main difference between the third meta-
analysis [119] and the fourth meta-analysis [124] lay in the choice of  the risk estimates 
used in the meta-analysis.  Despite a fair number of changes in the input values, the 
results of the reanalysis agreed generally well with those of the original analysis.  Thus 
the author concluded that cancers of the nasopharynx and nose appear to be the most 
likely targets for the carcinogenic action of formaldehyde in humans that it remained 
unlikely that workplace exposures to formaldehyde posed any substantial cancer hazard 
among humans [124]. 
A fifth meta-analysis of formaldehyde exposure and respiratory system cancers included 
results from 47 studies [76].  In industrial cohorts, the meta-RR for nasopharyngeal 
cancer was 1.36 (0.50 to 2.97), based on six deaths from six studies.  The meta-RR for 
sinonasal cancer was 0.6 (0.1 to 1.7), based on three deaths from six studies.  For lung 
cancer the meta-RR was 1.1 (1.0 to 1.2), based on 757 deaths from six studies, a result 
that is marginally statistically significant. Among cohorts of pathologists and 
embalmers, the meta-RR for nasopharyngeal cancer was 0.91 (0.25 to 2.33), based on 
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four deaths from eight studies.  There were no sinonasal cancer deaths and the meta-RR 
for lung cancer was 0.77 (0.71 to 0.83), based on 562 deaths from eight studies, a 
statistically significant deficit.  From non-nested case-control studies, the meta-RR for 
nasopharyngeal cancer was 1.3 (0.9 to 2.1), based on 445 exposed cases from six 
studies.  The meta-RR for sinonasal cancer was 1.8 (1.4 to 2.3), based on 933 exposed 
cases from 11 studies, a statistically significant excess.  For lung cancer the meta-RR 
was 0.8 (0.7 to 1.0), based on 301 exposed cases from six studies, a marginally 
statistically significant deficit.  For nasopharyngeal cancer the authors concluded that 
the cohort studies did not show an overall excess when corrected for unreported data 
and that, taken together, the cohort and case-control studies did not provide convincing 
evidence of a causal relationship between formaldehyde and nasopharyngeal cancer.  
For sinonasal cancer, they concluded overall that the data did not suggest a relationship 
with formaldehyde exposure, although many studies did not distinguish between 
cancers of the nasal cavity and nasal sinuses, since formaldehyde does not seem to 
penetrate into the nasal sinuses where most human sinonasal cancer originate.  The 
authors concluded that the results of the meta-analysis suggested there was no 
relationship between lung cancer and formaldehyde exposure [76]. 
A subsequent sixth meta-analysis examined the evidence for carcinogenicity in cohort 
studies of industrial and professional workers [121].  The relative risk for 
nasopharyngeal cancer in industrial cohorts was 1.33 (0.61 to 2.53) based on nine 
deaths from three studies.  For sinonasal cancer, the meta-RR from industrial cohorts 
was 1.01 (0.33 to 2.35) based on five deaths from three studies and for lung cancer the 
meta-RR was 1.07 (1.01 to 1.12) based on 1459 cases from six studies, an excess that 
was statistically significant.  Nasopharyngeal cancer was not examined.  There was no 
sinonasal cancer deaths in the studies looked at and the meta-RR for lung cancer was 
0.68 (0.63 to 0.74) based on 703 deaths from 13 studies, a statistically significant 
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deficit.  The authors concluded that a comprehensive review of cancer in industry 
workers and professionals exposed to formaldehyde showed no appreciable excess risk 
for pharyngeal, sinonasal or lung cancers. 
In a more recent seventh meta-analysis of nasopharyngeal cancer, the meta-RR was 0.72 
(0.40 to 1.29) based on 39 deaths from 11 cohort studies [125].  From case-control 
studies, the meta-RR was 1.22 (1.00 to 1.50) based on 502 exposed cases from seven 
studies.  The authors concluded that restricting attention to stronger cohort and case-
control study designs, considering the effects of smoking, and ignoring the results from 
an anomalous plant in the NCI cohort study, their meta-analysis provided little support 
for a causal relationship between formaldehyde exposure and nasopharyngeal cancer. 
The most recent eighth meta-analysis examining the relationship between formaldehyde 
exposure and sinonasal cancer produced a meta-RR of 1.68 (1.37 to 2.06) for case 
control and 1.09 (0.66 to 1.79) for cohort studies.  The authors concluded that their 
summary risk estimate strongly suggested that exposure to formaldehyde increased the 
risk of developing sinonasal cancer. 
In terms of the choice of effect estimates to extract from the individual studies, it is 
interesting to note that Partanen in his meta-analysis [124] criticized the earlier meta-
analysis by Blair et al [119] for not adopting the general principle of contrasting the risk 
connected with formaldehyde exposure that exceeded background exposure to that 
associated with background exposure (so called unexposed).  Partanen stated that the 
predetection latency period was accounted for when lagged inputs (referring to a period 
of 10 years after the onset of exposure) could be used in the meta-analysis and in 
addition confounder-adjusted values whenever available. 
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5.1.8 Motivation and scope of this meta-analysis 
The controversy over the so-called anomalous factory in the NCI cohort (see opening 
section of this Chapter), together with inconsistencies in the findings of the meta-
analyses, caused sometimes by different inclusion criteria for the meta-analysis that 
have been conducted, and the exclusion from quantitative consideration of the cohort 
studies that have no cases, all emphasise the complex nature of the epidemiological 
literature.  The aim of this meta-analysis was to determine: 
(i) whether there is evidence that occupational exposure to formaldehyde might 
be associated with an increased risk of lung cancer; 
(ii) how robust is the conclusion in relation to nasopharyngeal cancer 
determined by IARC [88]; and 
(iii) how robust is the conclusion in relation to sinonasal cancer from the most 
recent meta-analysis [123].   
An updated meta-analysis is also timely, because of recent updates to the three large 
industrial cohorts [89, 126, 127]. 
5.2 METHODS 
The reporting for this meta-analysis carried out in this Chapter will follow the MOOSE 
guidelines [128].  The checklist is set out in Table 5.3. 
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Table 5.3 – MOOSE checklist for meta-analyses in observational epidemiology 
Study Characteristic Items to be reported 
Background Problem definition 
Hypothesis statement 
Description of study outcome(s) 
Type of exposure 
Type of study designs used 
Study population 
Search strategy Qualifications of searchers (e.g. librarians, investigators) 
Search strategy, including time period included in the synthesis 
and keywords 
Efforts to include all available studies, including contact with 
authors 
Databases and registries searched 
Search software used, name and version, including special 
features (e.g. explosion) 
Use of hand searching (e.g. reference lists of obtained articles) 
List of citations located and those excluded, including 
justification 
Method of addressing articles published in languages other than 
English 
Method of handling abstracts and unpublished studies 
Description of any contact with authors 
Methods Description of relevance or appropriateness of studies 
assembled for assessing the hypothesis to be tested 
Rationale for the selection and coding of data 
Documentation of how data were classified and coded 
Assessment of confounding 
Assessment of study quality, including blinding of study 
assessors;  stratification or regression on possible predictors of 
study results 
Assessment of heterogeneity 
Description of statistical methods (e.g. complete description of 
fixed or random effects models, justification of whether the 
chosen models account for predictors of study results, dose-
response models, or cumulative meta-analysis) in sufficient 
detail to be replicated. 
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Study Characteristic Items to be reported 
Provision of appropriate tables and graphs 
Results Graphic summarizing individual study estimates and overall 
estimate 
Table giving description of for each study included 
Results of sensitivity testing (e.g. subgroup analysis) 
Indication of statistical uncertainty of findings 
Discussion Quantitative assessment of bias (e.g. publication bias) 
Justification of exclusion (e.g. exclusion of non-English-
language citations) 
Assessment of quality of included studies (in this case the 
Newcastle-Ottawa scale [129] for use with cohort and case-
control studies) 
Conclusions Consideration of alternative explanations for observed results 
Generalisation of conclusions (i.e. appropriate for the data 
presented and within the domain of the literature review) 
Guidelines for future research 
Disclosure of funding source 
5.2.1 Study identification 
Epidemiological studies (no restriction on study design) that examined the risk of 
nasopharyngeal cancer, sinonasal cancer, or lung cancer (mortality or cancer incidence) 
from occupational exposure to formaldehyde were originally identified by searching 
online the databases Medline and Embase covering papers from 1980 to the latest 
available in August 2002.  This included papers published in languages other than 
English.  The searches were carried out in consultation with qualified librarians from the 
Health and Safety Executive’s Information Centre in Sheffield, who had many years of 
experience of searching scientific databases.  Search terms that were used for 
formaldehyde were: formaldehyde, formalin, fannoform, formalith, formic aldehyde, 
formol, fyde, lysoform, methaldehyde, methanal, methyl aldehyde, methylene oxide, 
methyl oxide, morbicid, oxomethane, oxymethylene, paraform or supersyloform.  
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Occupational studies were identified using the terms: occupation*, work*, employ*, 
job*, industry*, labor* and labour*.  Cancers of the respiratory system were identified 
using: nasopharyn*, nose, nasal, pharynx*, respira*, thorax*, thorac*, trachea*, chest*, 
windpipe*, lung*, pulmon*, pneumo*, laryn*, glott*, epiglott*, bronch*, alveoli*, 
pleura*, and pleuri* combined with cancer*, tumour*, tumor*, neoplasm*, and 
carcinoma*.  Thus potentially relevant papers were identified if they contained at least 
one of the terms for formaldehyde, occupational studies and a relevant tumour.  
Citations from the relevant previously published meta-analyses [76, 117-119, 124] were 
also used, together with any other relevant papers already held.  Some papers included 
in the previous meta-analyses were obtained by contacting the principal author of one of 
the meta-analyses [76].  Citations were examined for other relevant studies, particularly 
the bibliographies of two more recent meta-analyses involving formaldehyde and 
pancreatic cancer and leukaemia [130, 131].  Material not published in the scientific 
literature and abstracts were not specifically searched for, but were obtained where 
possible, if cited in a previous meta-analysis. 
The literature search was supplemented by a search of PubMed and Medline from 2002 
to April 2016 carried out by the author of this work, with advice from a university 
librarian, using the same search strings as set out above, and inclusion of any additional 
studies cited in the more recent meta-analyses [121, 123, 125]. 
5.2.2 Selection criteria for study inclusion in the meta-analysis 
Studies were included in the meta-analysis if they contained a risk estimate that allowed 
inclusion in a meta-analysis of occupational exposure to formaldehyde in relation to at 
least one of the cancers of interest: nasopharyngeal cancer, sinonasal cancer and lung 
cancer. 
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Studies which presented a relative risk without a measure of uncertainty and a means of 
calculating one were excluded for example Petersen, 1980, Hernberg et al, 1983, Zhang 
& Jiang, 1988 and Krieger 1983 [132-134].  Studies where formaldehyde was not of 
interest or was not of interest in relation to respiratory cancer such as Dubrow & 
Wegman, 1984 and Band et al, 1997 [135, 136], and studies where the exposure was not 
occupational for example Friedman & Ury 1983, Vaughan et al, 1986 and Walrath et al, 
1985 [137-139] were also excluded.  Studies not examining a cancer site of interest 
were also excluded such as Zhang & Jiang, 1988[134]. 
Studies where there was potential for substantial co-exposure to another occupational 
respiratory carcinogen, but where the risk associated with formaldehyde exposure was 
not adjusted for these co-exposures were not included, for example Coggon et al, 1984, 
Costanini et al, 1989, and Chiazze et al, 1997 [140-142]. 
Studies that were updated by subsequent studies or studies where more than half the 
study subjects were included in a subsequent study were also excluded for example  
Marsh et al 1996, Fayerweather et al, 1983 and Liebling et al, 1984 [143-145]. 
5.2.3 Extraction and coding of study characteristics 
Where there was a choice of more than one risk estimate to extract, the following 
preferences were made: 
 Where a subpopulation of a study were assessed as having been the only 
part of the cohort occupationally exposed to formaldehyde, then results 
for the exposed sub-cohort were extracted, for example Beane Freeman 
et al [89]. 
 Where there existed co-exposure to another occupational respiratory 
carcinogen, but rather than adjust for the co-exposure, the data were 
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presented for those exposed to formaldehyde in the absence of the co-
exposure, then these results were extracted, for example Partanen et al, 
1990 [146]. 
 Where lagged and unlagged risk estimates were available, the lagged 
results, the optimum lag as determined by the authors of the paper, were 
extracted, for example Partanen et al, 1990 [146]. 
 In the absence of specific results for lung cancer, results for all 
respiratory cancer combined or for lung and pleura combined was 
assumed sufficiently relevant to be regarded as lung cancer results for 
example, Walrath and Fraumeni et al, 1984 [147]. 
 For nested case-control studies, where presented, the results for the 
nested case-control study were preferred to those of the cohort study, for 
example Bond et al, 1986 [148] 
 Where results for PCMRs were presented alongside PMRs, the results 
based on PCMRs were preferred, although in practice, the percentage 
difference in RRs was very small, for example, Walrath and Fraumeni, 
1983 [149].  (If PMRs are the proportion of deaths due to a specific cause 
expressed as a proportion of all causes of death, then the PCMR is the 
same entity, but expressed as a proportion of all deaths due to cancer). 
 Confounder-adjusted results were preferred to those unadjusted for 
confounders, for example, Armstrong et al, 2000 [98]. 
 
In the absence of an expected number of nasopharyngeal cancer deaths or an expected 
number of sinonasal cancer deaths in a study, the expected numbers were estimated 
using the expected number of lung cancer deaths (ELD), by taking their ratio as to the 
expected number of lung cancer deaths as applicable to occupational cohort studies.  For 
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nasopharyngeal cancer the expected number was taken as 0.004*ELD for example in 
Meyers et al, 2013  and for sinonasal cancer the expected number was taken as 
0.003*ELD, for example, Meyers et al, 2013 [127]. . 
The standard error for the log of the relative risk was estimated as follows: 
Study Type SE(logRR) 
Cohort, PMR, Case-
control and other 
studies 
92.3
)%95log()%95log( CLLCLU 
  
When O = 0. Undefined 
 
The standard error for the relative risk was estimated as follows: 
Study Type SE(RR) 
Cohort studies or 
PMR studies 
1 √𝐸⁄  
Case-control studies 𝑅𝑅 ∗ 𝑆𝐸(log 𝑅𝑅) (using the Delta method [78]). 
 
The delta method is an intuitive technique for approximating the moments of functions 
of random variables  and  the delta method utilizes a truncated Taylor series expansion 
[78]. 
Missing 95% confidence intervals were calculated using an exact method via the 
Poisson distribution [74], for example in Meyers et al, 2013 [127]. 
5.2.4 Meta-analytical methods 
Statistical analyses were performed with the “metan”  and “metabias” commands in 
Stata version 13 [53].  Data utilized when analyses were carried out on the log scale 
were the natural log-transformed risk ratios and their associated standard errors.  For 
analyses on the original untransformed scale, the data utilized were the risk ratios and 
their associated standard errors.  The coefficients of inconsistency (I
2
) were estimated to 
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assess heterogeneity between studies [150].  I
2
 is an estimate of the percentage of total 
variation in study estimates due to heterogeneity rather than chance, and is considered 
substantial if it exceeds 50%.  When significant heterogeneity is present, the random 
effects analysis is preferred to the fixed effect analysis.  Random effects models [18] 
were applied to calculate the (reverse transformed) pooled risk ratios and associated 
95% CIs and z scores of all studies. 
Differences between subgroups, due to study characteristics or study quality, were 
assessed via subgroup analyses in ‘metan’.  Study quality was assessed using the 
Newcastle-Ottawa scale for cohort and case-control studies [129].  Note that weighting 
studies based on quality scores was not carried out as this can be problematic and 
produce biased pooled effect estimates [34].  The subgroups defined a priori were 
newer versus older studies, study location, whether risk estimate adjusted for smoking, 
whether outcome was mortality or incidence, and study quality. 
Publication bias was assessed by constructing funnel plots of the log risk ratio versus 
the standard error of the log risk ratio and of the risk ratio versus the standard error of 
the risk ratio [151].  To supplement the funnel plot approach, the adjusted rank 
correlation method suggested by Begg and Mazumdar [27] and the regression 
asymmetry test proposed by Egger et al [26] were applied. 
5.3 RESULTS 
5.3.1 Characteristics of the studies analysed 
Figure 5.1 contains the results of the literature searching.  A total of 34 studies giving 
rise to 73 relative risk estimates of occupational exposure to formaldehyde for a cancer 
site of interest were available for inclusion in the meta-analyses.  Six studies were 
industrial cohort studies, four were studies of professionals such as pathologists, 
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anatomists, embalmers and funeral directors, 16 were case-control studies (including 
one case-cohort study) and eight other study (mainly registry-based) types.  The process 
of identification of the relevant studies is shown diagrammatically in Figure 5.1.  
Figure 5.1 - Identification of studies for including the meta-analysis 
 
The characteristics of these studies are set out in Table 5.4 (industrial cohort studies), 
Table 5.5 (cohort studies of pathologists, anatomists and funeral directors and 
embalmers, Table 5.6 (nasopharyngeal cancer case control studies), Table 5.7 (sinonasal 
cancer case-control studies), Table 5.8 (lung cancer case-control studies), and Table 5.9 
(other study types). 
 
Total  identified 
n = 1298 
Studies included in one or 
more meta-analyses 
n = 34 
Not of formaldehyde 
exposurein humans 
n = 1249 
 
Formaldehyde exposure not 
occupational 
n = 3 
RR without measure of 
uncertainty 
N = 6 
Superseded by updated 
study 
n = 28 
Formaldehyde not of 
primary interest 
n = 2 
Unadjusted for potentially 
important co-exposures 
n = 9 
Cancer sites studied not 
relevant 
n = 1 
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Table 5.4 – Occupational cohorts of industrial workers 
Reference Location Number 
of cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Newcastle-
Ottawa 
scale score 
Effect estimate (95% CI) 
Edling et al, 
1987 [152] 
Sweden L: 2 
N: 1 
521 Abrasive 
manufacture 
1958-1983 National 
population 
A, S, Y Not defined. 6 L: 0.57 (0.1 to 2.1) 
N: 95.2 (0.0 to 351.3#) 
Bertazzi et al, 
1989 [153] 
Italy L: 6 1330 Resin 
manufacture 
1959-1986 Local 
population 
(not defined) 
A, S, Y Ever 
exposed, 
duration 
5 L: 0.69 (0.25 to 1.50) 
Andjelkovich et 
al, 1995 [154] 
USA L: 51 
N: 0 
SN: 0 
3,929 Automotive 
iron foundry 
workers 
1960-1989 National 
population 
A, S, Y Ever 7 L: 1.20 (0.89 to 1.58) 
N: 0.00 (0.00 to 23.55) 
SN: 0.00 (0.00 to 17.62) 
Beane Freeman 
et al, 2013 [89] 
USA N: 9 
SN: 3 
L: 1,130 
25,619 Industrial 
workers 
1934-2004 National 
population 
A, S, Y Average 
intensity, 
peak, 
cumulative, 
duration 
6 N: 1.84 (0.84 to 3.49) 
SN: 0.90 (0.18 to 2.62) 
L: 1.14 (1.07 to 1.20) 
Meyers et al, 
2013 [127] 
USA N: 0 
SN: 0 
L: 267 
11,043 Garment 
industry 
workers 
1960-2008 National 
population 
A, S, Y Ever vs 
never, 
duration 
6 N: 0.00 (0.00 to 2.77) 
SN: 0.00 (0.00 to. 3.89) 
L: 1.04 (0.92 to 1.17) 
Coggon et al, 
2014 [126] 
UK N: 0 
SN: 1 
L: 813 
 
14,008 Industrial 
workers 
1941-2012 National 
population 
A, S, Y Highest level, 
duration 
6 N: 0.00 (0.00 to 1.90) 
SN: 0.52 (0.01 to 2.88) 
L: 1.26 (1.17 to 1.35) 
Abbreviations: A = age;  S = sex;  Y = year;  L = lung cancer;  N = nasopharyngeal cancer;  SN = sinonasal cancer 
Notes: # Expected value derived using ratio of nasopharyngeal cancers to lung cancers (based on data for England and Wales) applied to the lung cancer expectation 
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Table 5.5 – Occupational cohort studies of pathologists, anatomists, funeral directors and embalmers 
Reference Location Number 
of cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Newcastle-
Ottawa 
scale score 
Effect estimate (95% CI) 
Harrington 
& Shannon, 
1975 [155] 
United 
Kingdom 
L: 11 2,079 Pathology 1955-1973 National 
populations 
A, S, Y None 7 L: 0.39 (0.20 to 0.71) 
Levine et al, 
1983 
Canada SN: 0 
L: 19 
1,477 men Undertakers 1950-1977 National 
population 
A, Y None 6 SN: 0.0 (0.0 to 15.0) 
L: 0.94 (0.6 to 1.5) 
Stroup et al, 
1986 [156] 
USA L: 12 
SN: 0 
N:  
2,317 Anatomy 1925-1979 National 
population 
A, S, Y None 5 L: 0.3 (0.1 to 0.5) 
SN: 0.0 (0.0 to 2.0) 
N: 0.0 (0.0 to 23.2) 
Hall et al, 
1991 [157] 
England 
and Wales 
Scotland 
L: 9 
L: 5 
4,512 Pathology 1974-1987 National 
populations 
A, S, Y None 6 L: 0.19 (0.09 to 0.36) – E&W 
(England and Wales) 
L: 0.60 (0.16 to 1.54) – S 
(Scotland) 
Abbreviations: A = age;  S = sex;  Y = year;  L = lung cancer;  N = nasopharyngeal cancer;  SN = sinonasal cancer 
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Table 5.6 – Nasopharygeal cancer case-control studies 
Reference Location Number of 
cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Newcastle-
Ottawa 
scale score 
Effect 
estimate 
(95% CI) 
Roush et al, 
1987 [158] 
USA 173 976 Population 
study 
1935-1975 Deaths in the 
region 
A, Y, AO Probability of 
exposure, level of 
exposure. 
5 1.3 (0.7 to 
2.4) 
West et al, 
1993 [159] 
Philippines 104 309 Population-
based 
Two-year 
period in late 
1980s/early 
1990s 
Hospital and 
community 
EL, DE, D, 
TS, AMC, 
HM 
Likely/unlikely 
exposed 
5 1.2 (0.31 
to 3.6) =- 
<15y (lag 
less than 
15 years) 
4.0 (1.3 to 
12.3) – 
15+ (lag 
15 years 
or more) 
Armstrong et 
al, 2000 [98] 
Malaysia 530 1060 Population-
based 
1990-1992 Community D, TS Ever exposed 6 0.71 (0.34 
to 1.43) 
Vaughan et al, 
2000 [160] 
USA 196 440 Population-
based 
1987-1993 Community A, S, E, LN, 
TS, AL, EL 
Probability, 
maximum, 
duration, 
cumulative 
6 1.3 (0.8 to 
2.1) 
Hildesheim et 
al, 2001  
Taiwan 375 702 Population-
based 
1991-1994 Community A, S, EL, E, 
HLA, FH, TS, 
G, D = diet 
Probability, 
intensity, 
duration 
6 1.4 (0.93 
to 2.2) 
Abbreviations: A = age;  E = ethnicity;  Y = year;  AO = availability of occupational data;  S = Sex;  EL = Education level;  DE = dust/exhaust;  D =  diet;  TS = tobacco smoking, 
AMC = anti-mosquito coils, HM = herbal medicine, E = ethnicity, HLA = HLA allele, FH = family history, G = genotype, D =  diet, LN = location, AL = alcohol 
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Table 5.7 – Sinonasal cancer case-control studies 
Reference Location Number of 
cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustmen
t 
Exposure 
assessment 
Newcastle
-Ottawa 
scale 
score 
Effect estimate (95% CI) 
Olsen & 
Anaes, 1986 
[161] 
Denmark 2 (squamous cell 
carcinoma) 
1 
(adenocarcinoma
) 
2465 Populatio
n study 
1970-1982 Cancer 
registry 
W Ever exposed 
(hygiene 
assessment 
based on job 
histories) 
4 1.4 (0.3 to 6.4) – SCC 
(squamous cell carcinoma) 
9.5 (1.6 to 57.8) – A 
(adenocarcinoma) 
Roush et al, 
1987 [158] 
USA 198 976 Populatio
n study 
1935-1975 Deaths in 
the region 
A, Y, AO Probability of 
exposure, 
level of 
exposure. 
5 1.0 (0.5 to 1.8) 
Luce et al, 
2002 [162] 
Various 
(pooled 
analysis) 
1,213 4,349 Various 1970-1990 Hospital, 
Community 
A, S, SY Level of 
exposure 
7 1.2 (0.8 to 1.8) – M SCC 
low (Male squamous cell 
carcinoma low exposure) 
1.1 (0.8 to 1.6) – M SCC 
med (Male squamous cell 
carcinoma medium) 
1.2 (0.8 to 1.8) – M SCC 
high (Male squamous cell 
carcinoma high) 
0.7 (0.3 to 1.9) – M A low 
(male adenocarcinoma low) 
2.4 (1.3 to 4.5) – M A med 
(male adenocarcinoma 
medium) 
3.0 (1.5 to 5.7) – M A high 
(male adenocarcinoma high) 
0.6 (0.2 to 1.4) – F SCC low 
(Female squamous cell 
carcinoma low) 
1.3 (0.6 to 3.2) – F SCC 
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Reference Location Number of 
cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustmen
t 
Exposure 
assessment 
Newcastle
-Ottawa 
scale 
score 
Effect estimate (95% CI) 
med (Female squamous cell 
carcinoma medium) 
1.5 (0.6 to 3.8) – F SCC 
high (Female squamous cell 
carcinoma high) 
2 (0.2 to 4.1) – F A low 
(Female adenocarcinoma 
low) 
6.2 (2.0 to 19.7) – F A high 
(Female adenocarcinoma 
high) 
Pesch et al, 
2008 [163] 
Germany 86 290 Industry-
based 
2003-2005 Insurance 
database 
A, R, RS, 
TS 
Ever versus 
never 
6 0.46 (0.24 to 1.54) 
0.94 (0.47 to 1.90) 
Abbreviations: W = wood dust;  A = age;  Y = year;  AO = availability of occupational information;  R = region;  RS = respondent status;  SY = study;  TS = tobacco smoking 
 
  
 122 
Table 5.8 – Lung cancer case-control studies 
Reference Location Number 
of cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Newcastle-
Ottawa scale 
score 
Effect estimate 
(95% CI) 
Bond et al, 
1986 [148] 
USA 4 19,608 Chemical 1940-1981 Decedent and 
live controls 
from within 
cohort 
TS, V, YM, 
DR, EL 
Ever exposed 6 0.31 (0.11 to 
0.86) 
Gerin et al, 
1989 [164] 
Canada 857 2,380 Population-
based 
1979-1985 General 
population 
A, E, SES, TS, 
DJ 
Ever exposed, 
probability of 
exposure, 
frequency of 
exposure, 
concentration, 
duration, era of 
first exposure 
(hygiene 
assessment based 
on job histories) 
7 1.0 (0.6 to 1.8) - 
Short (short 
exposed) 
0.5 (0.3 to 0.8) - 
Long_low (long 
low exposure) 
0.9 (0.5 to 1.6) 
Long_med (long 
medium 
exposure) 
1.0 (0.4 to 1.0) – 
long_high (long 
high exposure) 
Partanen et 
al, 1990 
[146] 
Finland 6 7307 Woodworking 1957-1982 Cohort 
members 
without 
respiratory 
cancer 
VS, TS Ever exposed, 
duration, level of 
exposure, 
cumulative 
exposure, 
repeated peak 
exposure (hygiene 
assessment based 
on job histories) 
7 1.19 (0.31 to 
4.56) 
Brownson et 
al, 1993 
[165] 
USA 429 1,450 Population-
based 
1986-1991 Community TS, PH None 7 0.9 (0.2 to 3.3) 
De Stefani et Uruguay 338 1,352 Population- 1994-2000 Hospital TS Duration 6 1.7 (1.1 to 2.8) 
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Reference Location Number 
of cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Newcastle-
Ottawa scale 
score 
Effect estimate 
(95% CI) 
al, 2005 
[166] 
based 
Checkoway 
et al, 2011 
[167] (case-
cohort) 
China 628 267,400 Textile 
workers 
1989-1998 Referent 
subcohort 
A, TS, EN Duration 5 2.1 (0.4 to 11) 
Mahboubi et 
al, 2013 
[168] 
Canada 2060 4,106 Population-
based 
1979-1996 Community A, S, IL, E, RS, 
EL, TS, LC 
Age at first, 
average, peak 
7 1.06 (0.89 to 
1.27) 
Abbreviations: VS = vital status, S = smoking;  E = ethnicity;  SES = socio-economic status;  DJ = dirty jobs;  V = vitamin A;  YM = year of migration;  DR = duration of residence;  
EL = education level, EN = endotoxin;  IL = income level, RS = respondent status, LC = recognized lung carcinogens;  PH = previous history of lung disease 
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Table 5.9 – Other study types 
Reference Study 
Type 
Location Number 
of cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Effect estimate 
(95% CI) 
Jensen & 
Andersen, 
1982 [169] 
Registry-
based 
Denmark L: 8 
SN: 0 
302 Pathology 1943-76 Cancer 
registry 
A, S, Y None L: 1.0 (0.4 to 2.4) 
SN: 0.0 (0.0 to 93.6) 
Milham, 
1983[170] 
Registry-
based 
USA L: 13 454,992 Funeral directors 1950-79 Mortality 
registry 
A, S, Y None L: 0.75 (0.40 to 
1.28) 
Walrath & 
Fraumeni, 
1983 [149] 
PMR study USA L: 72 1,132 Embalmers 1925-1980 National 
population 
A, S, Y Approximate 
length of 
exposure 
L: 1.08 (0.84 to 
1.36) 
Walrath & 
Fraumeni, 
1984 [147] 
SMR study USA L: 41 
SN: 0 
1,109 Embalmers 1925-1980 National 
population 
A, S, Y Length of 
licensure 
L: 0.96 (0.69 to 
1.30) 
SN: 0.00 (0.00 to 
4.99) 
Hayes et al, 
1990 [171] 
PMR study USA L: 285 
L: 23 
SN: 0 
SN: 0 
N: 3 
N: 1 
3,866 Funeral 
directors/embalmers 
1975-1985 National 
population 
A, S, Y None L: 0.97 (0.86 to 
1.09) – W (white) 
L: 0.75 (0.47 to 
1.13) – NW (non-
white) 
SN: 0.00 (0.00 to 
2.00) – W (white) 
SN: 0.0 (0.0 to 
18.77) – NW (non-
white) 
N: 1.89 (0.39 to 
5.48) – W (white) 
N: 4.00 (0.10 to 
22.29) – NW (non-
white) 
Hansen & 
Olsen, 1995 
[172] 
PMR study 
(incidence) 
Denmark N: 4 
SN: 13 
L: 410 
126,347 Population-based 1970-1984 National 
population 
A, S, Y, 
White vs 
blue collar 
Low/High 
exposed 
N: 1.3 (0.3 to 3.2) 
SN: 2.3 (1.3 to 4.0) 
L: 1.0 (0.9 to 1.1) 
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Reference Study 
Type 
Location Number 
of cases 
Study 
Population 
Industry Follow-up Source of 
controls 
Variables 
included in 
adjustment 
Exposure 
assessment 
Effect estimate 
(95% CI) 
Stellman et al, 
1998 [173] 
Population-
based 
cohort 
USA L: 104 1.2 million Population-based  1982-1989 National 
population 
A, TS Ever versus 
never 
L: 0.93 (0.73 to 
1.18) 
Siew et al, 
2012 [174] 
Registry 
study 
Finland N: 292 
SN: 149 
L: 
30,137 
1.2 million Population-based 1971-1995 National 
population 
A, TS, 
Silica, 
Asbestos 
Probability, 
Level 
N: 0.87 (0.34 to 
2.20) 
SN: 1.11 (0.66 to 
1.87) 
L: 1.18 (1.12 to 
1.25) 
Abbreviations: A = age;  S = Sex;  Y = year;  TS = tobacco smoking;  L = lung cancer;  N = nasopharyngeal cancer;  SN = sinonasal cancer 
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5.3.2 Lung Cancer 
For lung cancer there were 30 estimates of relative risk incorporating 6,476 lung 
cancers.  The results of the fixed effect and random effects meta-analyses are set out in 
Table 5.10. 
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Table 5.10 – Summary risks for meta-analyses of all studies of lung cancer and subgroups – analyses on the log scale 
Analysis No. of risk 
estimates 
Summary 
fixed effect 
RR 
(95% CI) 
Z (p 
value) 
Summary 
random 
effects RR 
(95% CI) 
Z (p value) Heterogeneity 
I
2
 (p-value) 
Test of 
heterogeneity 
between 
subgroups 
References 
All Risk 
Estimates 
30 1.12 (1.08 
to 1.15) 
7.41 
(<0.001) 
0.98 (0.90 
to 1.07) 
0.52 (0.604) 72.8% (<0.001)  Edling et al, 1987;  Bertazzi et al, 1989;  
Andjelkovich et al, 1995;  Beane Freeman et al, 
2013;  Meyers et al, 2013;  Coggon et al, 2014;  
Harrington & Shannon, 1975;  Levine et al, 
1993;  Stroup et al, 1986;  Hall et al, 1991;  
Bond et al, 1986;  Gerin et al, 1989;  Partanen et 
al, 1990;  Brownson et al, 1993;  De Stefani et 
al, 2005;  Checkoway et al, 2011;  Mahboubi et 
al, 2013;  Jensen & Anderson, 1982;  Milham, 
1983;  Walrath & Fraumeni 1983;  Walrath & 
Fraumeni, 1984;  Hayes et al, 1990;  Hansen & 
Olsen, 1995;  Stellman et al, 1998;  Siew et al, 
2012. 
Published 
before 1990 
14 0.84 (0.73 
to 0.96) 
2.51 
(0.012) 
0.74 (0.59 
to 0.93) 
 2.61 (0.009) 52.0% (0.012) < 0.001 Edling et al, 1987;  Bertazzi et al, 1989;  
Harrinton & Shannon, 1975;  Levine et al, 1983;  
Stroup et al, 1986;  Bond et al, 1996;  Gerin et 
al, 1989;  Jensen & Andersen, 1983;  Milham, 
1883;  Walrath & Fraumeni, 1983;  Walrath & 
Fraumeni, 1984;   
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Analysis No. of risk 
estimates 
Summary 
fixed effect 
RR 
(95% CI) 
Z (p 
value) 
Summary 
random 
effects RR 
(95% CI) 
Z (p value) Heterogeneity 
I
2
 (p-value) 
Test of 
heterogeneity 
between 
subgroups 
References 
Published 
1990 or later 
16 1.13 (1.10 
to 1.16) 
8.13 
(<0.001) 
1.06 (0.98 
to 1.16) 
)1.43 (0.153) 75.8% (< 0.001) Andjelkovich et al, 1995;  Beane Freeman et al, 
2013;  Meyers et al, 2013;  Coggon et al, 2014;  
Hall et al, 1991;  Partanen et al, 1990;  
Brownson et al, 1993;  De Stefani et al, 2005;  
Checkoway et al, 2011;  Mahboubi et al, 2013;  
Hayes et al, 1990;  Hansen & Olsen, 1995;  
Stellman et al, 1998;  Siew et al, 2012 
Study design 
– industrial 
cohort 
6 1.16 (1.11 
to 1.21) 
6.90 (< 
0.001) 
1.04 (0.89 
to 1.21) 
0.43 (0.669) 81.7% (< 0.001)  < 0.001 Edling et al, 1987;  Bartazzi et al,  1989;  
Andjelkovich et al, 1995;  Beane Freeman et al, 
2013;  Myers et al, 2013;  Coggon et al, 2014 
Study design 
– 
professional 
cohort 
4 0.58 (0.41 
to 0.82) 
3.08 
(0.002) 
0.49 (0.23 
to 1.09) 
1.85 (0.065) 76.7% (0.014) Harrington & Shannon, 1975;  Levine et al, 
1983;  Stroup et al, 1986;  Hall et al, 1991 
Study design 
-case-control 
10 1.01 (0.87 
to 1.16) 
0.08 
(0.937) 
0.93 (0.70 
to 1.25) 
0.45 (0.650) 52.6% (0.025) Bond et al, 1986;  Gerin et al, 1989;  Partanen et 
al, 1990;  Brownson et al, 1993;  De Stefani et 
al, 2005;  Checkoway et al, 2011;  Mahboubi et 
al, 2013 
Study design 
- other 
9 1.09 (1.05 
to 1.14) 
4.16 (< 
0.001) 
1.01 (0.91 
to 1.12) 
0.21 (0.835) 62.3% (0.007) Jensen & Anderson, 1982;  Milham, 1983;  
Walrath & Fraumeni, 1983;  Walrath 
&Fraumeni, 1984;  Hayes et al, 1990;  Hansen & 
Olsen, 1995;  Stellman et al, 1988;  Siew et al, 
2012 
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Analysis No. of risk 
estimates 
Summary 
fixed effect 
RR 
(95% CI) 
Z (p 
value) 
Summary 
random 
effects RR 
(95% CI) 
Z (p value) Heterogeneity 
I
2
 (p-value) 
Test of 
heterogeneity 
between 
subgroups 
References 
Outcome - 
mortality 
19 1.11 (1.07 
to 1.15) 
5.46 (< 
0.001) 
0.91 (0.81 
to 1.03) 
1.49 (0.136) 78.2% (< 0.001) 0.654 Edling et al 1987;  Bertazzi et al, 1989;  
Andjelkovich et al, 1995;  Beane Freeman et al, 
2013;  Meyers et al, 2013;  Coggon et al, 2014;  
Harrington & Shannon, 1975;  Levine et al, 
1983;  Stroup et al, 1986;  Hall et al, 1991;  
Bond et al, 1986;  Jensen & Andersen, 1982;  
Milham, 1983;  Walrath & Fraumeni, 1983;  
Walrath & Fraumeni, 1984;  Hayes et al, 1990;  
Stellman et al, 1998.  
Outcome - 
cancer 
incidence 
11 1.12 (1.07 
to 1.18) 
5.03 (< 
0.001) 
1.05 (0.92 
to 1.20) 
0.77 (0.443) 57.6% (0.009) Gerin et al, 1989;  Partanen et al, 1990;  
Brownson et al, 1993;  De Stefani et al, 2005;  
Checkoway et al, 2011;  Mahboubi et al, 2013;  
Hansen & Olsen, 1994;  Siew et al, 2012. 
Geographic 
area - North 
America 
18 1.07 (1.02 
to 1.11) 
2.92 
(0.004) 
0.97 (0.88 
to 1.06) 
0.71 (0.477) 57.7% (0.001) 0.005 Andjelkovich et al, 1995;  Bean Freeman et al, 
2013;  Meyers et al, 2013;  Levine et al, 1983;  
Stroup et al, 1986;  Bond et al, 1986;  Gerin et 
al, 1989;  Brownson et al, 1993;  Mahboubi et 
al, 2013;  Milham, 1983;  Walrath & Fraumeni, 
1983;  Walrath & Fraumeni, 1984;  Hayes et al, 
1990;  Stellman et al, 1998.  
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Analysis No. of risk 
estimates 
Summary 
fixed effect 
RR 
(95% CI) 
Z (p 
value) 
Summary 
random 
effects RR 
(95% CI) 
Z (p value) Heterogeneity 
I
2
 (p-value) 
Test of 
heterogeneity 
between 
subgroups 
References 
Geographic 
area - 
Europe 
10 1.16 (1.11 
to 1.21) 
7.24 (< 
0.001) 
0.93 (0.78 
to 1.11) 
0.78 (0.434) 83.5% (< 0.001) Edling et al, 1987;  Bertazzi et al, 1989;  Coggon 
et al, 2014;  Harrington & Shannon, 1975;  Hall 
et al, 1991;  Partanen et al, 1990;  Jensen & 
Andersen, 1982;  Hansen & Olsen, 1995;  Siew 
et al, 2012.  
Adjusted for 
smoking - 
yes 
22 1.00 (0.88 
to 1.13) 
0.02 
(0.984) 
0.98 (0.79 
to 1.21) 
0.21 (0.836) 48.5% (0.059) 0.071 Edling et al, 1987;  Bertazzi et al, 1989;  
Andjelkovich et al, 1995;  Beane Freeman et al, 
2013;  Meyers et al, 2013;  Coggon et al, 2014;  
Harrington & Shannon, 1975;  Levine et al, 
1983;  Stroup et al, 1986;  Hall et al, 1991. Bond 
et al, 1986;  Brownson et al, 1993;  Checkoway 
et al, 2011;  Jensen & Andersen, 1982;  Milham 
1983;  Walrath & Fraumeni, 1983;  Walrath & 
Fraumeni, 1984;  Hayes et al, 1990;  Hansen & 
Olsen, 1995;  Siew et al, 2012. 
Adjusted for 
smoking - no 
8 1.12 (1.09 
to 1.16) 
7.63 (< 
0.001) 
0.98 (0.89 
to 1.08) 
0,43 (0.664) 76.6% (< 0.001) Mahboubi et al, 2013;  Gerin et al, 1989;  De 
Stefani et al, 2005;  Stellman et al, 1998;  
Partanen et al, 1990.  
Newcastle-
Ottawa scale 
score - 7 
8 0.98 (0.86 
to 1.11) 
0.35 
(0.728) 
0.86 (0.66 
to 1.13) 
1.09 (0.275) 61.1% (0.012) 
0.001 
Harrington & Shannon, 1975;  Gerin et al, 1989;  
Partanen et al, 1990;  Andjelkovich et al, 1995;  
Mahboubi et al, 2013 
Newcastle-
Ottawa scale 
score - 6 
10 1.16 (1.11 
to 1.21) 
6.86 (< 
0.001 
1.01 (0.86 
to 1.20) 
0.17 (0.868) 80.7% (< 0.001) Levine et al, 1983;  Bond et al, 1986;  Edling et 
al, 1987;  Hall et al, 1991l;  Brownson et al, 
1993;  De Stefani et al, 2005;  Meyers et al, 
2013;  Beane Freeman et al, 2013;  Coggon et al, 
2014 
Newcastle-
Ottawa scale 
score - 5 
3 0.50 (0.29 
to 0.88) 
2.39 
(0.017) 
0.61 (0.23 
to 1.66) 
0.97 (0.332) 63.0% (0.067) Stroup et al, 1986; Bertazzi et al, 1989; 
Checkoway et al, 2011. 
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The forest plot for the random effects model is shown in Figure 5.2. 
Figure 5.2 – Random effects meta-analysis of lung cancer for all risk estimates 
 
The overall summary or meta-RR for lung cancer is 1.12 (1.08 to 1.15) based on the 
fixed effect meta-analyses.  However, there was significant heterogeneity, and so the 
random effects meta-analysis is to be preferred.  This gave a meta-RR of 0.98 (0.90 to 
1.07) which is no longer statistically significantly elevated. 
Table 5.10 also contains analysis of important subgroups of studies.  The first of these 
shows that there is a difference in the meta-RR based on the studies published before 
1990 and that based on those published in 1990 or later.  The meta-RR for the random 
effects model for pre-1990 publications which gave a meta-RR of 0.74 (0.59 to 0.93), 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 72.8%, p = 0.000)
Authors
Hall E&W
Stellman
Jensen
Gerin long_med
Harrington
Meyers
Hall S
De Stefani
Beane Freeman
Andjelkovich
Checkoway
Coggon
Levine
Mahboubi
Partanen
Bond
Hayes W
Hayes NW
Stroup
Gerin long_high
Siew
Edling
Walrath
Bertazzi
Brownson
Milham
Gerin long_low
Hansen
Walrath
Gerin short
Pubyear
1991
1998
1982
1989
1975
2013
1991
2005
2013
1995
2011
2014
1983
2013
1990
1986
1990
1990
1986
1989
2012
1987
1983
1989
1993
1983
1989
1995
1984
1989
0.98 (0.90, 1.06)
RR (95% CI)
0.19 (0.09, 0.36)
0.93 (0.73, 1.18)
1.00 (0.40, 2.40)
0.90 (0.50, 1.60)
0.39 (0.20, 0.71)
1.04 (0.92, 1.17)
0.60 (0.16, 1.54)
1.70 (1.10, 2.80)
1.14 (1.07, 1.20)
1.20 (0.89, 1.58)
2.10 (0.40, 11.00)
1.26 (1.17, 1.35)
0.94 (0.57, 1.47)
1.06 (0.89, 1.27)
1.19 (0.31, 4.56)
0.31 (0.11, 0.86)
0.97 (0.86, 1.09)
0.75 (0.47, 1.13)
0.28 (0.10, 0.50)
1.00 (0.40, 2.40)
1.18 (1.12, 1.25)
0.57 (0.10, 2.10)
1.08 (0.84, 1.36)
0.69 (0.25, 1.50)
0.90 (0.20, 3.30)
0.75 (0.40, 1.28)
0.50 (0.30, 0.80)
1.00 (0.90, 1.10)
0.96 (0.69, 1.30)
1.00 (0.60, 1.80)
100.00
Weight
1.30
5.33
0.83
1.75
1.52
7.80
0.53
2.45
8.85
4.51
0.26
8.66
2.38
6.59
0.39
0.64
7.83
2.68
1.00
0.83
8.88
0.30
5.37
0.83
0.36
1.74
2.28
8.18
4.04
1.91
%
  
1.09 11.1
Lung cancer - Random effects, Log scale
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which was statistically significantly low, whereas the random effect meta-RR for 
studies published in 1990 or later was 1.06 (0.98 to 1.16) and so was not statistically 
significantly different to one.  The forest plot illustrating this is shown in Figure 5.3. 
Figure 5.3 – Random effects meta-analysis of lung cancer by year of publication 
category 
 
Examining the results by study design gave interesting and contrasting meta-RR 
estimates.  Again from the random effect model, the meta-RR for professional cohort 
studies was 0.49 (0.23 to 1.01) which was borderline statistically significantly low, 
whereas that based on industrial cohorts was 1.04 (0.89 to 1.21) which not statistically 
significantly different from one.  Case-control studies had a meta-RR of 0.93 (0.70 to 
1.25) which was also not statistically significantly different from one.  Other studies, 
such as PMR studies, which are thought to be more prone to bias, gave a meta-RR of 
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 72.8%, p = 0.000)
Authors
Gerin short
Partanen
Levine
Post-1990
Gerin long_med
Gerin long_high
Edling
Before 1990
Bond
Mahboubi
Bertazzi
Checkoway
Subtotal  (I-squared = 75.8%, p = 0.000)
Subtotal  (I-squared = 52.0%, p = 0.012)
De Stefani
Walrath
Siew
Jensen
Hall E&W
Hansen
Meyers
Beane Freeman
Milham
Stellman
Hayes W
Brownson
Gerin long_low
Hayes NW
Coggon
Hall S
Stroup
Harrington
Walrath
Andjelkovich
Pubyear
1989
1990
1983
1989
1989
1987
1986
2013
1989
2011
2005
1984
2012
1982
1991
1995
2013
2013
1983
1998
1990
1993
1989
1990
2014
1991
1986
1975
1983
1995
0.98 (0.90, 1.06)
RR (95% CI)
1.00 (0.60, 1.80)
1.19 (0.31, 4.56)
0.94 (0.57, 1.47)
0.90 (0.50, 1.60)
1.00 (0.40, 2.40)
0.57 (0.10, 2.10)
0.31 (0.11, 0.86)
1.06 (0.89, 1.27)
0.69 (0.25, 1.50)
2.10 (0.40, 11.00)
1.06 (0.98, 1.16)
0.74 (0.59, 0.93)
1.70 (1.10, 2.80)
0.96 (0.69, 1.30)
1.18 (1.12, 1.25)
1.00 (0.40, 2.40)
0.19 (0.09, 0.36)
1.00 (0.90, 1.10)
1.04 (0.92, 1.17)
1.14 (1.07, 1.20)
0.75 (0.40, 1.28)
0.93 (0.73, 1.18)
0.97 (0.86, 1.09)
0.90 (0.20, 3.30)
0.50 (0.30, 0.80)
0.75 (0.47, 1.13)
1.26 (1.17, 1.35)
0.60 (0.16, 1.54)
0.28 (0.10, 0.50)
0.39 (0.20, 0.71)
1.08 (0.84, 1.36)
1.20 (0.89, 1.58)
100.00
Weight
1.91
0.39
2.38
1.75
0.83
0.30
0.64
6.59
0.83
0.26
74.60
25.40
2.45
4.04
8.88
0.83
1.30
8.18
7.80
8.85
1.74
5.33
7.83
0.36
2.28
2.68
8.66
0.53
1.00
1.52
5.37
4.51
%
  
1.09 11.1
Lung cancer - Random effects, Log scale
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1.01 (0.91 to 1.12) which was also not statistically significantly different to one.  This is 
illustrated in Figure 5.4. 
Figure 5.4 - Random effects meta-analysis of lung cancer by study type 
 
As anticipated for a fairly fatal cancer such as lung cancer, from the random effects 
model, the meta-RR from mortality studies 0.91 (0.81 to 1.03) gave a similar meta-RR 
estimate to studies based on cancer incidence data 1.05 (0.92 to 1.20).  The forest plot 
for this analysis is shown in Figure 5.5. 
  
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 72.8%, p = 0.000)
Gerin long_low
Hall S
Beane Freeman
Gerin long_med
Coggon
Partanen
Subtotal  (I-squared = 76.7%, p = 0.014)
Checkoway
Case-control
Walrath
Other
Subtotal  (I-squared = 52.6%, p = 0.025)
Harrington
Hayes W
Gerin short
Jensen
Andjelkovich
Stroup
Gerin long_high
Edling
Milham
Subtotal  (I-squared = 81.7%, p = 0.000)
Hayes NW
Subtotal  (I-squared = 62.3%, p = 0.007)
Authors
Siew
Bertazzi
Professional cohort
Mahboubi
Stellman
Hansen
Hall E&W
Meyers
Brownson
De Stefani
Walrath
Levine
Bond
Industrial Cohort
1989
1991
2013
1989
2014
1990
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Figure 5.5 - Random effects meta-analysis of lung cancer by mortality or incidence 
study 
 
Studies from North America, again using the random effects model, had a meta-RR of 
0.97 (0.88 to 1.06) and for Europe the meta-RR was 0.93 (0.78 to 1.11).  (One study 
from South America and one containing studies from multiple countries were excluded 
from this comparison).  The forest plot for this analysis is contained in Figure 5.6. 
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Figure 5.6 - Random effects meta-analysis of lung cancer by study location 
 
Studies that contained an adjustment for smoking gave a meta-RR of 0.98 (0.79 to 1.21) 
and studies that did not adjust for smoking a meta-RR 0.98 (0.89 to 1.08), provided 
some evidence that smoking was not a strong confounder for lung cancer in these 
studies.  The forest plot for this analysis is contained in Figure 5.7. 
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Figure 5.7 - Random effects meta-analysis of lung cancer by whether or not the study 
adjusted for smoking 
 
The final subgroup analysis was based on quality score, according to the Newcastle-
Ottawa scale.  This was only applied to the occupational cohort studies and the case-
control studies.  The studies with a Newcastle-Ottawa scale score of 7, had a meta-RR 
of 0.86 (0.66 to 1.13).  The meta-RR for studies with a Newcastle-Ottawa scale score of 
6 was 1.01 (0.86 to 1.20).  The meta-RR for studies with a score of 5 was 0.61 (0.23.to 
1.66) albeit based on only three estimates.  The forest plot for this analysis is contained 
in Figure 5.8. 
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Figure 5.8 – Random effects meta-analysis of lung cancer by study quality category 
 
The lung cancer data displayed considerable heterogeneity, with the value of I
2
 being 
greater than 50% for the vast majority of the subgroups examined. 
A sensitivity analysis excluding each study in turn from the random effects analysis is 
set out in Table 5.11. 
  
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 72.8%, p = 0.000)
Gerin long_med
Subtotal  (I-squared = 62.3%, p = 0.007)
Subtotal  (I-squared = 63.0%, p = 0.067)
Gerin short
Walrath
Gerin long_low
Hayes W
Subtotal  (I-squared = 61.1%, p = 0.012)
Andjelkovich
Mahboubi
7
6
Hall S
Brownson
Meyers
Bertazzi
Hansen
Authors
Hall E&W
Stellman
Harrington
Bond
5
Walrath
Siew
Levine
Milham
De Stefani
Coggon
Gerin long_high
Beane Freeman
Partanen
Subtotal  (I-squared = 80.7%, p = 0.000)
Edling
Stroup
Checkoway
.
Jensen
Hayes NW
1989
1989
1984
1989
1990
1995
2013
1991
1993
2013
1989
1995
Pubyear
1991
1998
1975
1986
1983
2012
1983
1983
2005
2014
1989
2013
1990
1987
1986
2011
1982
1990
0.98 (0.90, 1.06)
0.90 (0.50, 1.60)
1.01 (0.91, 1.12)
0.61 (0.22, 1.66)
1.00 (0.60, 1.80)
0.96 (0.69, 1.30)
0.50 (0.30, 0.80)
0.97 (0.86, 1.09)
0.86 (0.66, 1.13)
1.20 (0.89, 1.58)
1.06 (0.89, 1.27)
0.60 (0.16, 1.54)
0.90 (0.20, 3.30)
1.04 (0.92, 1.17)
0.69 (0.25, 1.50)
1.00 (0.90, 1.10)
RR (95% CI)
0.19 (0.09, 0.36)
0.93 (0.73, 1.18)
0.39 (0.20, 0.71)
0.31 (0.11, 0.86)
1.08 (0.84, 1.36)
1.18 (1.12, 1.25)
0.94 (0.57, 1.47)
0.75 (0.40, 1.28)
1.70 (1.10, 2.80)
1.26 (1.17, 1.35)
1.00 (0.40, 2.40)
1.14 (1.07, 1.20)
1.19 (0.31, 4.56)
1.01 (0.86, 1.20)
0.57 (0.10, 2.10)
0.28 (0.10, 0.50)
2.10 (0.40, 11.00)
1.00 (0.40, 2.40)
0.75 (0.47, 1.13)
100.00
1.75
44.87
2.09
1.91
4.04
2.28
7.83
19.76
4.51
6.59
%
0.53
0.36
7.80
0.83
8.18
Weight
1.30
5.33
1.52
0.64
5.37
8.88
2.38
1.74
2.45
8.66
0.83
8.85
0.39
33.28
0.30
1.00
0.26
0.83
2.68
  
1.09 11.1
Lung cancer - Random effects, Log scale
 138 
Table 5.11 – Meta-RR for random effects model excluding each study in turn 
Study Excluded Meta-RR 95% CI 
 0.98 0.90 to 1.07 
Edling 0.98 0.90 to 1.07 
Bertazzi 0.98 0.90 to 1.07 
Andjelkovich 0.97 0.89 to 1.06 
Beane Freeman 0.95 0.86 to 1.04 
Meyers 0.97 0.88 to 1.06 
Coggon 0.95 0.87 to 1.04 
Harrington 1.00 0.92 to 1.08 
Levine 0.98 0.90 to 1.07 
Stroup 1.00 0.92 to 1.08 
Hall 1.02 0.94 to 1.10 
Bond 0.99 0.91 to 1.07 
Gerin 1.00 0.92 to 1.09 
Partanen 0.98 0.90 to 1.06 
Brownson 0.98 0.90 to 1.07 
De Stefani 0.97 0.89 to 1.05 
Checkoway 0.98 0.98 to 1.06 
Mahboubi 0.97 0.89 to 1.06 
 
The most influential study in terms of altering the meta-RR when excluded was the 
study of pathologists by Hall et al.  However, the overall findings were relatively robust 
to the exclusion of a single study. 
In terms of the effect on the analysis, of possible alternative risk estimates being chosen, 
none of the studies with a weight of 5% or more in the main analysis had alternative 
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estimates and so this was judged not likely to have any impact on the overall 
conclusions.  
The existence of publication bias was first examined using a funnel plot.  The plot 
contains the regression line corresponding to the regression test for funnel-plot 
symmetry proposed by Egger et al [26]  This is set out in Figure 5.4.  There is a 
suggestion of asymmetry in the plot with a tendency for studies showing a lack of 
effect.  However, a lack of symmetry in funnel plots does necessarily indicate the 
presence of publication bias.  The asymmetry in this plot is in the opposite direction to 
that expected with the usual publication bias (non-publication of small non-positive 
studies). 
Figure 5.9 – Funnel plot of relative risk estimates for lung cancer in relation to 
occupational exposure to formaldehyde 
 
Looking at the plot by study type yields the graph set out in Figure 5.10.  
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Figure 5.10 - Funnel plot of relative risk estimates for lung cancer in relation to 
occupational exposure to formaldehyde by study type 
 
The estimated bias coefficient from Egger’s test is -1.47 with a standard error of 0.38, 
giving a p-value of 0.001, which is highly statistically significant.  Repeating the test 
excluding the professional cohort studies, yields a p-value of 0.004 which is still highly 
significant. 
The significant excess of lung cancer from the fixed effect model was not evident in the 
random effects model, nor were there any statistically significant excesses in any of the 
important subgroups for this model. 
The findings for lung cancer generally substantiate the prior belief that there was no 
association between occupational exposure to formaldehyde and increased risk of lung 
cancer, as exemplified by the IARC monograph not giving lung cancer a mention in its 
evidence synthesis statement [88].  The literature has recently focussed in on 
nasopharygeal cancer and risk from haematopoietic cancers such as leukaemia, see for 
example [175].  The absence of an exposure-response relationship in studies also argued 
against a causal interpretation, although dose-response was not explicitly examined as 
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part of this analysis.  The most recent meta-analyses that predated the current study that 
looked at lung cancer in relation to formaldehyde both found significant excess risks 
[76, 176].  Despite being chemically very reactive, it is plausible for formaldehyde to be 
adsorbed onto particles and be transported deep into the lungs [177].  However, there is 
no evidence that exposures received in industry are substantially higher than those in, 
for example, funeral homes. 
It is noteworthy that two of the large industrial cohort studies found a statistically 
significantly raised relative risk [89, 126].  It is plausible that this could be due to 
exposure to other occupational lung carcinogens likely to be present in the 
manufacturing plants included in the studies. 
5.3.3 Nasopharyngeal cancer 
For nasopharyngeal cancer there were 16 risk estimates from 14 studies containing 240 
nasopharyngeal cancers.  The fixed effect analysis on the original scale gave a meta-RR 
of 1.19 (0.94 to 1.44).  Between-study heterogeneity was highly statistically significant 
and so the random effects analysis is to be preferred.  Here the meta-RR was 1.41 (0.60 
to 2.22).  It is noteworthy that the analysis on the original scale allowed inclusion of 
four relative risk estimates where there were no observed cases. 
The forest plot for all risk estimates is set out in Figure 5.11 
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Figure 5.11 – Random effects meta-analysis of nasopharyngeal cancer on the original 
scale  
 
 
Note: the meta-RR was 1.41 (0.60 to 2.22).  In order to avoid negative lower confidence limits a version 
of metan that respected CIs is given but this meant the meta-RR was excluded. 
A sensitivity analysis excluding each study in turn from the fixed effect analysis is set 
out in Table 5.12. 
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Table 5.12 – Meta-RR for fixed effect model on original scale excluding each study in 
turn 
Study Excluded Meta-RR 95% CI 
 1.41 0.60 to 2.22` 
Edling 1.17 0.92 to 1.43 
Roush 1.44 0.55 to 2.33 
Hayes 1.29 0.43 to 2.15 
West 1.36 0.46 to 2.25 
Hildesheim 1.45 052 to 2.37 
Armstrong 1.52 0.59 to 2.45 
Hansen 1.43 0.57 to 2.28 
Vaughan 1.45 0.53 to 2.37 
Beane Freeman 1.38 0.51 to 2.26 
Siew 1.48 0.59 to 2.37 
Andjelkovich 1.44 0.62 to 2.25 
Stroup 1.44 0.62 to 2.25 
Coggon 1.50 0.66 to 2.34 
Meyers 1.51 0.67 to 2.36 
 
Of these studies, the exclusion of the Edling study has the largest influence on the meta-
RR as it decreased to 1.17although it remained not statistically significant.  
Formal sub-group analyses would of limited value given the Edling outlier and the 
sensitivity of pooled estimate to method. 
The funnel plot of relative risk estimates for nasopharyngeal cancer in relation to 
occupational exposure to formaldehyde is set out in Figure 5.12. 
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Note that this plot excludes the RR from the Edling study because of its very large 
standard error.  There is a lack of asymmetry and the Egger regression test is not 
significant. 
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Figure 5.12 – Funnel plot of relative risk estimates for nasopharyngeal cancer in 
relation to occupational exposure to formaldehyde 
 
The findings of this meta-analysis are consistent with the most recent meta-analyses 
conducted by Bachand et al [122], Bosetti et al [121], and Collins et al [76], suggesting 
that there is insufficient evidence of a statistically significantly elevated meta-RR.  It 
may turn out that formaldehyde does cause nasopharyngeal cancer, but on the present 
evidence, there is insufficient evidence of a raised relative risk.  This is further 
exacerbated by the relatively poor exposure assessment from the case-control studies 
and the problems in the interpretation of the excess found in one plant in the NCI 
cohort, albeit with the latter being a post hoc finding. 
5.3.4 Sinonasal cancer 
For sinonasal cancer there were 28 estimates from 15 studies incorporating 367 cases.  
The fixed effect analysis on the original scale gave a meta-RR of 1.01 (0.85 to 1.17).  
Between-study heterogeneity was not statistically significant and so the fixed effect 
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analysis is to be preferred.  It is noteworthy that the analysis on the original scale 
allowed inclusion of eight relative risk estimates where there were no observed cases. 
The forest plot for all risk estimates is set out in Figure 5.13. 
Figure 5.13 – Fixed effect meta-analysis of sinonasal cancer on the original scale  
 
 
Note: the meta-RR was 1.01 (0.85 to 1.17).  In order to avoid negative lower confidence limits a version 
of metan that respected CIs is given but this meant the meta-RR was excluded. 
A sensitivity analysis excluding each study in turn from the fixed effect analysis is set 
out in Table 5.14. 
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Table 5.14 – Meta-RR for fixed effect model on original scale excluding each study in 
turn 
Study Excluded Meta-RR 95% CI 
 1.01 0.85 to 1.17 
Olsen 1.00 0.85 to 1.l7 
Roush 1.01 0.85 to 1.18 
Hansen 0.98 0.82 to 1.15 
Beane Freeman 1.01 0.85 to 1.17 
Coggon 1.01 0.85 to 1.18 
Luce 0.86 0.59 to 1.13 
Siew 1.00 0.83 to 1.17 
Pesch 1.07 0.89 to 1.24 
Andjelkovich 1.01 0.85 to 1.17 
Stroup 1.01 0.85 to 1.17 
Jensen 1.01 0.85 to 1.17 
Hayes 1.02 0.85 to 1.18 
Walrath 1.01 0.85 to 1.17 
Levine 1.01 0.85 to 1.17 
Meyers 1.01 0.85 to 1.18 
 
Of these studies, the exclusion of the Luce study, not surprisingly, has the largest 
influence on the meta-RR as it reduces to 0.86 and therefore not statistically 
significantly raised. 
Exploration of subgroup meta-RRs is not presented for sinonasal cancer, because of the 
absence of any evidence of heterogeneity, but tests of variation of subgroups were 
carried out and no significant differences were found. 
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The funnel plot of relative risk estimates for nasopharyngeal cancer in relation to 
occupational exposure to formaldehyde is set out in Figure 5.14. 
Figure 5.14 – Funnel plot of relative risk estimates for sinonasal cancer in relation to 
occupational exposure to formaldehyde 
 
There is a lack of asymmetry and the Egger regression test is not significant. 
The findings of this meta-analysis are consistent with the most recent meta-analyses 
conducted by Binazzi et al, [123], Bachand et al [122], and Bosetti et al [121], 
suggesting that there is insufficient evidence of a statistically significantly elevated 
meta-RR. 
5.4 DISCUSSION AND CONCLUSIONS 
This meta-analysis substantiates the available evidence on risks of lung cancer and 
sinonasal cancer from occupational exposure to formaldehyde.  The meta-RR for lung 
cancer, based on the random effects meta-analysis on the log scale was 0.98 (0.90 to 
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1.07) suggesting no overall increase in relative risk.  For sinonasal cancer, the fixed 
effect meta-analysis gave a meta-RR of 1.01 (0.85 to 1.17). 
The random effects meta-analysis for nasopharyngeal cancer gave a meta-RR of 1.41 
(0.60 to 2.22).  A naïve fixed effect meta-analysis on the log scale (thus excluding the 
studies with no observed cases) gave a meta-RR of 1.38 (1.11 to 1.71), a meta-relative 
risk which was of similar magnitude, but more precise.  Examination of the totality of 
the evidence, including studies that have zero observed cases, does not provide support 
for the IARC classification that formaldehyde is a definite carcinogen in relation to 
nasopharyngeal cancer. 
An association has been postulated for lung cancer on the basis that formaldehyde can 
be adsorbed onto the surfaces particles and therefore taken into the inner lung.  The 
association with sinonasal cancer was considered as the nose and nasal cavities are the 
first point of contact for formaldehyde when breathed in through the nose.  
Nasopharyngeal cancer however, is thought to be the most plausible respiratory cancer 
site, because it is accepted that formaldehyde causes sinonasal cancer in rates and the 
equivalent organ site in humans is the nasopharynx [96]. 
For lung cancer, significant heterogeneity was explored via subgroup analysis using the 
random effects model.  However, none of the subgroups showed a statistically 
significant excess.  This finding was robust to sensitivity analyses such as excluding one 
study at a time from the analysis and from choosing alternative risk estimates and are 
generally consistent with all the previously conducted meta-analyses [76, 117-119, 122, 
124, 176].  Likewise, the findings for sinonasal cancer and nasopharyngeal cancer were 
also consistent with the earlier meta-analyses. 
Some aspects of study heterogeneity, in particular, differences in exposure levels and 
methods of exposure assessment were not explored in detail in these analyses and 
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should be examined, as they have the potential to mask differences between study types.  
Some of the studies were also limited, in some cases by design and in others by 
conduct, in their ability to control for known and suspected confounding factors, either 
occupational or non-occupational in origin.  However, it is noteworthy that whether or 
not a study adjusted for smoking did not seem to have any impact on the meta-analyses 
conducted. 
The meta-analyses carried out here used an indirect method of calculating an expected 
number of cases for the rarer cancers based on an appropriate fraction of the expected 
number of lung cancers.  Other approaches to deriving an expected number are possible 
and it would be a useful comparison exercise for this to be done.  Only studies where an 
actual number of cases could be deduced from reading the manuscripts were included.  
Although efforts were made to include studies where an observed number of cancers 
could be deduced (and therefore a relative risk could be estimated), studies where this 
could not be done were not included.  This has not been attempted, but might further 
reduce the meta-RR for both nasopharyngeal and sinonasal cancers were such an 
exercise to be carried out. 
A limitation of the meta-analyses carried out here is that some of the studies were based 
on administrative data, such as cancer registries, and thus often lacked information on 
risk factors and estimates of formaldehyde exposure.  Indirect methods of assessing 
exposure to formaldehyde were used based on job history, rather than on actual 
measurement data. 
Other aspects importantly not controlled for in the meta-analyses were differences in the 
baseline characteristics of the study populations and differences in length of follow-up 
for cohort studies making the pooling of SMRs questionable. 
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The lack of heterogeneity in the sinonasal cancer analyses could be due to a lack of 
statistical power to detect it. 
Future research should aim to collect more detailed data on study characteristics and 
should assess the exposure-response relationship, perhaps by indirectly assessing 
exposures for those studies lacking in an exposure assessment.  Assessing the potential 
for an impact of co-exposures should also be considered. 
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6 CONCLUSIONS 
6.1 OVERVIEW 
This thesis set out with the intention of improving on current practice of meta-analyses 
of rare diseases in occupational epidemiology.  The example which motivated the work 
was prompted by the announcement by the International Agency for Research on 
Cancer that formaldehyde was a definite carcinogen in humans, because it was a proven 
carcinogen for sinonasal cancer in rats and from occupational cohort and population-
based case-control studies of nasopharyngeal cancer in humans [178].  The evidence 
from occupational cohort studies seemed over-reliant on the single study carried out by 
the National Cancer Institute in the USA [82].  A potentially important source of bias 
for these studies could have been the exclusion of studies with no exposed cases.  The 
evidence was also reliant on a number of population-based case-control studies that can 
be prone to bias [179].  This could have arisen in two important ways: inadequate 
control of exposure to Epstein Barr virus, a known risk factor for nasopharyngeal 
cancer, the prevalence of which is particularly high in Asian populations could have 
resulted in a selection bias; poor characterisation and control of known or suspected 
confounding factors.  
Eight meta-analyses of one or more of lung cancer, nasopharyngeal cancer and 
sinonasal cancer have been published in the epidemiological literature [76, 117, 118, 
121-123, 180, 181].   None of them has found strong evidence of an increased risk for 
any of these cancers, making the most recent IARC findings [88] somewhat at odds 
with the totality of the literature. 
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6.2 PAST PRACTICE OF META-ANALYSIS IN 
OCCUPATIONAL EPIDEMIOLOGY 
The published review of past practice only contained a review of practice until 2001 and 
so is now somewhat out of date.  The call for better approaches to integrate sources of 
variation including potentially diverse measures of occupational exposure and SMRs 
based on different study populations, comparator populations and lengths of follow 
remains as relevant today as it did then.  Petitti’s cautionary note on meta-analysis [2] is 
better heeded now than in was some 10 years ago.  Reporting of meta-analyses 
according to guidelines such as the MOOSE guidelines [128] are generally insisted 
upon by journal editors of the better occupational epidemiology journals.  They 
importantly recommend including a flow diagram of study identification and selection, 
double independent data extraction, robust classification of exposure to the agent or 
substance of interest as well as any important known or suspected occupational and 
non-occupational confounding factors and exploration of heterogeneity (now becoming 
known as bias exploration in some fields [182]).  Appropriate sensitivity analysis to test 
the robustness of any findings such as in Bachand et al [122] should also be included. 
Therefore, although current practice has certainly improved since the earlier review [3], 
there remains many unanswered issues about the robustness of the meta-analysis 
methodology as employed in occupational epidemiology, particularly with respect to 
rare diseases such as nasopharyngeal cancer and sinonasal cancer.  In particular the 
issues of diverse measures of occupational exposures between studies and the 
comparability and combination of SMRs have not yet been fully resolved. 
6.3 REVIEW OF METHODS 
Specific methods exist for combining odds ratios, SMRs, correlation coefficients and 
generic measures of relative risk.  A fixed effect approach exists for estimating the 
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meta-RR in the absence of between-study heterogeneity exists as does a random effects 
approach for the presence of significant heterogeneity.  Bayesian methods also exist.  
Heterogeneity can be explored informally via subgroup analysis or via regression 
modelling, either via meta-regression or for observed cases from cohort studies via 
Poisson or negative binomial regression.  These models can also incorporate random 
effects terms.  Methods also exist for assessing and testing for publication bias.  
Specific methods for dealing with exposure-response data also exist, but they are 
outside the scope of this research.  Sensitivity analyses to assess the robustness of any 
findings now play a key role in any meta-analysis.  More recent developments include, 
particularly in multivariate method analysis and in network analysis.  A very recent 
development is the so-called IVhet model for which it is claimed to be an improvement 
on both fixed effect and random effects models. 
6.4 RARE DISEASE OUTCOMES 
The use of adding a small correction to the observed number of cases or the observed 
and expected number of cases seems to be problematic as the optimum value of this 
correction, that is the one that minimizes the introduction if bias into the analysis, 
cannot be chosen in advance, but depends on the data being analysed.  Methods that 
utilise analysis on the log scale and by so doing exclude studies are to be avoided 
because of the inflationary tendency for the relative risks in such studies.  Analyses on 
the original untransformed scale obviate the need to exclude such studies.  However, 
further exploration of the reliance of this approach on a normality assumption is 
warranted.  Further exploration of Poisson regression and in the presence of over-
dispersion negative binomial fixed and random effects models for their relevance for 
occupational epidemiological studies should be undertaken (there may be difficulties for 
studies other than cohort studies). 
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6.5 META-ANALYSES OF FORMALDEHYDE 
The most recent meta-analysis of formaldehyde and lung cancer gave a meta-RR of 1.07 
(1.01 to 1.12) for industrial cohort studies and 0.68 for professional cohort studies 
[121].  The most recent meta-analysis of lung cancer in case-control studies yielded a 
meta-RR of 0.8 (0.7 to 1.0) [76].  For nasopharyngeal cancer the meta-RR for industrial 
cohort studies was 0.72 (0.40 to 1.29) [122], for professional cohort studies was 0.91 
(0.25 to 2.33) [76] and for case-control studies was 1.22 (1.00 to 1.50) [122].  For 
sinonasal cancer the meta-RR for industrial cohort studies was 1.09 (0.66 to 1.79) 
[123]for professional cohort studies was 0.00 (0.00 to 3.51) [183] and for case-control 
studies was 1.68 (1.37 to 2.06) [123]. 
For lung there were 30 estimates of relative risk incorporating 6,476 lung cancers.  The 
fixed effect analysis gave a meta-RR of 1.12 (1.08 to 1.15).  However, there was 
significant heterogeneity (p < 0.001).  The random effects model gave a meta-RR of 
0.98 (0.90 to 1.07) suggesting that there was no association between occupational 
exposure to formaldehyde and increased risk of lung cancer.  This finding was 
consistent with the earlier meta-analyses. 
None of the subgroups defined a priori contained a statistically significant excess.  The 
findings were robust to the exclusion of single studies and also to the choice of 
alternative (suboptimal) effect estimates.  There was no evidence of publication bias in 
the form of likely missing small studies showing small effects.  This finding was 
consistent with previous meta-analyses and also with the views of the IARC working 
group. 
There were a number of limitations to the lung cancer analysis, the most important of 
which was the lack of consideration of exposure-response.  Exposure-response is 
considered an important aspect of the Bradford Hill causality considerations [184].  
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Good practice would normally involve at least two researchers independently extracting 
the data for the study and resolving any differences found.  This did not happen and 
would need to happen before the substantive meta-analysis could be written up for 
submission for publication in a peer-reviewed scientific journal.  Other forms of bias 
assessment could also be carried out in relation to the assessment of ever or never 
exposed to formaldehyde.  It is likely that this assessment might vary over time for 
example, and it is a moot point as to what is regarded as unexposed for a substance that 
is regarded as ubiquitous in the environment.  This is probably best undertaken as part 
of consideration of exposure response. A consistent assessment of exposure across the 
studies in the absence of knowledge of study outcome is required and is probably best 
carried out by an experienced occupational hygienist or exposure scientist.  Other 
sources of heterogeneity include the inclusion and exclusion criteria applied to study 
populations, although these are not always reported, together with the length of follow-
up in occupational cohort studies.  Ideally an adjustment for individual-level exposure 
to tobacco smoking and other known or suspected occupational lung carcinogens would 
be available, but this rarely happens in practice.  Nevertheless, some indication of the 
potential impact on the meta-RR would be useful.  Thus although the confidence 
intervals from the random effects meta-analysis reflect statistical heterogeneity, other 
variations between studies suggest that the true level of uncertainty surrounding the 
meta-RR is probably greater than that expressed by the confidence interval. 
It is noteworthy that two of the large industrial cohort studies found a statistically 
significantly raised relative risk [89, 126].  It is plausible that this could be due to 
exposure to other occupational lung carcinogens likely to be present in the 
manufacturing plants included in the studies. 
For nasopharyngeal cancer there were 16 risk estimates from 14 studies containing 240 
nasopharyngeal cancers.  Four studies contained no observed cases.  The random effects 
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meta-analysis on the original scale gave a meta-RR of 1.41 (0.60 to 2.22).  This finding 
is consistent with previous meta-analyses, for example Bachand et al, Bosetti et al and 
Collins et al [122, 176, 185] that have been carried out, but does not provide strong 
support for the IARC view that exposure to formaldehyde causes nasopharyngeal cancer 
[88].   
Formaldehyde causes nasal cancer in rats and due to differences in the nature of the 
nasal passage between rats and humans; the equivalent site in humans is the 
nasopharynx.  However, the meta-analyses undertaken here is not supportive of a casual 
interpretation.  It may turn out with further evidence that formaldehyde causes 
nasopharyngeal cancer, but the evidence to support this conclusion is insufficient.  The 
same shortcomings that apply to the evidence relating to lung cancer also apply to 
nasopharyngeal cancer.  In addition, the inclusion of evidence from studies that had the 
potential to report on nasopharyngeal cancer, but provided no way of deducing the 
number of cases, could be additionally included in the meta-analysis assuming there 
were no actual cases.  Alternative methods of estimating the expected number of 
nasopharyngeal cancer cases, rather than taking a fixed fraction of the expected number 
of lung cancer cases might also be explored.  Whilst the argument in the literature over 
plant 1 in the NCI cohort study continues [91], it appears to not unduly influence the 
findings of the meta-analysis presented in this thesis as the study has much less 
influence on the meta-RR than for example the Armstrong case-control study [98].  
There appears to be no evidence of publication bias for nasopharyngeal cancer in 
relation to formaldehyde exposure. 
For sinonasal cancer there were 28 estimates from 15 studies incorporating 367 cases.  
The fixed effect analysis on the original scale gave a meta-RR of 1.01 (0.89 to 1.17).  
There was no significant between-study heterogeneity and the findings were robust to 
the exclusion of individual studies and no evidence of publication bias.  A similar 
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discussion applies to that for nasopharyngeal cancer, except that the nasopharynx is the 
more relevant site of contract for formaldehyde than the nose and nasal cavities.  It is 
also worth noting that an additional limitation of the sinonasal cancer analysis is the 
lack of separate (due to small numbers) of the nasal cancers from those of the sinonasal 
cavities as it is possible that the two cancer sites may have different aetiologies. 
6.6 CLOSING REMARKS 
Meta-analysis has been used to demonstrate that there is a lack of evidence that 
occupational exposure to formaldehyde increases the risk of nasopharyngeal cancer, 
sinonasal cancer or lung cancer.  Studies of rare diseases in occupational epidemiology 
should take care to include evidence from studies with no observed cases as the 
resulting bias could lead to spuriously significant excesses being found. 
For future research priorities, my experience suggests that bias analysis methods should 
be exploited as there is a significant potential for bias in studies in occupational 
epidemiology.  The combination of risk estimates from different study types and 
whether or not that is appropriate still requires resolution.  More important for 
occupational epidemiology is whether SMRs can be combined to produce a meta-SMR 
when heterogeneous study populations and comparison populations are used and 
cohorts have different lengths of follow-up and exposures in the cohorts may not be 
directly comparable.  Some clear guidance on whether and when relative risk estimates 
from different study types might be combined would be useful.  Meta-analysis seems to 
be used a little more cautiously now in occupational epidemiology.  Generally studies 
follow the MOOSE reporting guidelines and the robustness of findings and assessment 
of publication bias are carried out.  However, other forms of bias, principally around 
study characteristics and exposure data require resolution.  It is important this issue is 
brought to the attention of research funders, as at present, most of the methodological 
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development in meta-analyses occurs within the randomized controlled clinical trial 
setting.  However, the issues specific to occupational epidemiology may not be being 
addressed as a matter of priority.  There is a growing awareness of the issue of meta-
analysis of rare diseases in occupational epidemiology and the methodology for dealing 
with is partly stems from that developed for dealing with rare adverse events in meta-
analyses of randomized controlled clinical trials.  However there remains a current lack 
of consensus on how this issue should be dealt with.  Finally, the statistical issues 
relating to analysis on the original scale require clarifying as to whether distributional 
assumptions have been violated. 
Meta-analysis remains a powerful technique for helping to make sense of associations 
in a variety of occupational and population settings.  However, a number of unresolved 
issues remain with its application in the field of occupational epidemiology. 
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APPENDIX 1 – SUMMARY OF THE EPIDEMIOLOGICAL 
STUDIES INCLUDED IN THE META-ANALYSIS IN 
CHAPTER 5 
A1.1 THE NATIONAL CANCER INSTITUTE (NCI) COHORT 
The NCI cohort study is a study of industrial workers employed at 10 formaldehyde-
producing or formaldehyde-using plants in the USA.  A series of publications have been 
produced of some of the individual plants and of all the plants combined.  They are 
summarised below. 
The latest analysis of the full NCI cohort, which updated earlier publications of analyses 
of the same cohort or parts thereof [89, 186-197], included 25,619 workers employed at 
one of ten plants prior to 1 January 1966 in the US formaldehyde industry [82].  
Subjects were followed-up from the year in which employment records were considered 
complete at the plant - earliest 1934 - or date of first employment at the plant, if later, to 
the end of 204.  Exposures to formaldehyde were estimated from work histories up to 
1980 and were based on job title, tasks, and visits to the plant by industrial hygienists, 
discussions with plant workers and managers, and monitoring data.  Exposure 
assessments over time to 1980 were made for cumulative exposure in ppm-years, 
average exposure intensity in ppm, duration of exposure in years, highest peak exposure 
category in ppm, exposure to formaldehyde-containing particulates summarised as 
ever/never, duration of exposure to 11 other suspected carcinogens and widely-used 
chemicals, and duration of working as a chemist or laboratory technician in years.  All 
exposures were lagged by 15 years to account for the latency of solid cancers.  SMRs 
were calculated using the person-years method and relative risks were calculated using 
Poisson regression models, adjusting for calendar year, age, sex, race and pay category.  
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Potential confounding by other chemicals or work as a chemist or laboratory technician 
was evaluated. 
Based on comparisons with the US population, mortality from nasopharyngeal cancer 
was non-significantly raised among those exposed to formaldehyde (SMR =184, 95% 
CI 84 to 349, 9 deaths).  There was a highly statistically significant increasing trend in 
relative risk for increased level of peak exposure (p < 0.001).  The increasing trends for 
nasopharyngeal cancer for average exposure intensity (p = 0.09) and cumulative 
exposure (p = 0.06) were of borderline.  There was an increased RR of nasopharyngeal 
cancer in the highest categories of formaldehyde exposure, with eight of 10 deaths 
occurring among formaldehyde-exposed workers.  The RR was 7.66 (0.94 to 62.34) for 
peak exposures, 11.54 (1.38 to 96.81) for average exposure intensity and 2.94 (0.65 to 
13.28) for cumulative exposure, compared with the lowest exposure category.  Duration 
of exposure, regardless of exposure level, resulted in a RR of 2.53 (0.4 to 15.0) in the 
highest category (>15) years, p-trend = 0.4.  Five of the 10 deaths occurred in the plant 
singled out for attention by Marsh in his critique of the NCI study.  They conducted an 
influence analysis excluding one plant at a time.  When any plant other than plan 1 was 
excluded, the results were similar to the overall analysis.  When plant 1 was excluded, 
the number of nasopharyngeal cancer deaths was two in the highest peak exposure 
category RR = 3.36 (0.3 to 37.27), one in the highest average intensity category and 
zero in the highest cumulative exposure category. 
Mortality from cancer of the nose and nasal cavity was around expected SMR = 90 (18 
to 262, 3 deaths).  There was no evidence of any exposure-response relationship for 
nose and nasal sinus cancer. 
There were 1,291 deaths from lung cancer and a significantly elevated SMR in those 
exposed to formaldehyde 114 (1.07 to 1.20).  [82]In internal analyses, there was a 
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significantly decreased risk in the highest category of peak RR = 0.77 (0.67 to 0.90, p-
trend = 0.001) and cumulative formaldehyde exposure RR = 0.78 (0.66 to 0.93, p-trend 
= 0.02).   
A1.2 THE NIOSH COHORT 
The latest analysis of the NIOSH cohort [127] updated two earlier analyses of the same 
cohort [198-200] and included 11,043 workers, predominantly white and female, 
exposed to formaldehyde for three months or more in three garment manufacturing 
plants.  Follow-up was from 1955 to 2008.  Forty two per cent of the cohort was first 
exposed before 1963, when formaldehyde exposure levels were thought to be higher 
than in later years.  The median duration of exposure was 3.3 years and the median time 
since first exposure was 39.4 years.  The authors reported that there was no evidence of 
the presence of other potentially carcinogenic exposures at the three plants. 
Mortality in the cohort was compared with the US and state populations using SMRs.  
Stratified analyses by duration of exposure, time since first exposure and year of first 
exposure were undertaken, together with tests for trends in SMRs.  Multiple cause 
analyses utilising non-underlying causes of death were also employed.  Poisson 
regression analysis was used to examine rate ratios by exposure duration. 
No deaths from cancer of the nasopharynx, SMR = 0 (0 to 277), or the nose and nasal 
sinuses, SMR = 0 (0 to 389), were observed.  Mortality from lung cancer was similar to 
that expected based on US rates with SMR = 104 (95% CI 92 to 117, 267 deaths).  The 
results using state rates were similar.  Lung cancer was elevated among workers first 
exposed in 1971 or later and was highest among person-time with < 10 years since first 
exposure.  There was no clear pattern of increased risk across increasing exposure 
duration categories and was less than expected for the longest duration of exposure (10+ 
years) category compared to the US population.  Overall, although lung cancer risk was 
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elevated in some subgroups, there was little evidence that formaldehyde was associated 
with lung cancer. 
A1.3 THE BRITISH COHORT 
The latest analysis of the British cohort [126]updated earlier analyses of the same cohort 
[201-205].  The cohort comprised 14,008 men who had been employed at six British 
chemical factories from 1938 to 1964 at a time when formaldehyde was produced or 
used, and follow-up was from 1941 to 2012.  Occupational histories were abstracted 
from employment records.  No formaldehyde measurements were available before 
1970, but later measurements and workers’ recall of irritant symptoms resulted in the 
following exposure classification: background (< 1 ppm); low (0.1 - 0.5 ppm); moderate 
(0.6 - 2.0 ppm); high (> 2.0 ppm); and unknown.  Some of the exposures may have been 
through inhalation of formaldehyde particles or particles of formaldehyde-based 
products.  In addition to formaldehyde, other potential carcinogenic exposures were 
present although any exposures were deemed to have been relatively low.  SMRs were 
calculated using national mortality rates and national rates with an adjustment for 
locality.  Poisson regression analysis was used to test for trends across ordered 
categorical exposures. 
There was only one death from nasopharyngeal cancer, with 2.0 expected (SMR = 50, 
95% CI 13 to 279) based on national rates, and the man concerned had not worked in a 
job with high exposure to formaldehyde. 
Overall there was an elevated risk of lung cancer (813 observed v 645.8 expected), 
which was significantly elevated.  When broken down by factory, one factory had no 
elevated risk, but the risk was elevated at each of the other five factories.  For nose and 
nasal sinuses there was 0 deaths v 0.9 expected and for nasopharyngeal cancer, the only 
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death occurred in a man with moderate/low exposure (1.7 deaths expected for exposures 
above background).   
For lung cancer, there was no exposure-response relationship.  Indeed risk was lower in 
men with prolonged high exposure than in those highly exposed for less than one year 
and this pattern persisted when each man’s first 35 years of follow-up were disregarded.  
The authors suggested that their finding for lung cancer was likely explained by non-
occupational factors. 
A1.4 OTHER INDUSTRIAL COHORT STUDIES 
The cancer morbidity and mortality of a cohort of 521 men manufacturing abrasive 
materials has been examined [152].  The cohort was followed-up from 1958 to 1983 and 
included men who were employed at least five years some time between 1955 and 1983.  
During the manufacture of grinding wheels bound by formaldehyde resins, there was 
moderate exposure to formaldehyde of 0.1 to 1 mg/m
3
.  During the manufacture of 
abrasive belts, workers had an intermittent heavy exposure to formaldehyde of 20 to 30 
mg/m
3
.  Mortality and morbidity were compared with the national Swedish data.  There 
was one case of nasopharyngeal cancer and no cases of sinonasal cancer. 
The most recent update of an Italian cohort of workers exposed to formaldehyde during 
the manufacture of resins [153] extended the follow-up of an earlier publication [206].  
From 1974 to 1979 the mean concentration ranged from 0.064 ppm to 2.13 ppm and the 
peak exposure ranged from 0.33 ppm to 6.53 ppm.  The latest analysis included 1330 
male workers who worked at the factory for 30 days or more between 1959 and 1980 
and who were followed-up until 1986.  Local and national populations were used as the 
basis for calculating SMRs.  In the latest report, no mention is made of nasopharyngeal 
cancer [153].  In the earlier report, there were no cases of nasal cancer, with 0.0327 
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expected [206].  The SMR for lung cancer for those exposed to formaldehyde based on 
local rates was 69 (95% CI 25 to 150, 6 deaths) [153]. 
The mortality experience of a subcohort 3929 men who worked at an iron foundry in the 
US and who were exposed to formaldehyde at for at least six months from 1960 to 1987 
was compared with the national population via SMRs and lung cancer mortality was 
also compared with an internal group of 2032 men unexposed to formaldehyde via 
Poisson regression analysis [154].  Findings for the full cohort have previously been 
reported [207].  Follow-up in this report was from 1950 to 1989 [154].  According to 
NIOSH surveys, the level of formaldehyde found in iron foundries ranged from < 0.02 
to 18.3 ppm.  Each of 107 occupational titles was categorised as high (1.5 ppm), 
medium (0.55 ppm), low (0.05 ppm) or no exposure to formaldehyde.  Among workers 
exposed to formaldehyde the SMR for cancer of the buccal cavity and pharynx was 101 
(95% CI 48 to 286, 6 deaths) and among the unexposed, the SMR was 169 (95% CI 54 
to 395, 5 deaths).  There was only one death from nasopharyngeal cancer and this was 
in an unexposed worker.  An approximate 95% confidence interval for the 
nasopharyngeal cancer SMR in formaldehyde-exposed men based on the expected 
number of lung cancer deaths is 0 to 1816.  There were no deaths from nasal cancer; an 
equivalent approximate 95% CI for the SMR is 0 to 7306.  For exposed men, the SMR 
for lung cancer was 120 (95% CI 89 to 158, 51 deaths) and for men unexposed to 
formaldehyde was 119 (95% CI 84 to 163, 38 deaths).  From the Poisson regression, the 
rate ratio for lung cancer for exposed versus unexposed was 0.71 (95% CI 0.44 to 1.21) 
[154]. 
 189 
A1.5 COHORT STUDIES OF PATHOLOGISTS, ANATOMISTS, 
FUNERAL DIRECTORS AND EMBALMERS 
The mortality of 2079 British pathologists alive in 1955 was followed-up to 1983.  
SMRs were calculated on the basis of rates for Great Britain.  Five unspecified 
malignant neoplasms were included in the total, and it is unclear whether any of them 
were nasopharyngeal or nasal cancers.  The SMR for lung cancer was 39 (95% CI 20 to 
71, 11 deaths) [155]. 
A cohort study of 1477 male undertakers in Ontario, Canada, examined mortality of 
those first licensed from 1928 to 1957 and followed up from 1950 to 1977 [117].  This 
study updated a slightly earlier report that used US rates for the comparison [208].  
SMRs for the latest report were calculated using mortality rates for Ontario.  The SMR 
for buccal cavity and pharynx cancer was 48 (95% CI 1 to 265, 1 death); it is not clear 
whether or not this death was due to nasopharyngeal cancer.  There were no deaths due 
to nasal cancer (95% CI 0 to 1498) and the SMR for lung cancer was 94 (95% CI 57 to 
147, 19 deaths) [117]. 
A retrospective cohort has been established of 2317 male anatomists in the US who 
joined the American Association of Anatomists between 1888 and 1969 and who were 
living in the US when they joined [156], with the work being completed for a PhD 
thesis [209].  Follow-up was from 1925 to 1979 and SMRs were calculated on the basis 
of US rates.  The SMR for buccal cavity and pharynx cancer was 20 (95% CI 0 to 80, 1 
death) and the death was not due to nasopharyngeal cancer.  The SMR for cancer of the 
nasal cavity and sinuses was 0 (95% CI 0 to 720, 0 deaths).  The SMR for lung cancer 
was 30 (95% CI 10 to 50, 12 deaths). 
A mortality experience of a separate cohort of 3,872 British pathologists has also been 
examined [157], which updated an earlier report [210].  Members of the Royal College 
 190 
of Pathologists from 1973 to 1986 who were alive at the end of 1973 were followed up 
from 1974 to 1987.  SMRs were calculated on the basis of rates for England and Wales 
and for Scotland.  Four unspecified neoplasms were included in the total for England 
and Wales in the latest update, and it is unclear whether any of them were 
nasopharyngeal or nasal cancers.  The SMR for lung cancer for England and Wales was 
19 (95% CI 9 to 36, 9 deaths), and for Scotland the SMR was 60 (95% CI 16 to 154, 4 
deaths) [157]. 
A1.6 CASE-CONTROL STUDIES OF NASOPHARYNGEAL 
CANCER 
A population-based case-control study of male nasopharyngeal cancer cases (n = 173) 
was carried out with subjects identified from the Connecticut Tumour Registry from 
1935 to 1975 [211].  Controls (n = 605) were deaths among Connecticut residents 
during the same time period and were selected randomly without stratification or 
matching.  Exposure to formaldehyde was assessed according to a probability and level 
of exposure blind to case-control status in the same way as the NCI cohort [187], with 
occupational histories being constructed from death certificates and City Directories.  
Odds ratios adjusted for age at death, year at death, and availability of occupational 
information were calculated using logistic regression, but were not adjusted for other 
occupational exposures.  For nasopharyngeal cancer the OR for probably exposed to 
some level for most of working life compared with all others was 1.0 (95% CI 0.7 to 
2.4).  For probable exposure to some level for most of working life and probable 
exposure to some level 20 or more years prior to death, the OR was 1.3 (95% CI 0.7 to 
2.4).  For probably exposed to some level for most of working life and probably 
exposed to high level in some year the OR was 1.4 (95% CI 0.6 to 3.1).  For those 
probably exposed to some level for most of working life and probably exceeded high 
level 20 years or more before death, the OR was 2.3 (95% CI 0.9 to 6.0).   
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A case-control study of nasopharyngeal cancer was carried out in the Philippines on 104 
predominantly non-Chinese cases and 205 hospital and community controls [159].  Risk 
factor information was obtained through personal interview.  The occupational history 
of each subject was reviewed in the absence of knowledge of case-control status by an 
industrial hygienist.  Exposure to formaldehyde, solvents, dusts, exhaust and pesticides 
were assessed.  After controlling for confounding, subjects who were first exposed for 
formaldehyde 25 years or more prior to diagnosis or interview or who first exposed 
before the age of 25 were found, in relation to those never exposed, to be at a 4.0 fold 
excess risk of disease (1.4 to 12.3).  The equivalent risk for <25 years since first 
exposure was 1.2 (0.41 to 3.6).  The adjusted odds ratio for <15 years duration of 
exposure was 2.7 (1.1 to 6.6) and for 15 years or more was 1.2 (0.48 to 3.2). 
During 1990-1992, 282 Chinese residents in Malaysia with histologically confirmed 
nasopharyngeal carcinoma were interviewed about occupational history, diet, alcohol 
consumption, and tobacco use, as were an equal number Malaysian Chinese population 
controls, pair-matched to cases by age and sex [98].  Exposure to 20 kinds of workplace 
substances, solar and industrial heat, and cigarette smoking were analysed univariably 
and multivariably.  No significant crude or adjusted association was found between 
nasopharygeal carcinoma and formaldehyde, adjusted OR – 0.71 (0.34 to 1.43). 
A multi-centred population-based case-control study was carried out at five cancer 
registries in the United States [160].  Cases (n = 196) with a newly diagnosed 
nasopharyngeal cancer between 1987 and 1993 and controls (n = 244) selected over the 
same period from the general population through random-digit dialing participated in a 
structured telephone interview which inquired about suspected risk factors for the 
disease, including lifetime history of occupational and chemical exposure.  Potential 
exposure to formaldehyde was assessed blind to case-control status on a job by job basis 
by experienced industrial hygienists.  For formaldehyde, after adjusting for cigarette 
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use, race, and other risk factors, a trend of increasing risk of squamous and unspecified 
epithelial carcinoma was found for increase duration (p = 0.014) and cumulative 
exposure (p = 0.033) but not for maximum exposure concentration.  The odds ratio for 
people cumulatively exposed to >1.10 ppm-years was 3.0 (1.3 to 6.6) compared with 
those considered unexposed.  In analyses limited to jobs considered definitely exposed, 
these trends became stronger.  The associations were most evidence among cigarette 
smokers.  By contrast, there was no association between potential exposure to 
formaldehyde and undifferentiated and non-keratinising carcinomas. 
A case-control study was conducted among 375 newly diagnosed cases of 
nasopharyngeal carcinoma in Taipei, Taiwan and 325 community controls matched to 
cases on age, sex and geographical residence.  Most cases were diagnosed with non-
keratinising and undifferentiated carcinomas [212].  A complete occupational history 
was obtained via a personal interview and blindly assessed by an industrial hygienist for 
intensity and probability of exposure to wood dust, formaldehyde and solvents.  
Information on socio-demographic characteristics, cigarette smoking, dietary 
consumption of nitrosamines, and other potential confounding factors was obtained via 
a personal interview.  Blood specimens were tested for human antigen class I/II 
genotypes, polymorphisms in cytochrome P450 2E1 genotype, and various anti-EBV 
antibodies known to be associated with nasopharyngeal carcinoma.  Individual exposed 
to formaldehyde had a non-significant increased risk RR = 1.4 (0.93 to 2.2).  Those 
exposed to formaldehyde for >10 years had an adjusted RR of 1.6 (0.91 to 2.9).  The 
association between formaldehyde and nasopharyngeal carcinoma was stronger in 
analyses restricted EBV seropositive individuals RR = 2.7 (1.2 to 5.9).  However, no 
dose response was observed with increasing duration or cumulative use. 
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A1.7 CASE-CONTROL STUDIES OF SINONASAL CANCER 
A study of 759 histologically verified cancer of the nasal cavity (287 cases) and 
paranasal sinuses (179 cases) and 2,465 cancer controls diagnosed in Denmark between 
1970 and 1982 was conducted to investigate the importance of occupational exposure to 
formaldehyde [161].  Information on job history for cases and controls was derived 
from a national data linkage system and exposure to formaldehyde and wood dust was 
assessed by industrial hygienists unaware of the case-control status of the patients.  The 
exposure rates for formaldehyde among male and female controls were 4.2% and 0.1% 
respectively.  After proper adjustment for contemporary wood dust exposure, relative 
risks of 2.3 (0.9 to 5.8) for squamous cell carcinoma and 2.2 (0.7 to 7.2) for 
adenocarcinoma of the nasal cavity and paranasal sinuses were detected among men 
who had ever been exposed to formaldehyde in their job compared with those never 
exposed.  The introduction of 10 year latency did not change the risk estimates 
substantially. 
A population-based case-control study of male sinonasal cancer (n = 198) cases was 
carried out with subjects identified from the Connecticut Tumour Registry from 1935 to 
1975 [211].  Controls (n = 605) were deaths among Connecticut residents during the 
same time period and were selected randomly without stratification or matching.  
Exposure to formaldehyde was assessed according to a probability and level of 
exposure blind to case-control status in the same way as the NCI cohort [187], with 
occupational histories being constructed from death certificates and City Directories.  
Odds ratios adjusted for age at death, year at death, and availability of occupational 
information were calculated using logistic regression, but were not adjusted for other 
occupational exposures.  For sinonasal cancer the OR for probably exposed to some 
level for most of working life compared with all others was 0.8 (95% CI 0.5 to 1.3).  
For probable exposure to some level for most of working life and probable exposure to 
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some level 20 or more years prior to death, the OR was 1.0 (95% CI 0.5 to 1.8).  For 
probably exposed to some level for most of working life and probably exposed to high 
level in some year the OR was 1.0 (95% CI 0.5 to 2.2).  For those probably exposed to 
some level for most of working life and probably exceeded high level 20 years or more 
before death, the OR was 1.5 (95% CI 0.6 to 3.9). 
Data from 12 case-control studies of sinonasal cancer were pooled and re-analysed 
[162].  The pooled data set included 195 adenocarcinoma cases (169 men, 26 women), 
432 squamous cell carcinomas (330 men, 102 women) and 3,136 controls (2,349 men, 
787 women).  Occupational exposure to formaldehyde, silica dust, textile dust, coal 
dust, flour dust, asbestos and man-made mineral fibres were assessed with a job-
exposure matrix.  Odds ratios were adjusted for age, study, wood dust, and leather dust, 
or other occupational exposures when relevant.  A significantly increase risk of 
adenocarcinoma was associated with exposure to formaldehyde.  The ORs for the 
highest level of exposure were 3.0 (1.t to 5.7) among men and 6.2 (2.0 to 19.7) among 
women.  An elevated risk of squamous cell carcinoma was observed among men OR = 
2.5 (0.6 to 10.1) and women OR = 3.5 (1.2 to 10.5) with a high probability of exposure 
to formaldehyde. 
An industry-based case-control study with 86 male adenocarcinomas of the nasal cavity 
and paranasal sinuses and 204 controls was conducted in the German wood working 
industries[163].  Cumulative and average wood-dust exposure was quantified with a 
job-exposure matrix.  Probability of exposure to formaldehyde and other relevant 
exposures were semi-quantitatively rated.  Logistic regression analyses were carried out 
conditional on age and adjusted for smoking and other factors.  No significant 
associations were estimated for formaldehyde. 
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A1.8 CASE-CONTROL STUDIES OF LUNG CANCER 
A nested case-control study of lung cancer among workers at a US chemical plant was 
carried out [148].  The cohort consisted of 19,608 males employees.  Included in the 
case-control study were 308 lung cancer deaths observed between 1940 and 1981.  Two 
control groups, one a decedent and other a “living” series, were individually matched to 
cases one-for-one.  Interviews were conducted with subjects or their next of kin to 
collect information on smoking and other potential confounders.  These data were 
combined with employee work history records and industrial hygiene data to form the 
basis of the analyses.  Traditional stratification methods and conditional logistic 
regression were employed to examine for effect modification and to control for 
confounding.  The relative risk for formaldehyde was 0.62 (0.28 to 1.34), based on nine 
exposed cases.  When restricted to exposures 15 or more years prior to death of the 
cases, the RR was 0.31 (0.11 to 0.86), based on four cases. 
A case-control study was undertaken in Montreal to investigation the possible 
associations between occupational exposures and a number of cancers including lung 
cancer.[164].  In total, 3,726 cancer patients and 533 population controls were 
interviewed to obtain detailed lifetime job histories and information on potential 
confounders.  Each job history was translated into a history of occupational exposures.  
For short exposure, the OR was 1.0 (0.6 to 1.8, 62 exposed cases).  For long-low 
exposure, the OR was 0.5 (0.3 to 1.0, 39).  For long-medium exposure, the OR was 1.0 
(0.6 to 1.7, 50).  For long-high exposure, the OR was 1.0 (0.4 to 2.4, 24).  Thus there 
was no persuasive evidence of an increased risk of any type of cancer among men 
exposed to various levels of formaldehyde, but the possibility of a small increase in risk 
could not be ruled out. 
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Respiratory cancer was examined in relation to occupational formaldehyde exposure in 
a case-referent study (136 cases, 408 referents) nested in a woodworker cohort [146].  
Plant- and time-specific job-exposure matrices were constructed for formaldehyde 
exposure.  Over 3 ppm-months of formaldehyde exposure was associated with an OR of 
1.4 (90% CI: 0.5 to 4.1).  The odds ratio for lung cancer was near unity, the excess risk 
concentrating on the upper respiratory tract.  That for combined exposure to 
formaldehyde-phenol exposure (all respiratory cancers) was 1.6 (90% CIL 0.6 to 4.4) 
but 1.0 for formaldehyde only. 
A population-based case-control study was carried out in Missouri in the United States 
[165].  Incident cases of lung cancer (n = 429) were identified through the Missouri 
cancer registry for the period 1986 to 1991 and included 294 lifelong non-smokers and 
135 former smokers who had stopped at least 15 years prior to diagnosis or had smoked 
for less than one pack-year.  Controls (n = 1,021) were selected through drivers’ license 
and Medicare files.  The odds ratio for exposure to formaldehyde, adjusted for age and 
history of previous lung disease was 0.9 (0.2 to 3.3) for all subjects and 0.9 (0.2 to 3.3) 
among lifetime non-smokers. 
A case-control study of men at four major hospitals in Montevideo was conducted to 
investigate risks of lung adenocarcinoma [166].  Interviews were carried out among 339 
cases and 1,014 hospital-based controls.  Odds ratios were calculated after adjustment 
for tobacco smoking, residence, urban/rural status, education, body mass index.  The 
odds ratio of ever exposed to formaldehyde was 1.7 (1.1 to 2.8).  The odds ratio for 
exposure 1-20 years compared with not smoking was 0.9 (0.4 to 1.9) and for 21 years or 
more was 3.0 (1.6 to 5.8) yielding a statistically significant positive trend (p = 0.004). 
A study to examine the effect of formaldehyde and other occupational exposures on 
lung cancer risk among 267,400 female textile workers in Shanghai, China was carried 
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out [167].  A case-cohort study nested within the cohort was used to compare work 
assignments and exposure histories of 628 incident lung cancer cases, diagnosed during 
1989-1998, with those of a reference subcohort of 3,188 workers.  Exposures were 
reconstructed with a job-exposure matrix developed specifically for textile factories.  
Cox proportional hazards models were applied to estimate age/smoking-adjusted 
relative risks (hazard ratios) and risk gradients associated with job assignments and 
specific agents other than cotton dust and endotoxin (such as formaldehyde).  Increased 
risk, although statistically imprecise, were noted for 10 years or more exposure to 
formaldehyde, adjusted hazards ratio 2.1 (0.4 to 11.0). 
Data were collected in two population-based case-control studies conducted in 
Montreal, Canada.  Cases were individuals diagnosed with incident, histologically 
confirmed lung cancer [168].  Controls were randomly selected from electoral lists and 
frequency-matched to cases by age, sex and electoral district of residence.  Interviews 
for the two studies were conducted in 1979-1986 and 1996-2002, using a virtually 
identical questionnaire to obtain lifetime occupational and smoking history and several 
lifestyle covariates.  Experts reviewed the detailed work history for each participant to 
assess exposure to several occupational agents, including formaldehyde.  Logistic 
regression was used to estimate odds ratios for the association between several metrics 
of formaldehyde exposure and lung cancer, adjusting for smoking and occupational and 
sociodemographic factors.  In all, 2060 lung cancer and 2,046 population controls were 
interviewed and assessed for exposure.  About 25% of subjects had been occupationally 
exposed to formaldehyde.  The adjusted odds ratio for lung cancer was 1.06 (0.89 to 
1.27) comparing ever versus never exposed to formaldehyde.  Analyses for age at first 
exposure, average, and peak intensity of exposure also suggested an absence of 
association between formaldehyde exposure and lung cancer risk.  Results did not vary 
by sex, lifetime smoking intensity or histological subtype. 
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A1.9 OTHER STUDIES INCLUDING REGISTRY-BASED 
Data from the Danish cancer registry for the period 1943-1976 were used to examine 
the association with formaldehyde exposure in a total of 84 cases of lung cancer (79 
male, 5 female) among Danish physicians [169].  Information on specialization and 
places of work during the professional career of these physicians with lung cancer was 
compared with the information for 252 controls, who were also physicians chosen to 
match cases for age, sex and survival at least until the time of lung cancer development.  
No male lung cancer cases had specialized in pathology (including forensic medicine 
and anatomy), and the risk in other medical specialties did not differ significantly from 
the risk among general practitioners.  The lung cancer risk associated with employment 
at some time during the professional career in pathology, forensic medicine, or anatomy 
was not increased, odds ratio 1.0 (0.4 to 2.4). 
A proportionate mortality study of occupational mortality among white residents of 
Washington State in the US examined 429,926 males deaths from 1950-1979 and 
25,066 female deaths from 1974-1979 [170].  The PMR among funeral directors was 
0.75 (0.40 to 1.28). 
The mortality pattern of 1132 white male embalmers licensed to practice in New York 
State between 1902 and 1980 and who were known to have died between 1925 and 
1980 has been examined [149].  PMRs and Proportionate Cancer Mortality Ratios 
(PCMRs) were calculated.  There were no deaths from nasopharyngeal cancer with 
approximately 0.26 expected.  There were also no deaths from nasal cancer with 
approximately 0.07 expected.  The PMR for lung and pleural cancer was 108 (84 to 
136, 72 deaths) and the PCMR for lung cancer was 111 (87 to 140, 70 deaths).  The 
authors assumed that persons licensed only as embalmers experienced a greater 
cumulative exposure to formaldehyde than did embalmers who were also funeral 
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directors.  The PMR for all respiratory system cancers for embalmers only was 94 (62 
to 137, 27 deaths) and for those both embalmers and funeral directors the PMR was 112 
(82 to 148, 47 deaths). 
The mortality pattern of 1007 white male embalmers who were first licensed to practice 
in California from 1916 to 1978 and who were known to have died between 1925 and 
1980 was examined [147].  PMRs and PCMRs were calculated.  There were no deaths 
from nasopharyngeal cancer included, with approximately 0.17 expected.  There was no 
nasal cancer cases with 0.6 expected.  The PMR for lung and pleura cancer was 96 (69 
to 130, 41 deaths) and the PCMR was 87 (62 to 118). 
The mortality of 3649 white and 397 non-white male US embalmers and funeral 
directors in 32 states and the District of Columbia, who had died between 1975 and 
1985 was examined in a proportional mortality study [171].  Deaths included in the 
Californian [149] and New York [147] studies were excluded.  PMRs were calculated 
using US rates.  The PMRs for nasopharynx were 189 (39 to 548, 3 deaths) among 
whites and 400 (10 to 2229, 1 death) among non-whites.  For sinonasal cancer the PMR 
was 0 (0 to 200, 0 deaths) among whites and 0 (0 to 1872, 0 deaths) among non-whites.  
For lung cancer the SMR was 97 (86 to 109, 285 deaths) among whites and 75 (47 to 
113, 23 deaths) among non-whites. 
The Danish Cancer Registry was used to identify 126,347 men with cancer born 
between 1897 and 1964 whose cancer was diagnosed in the period 1970 to 1984 [172].  
Individual employment histories were constructed via linkage with the Supplementary 
Pension Fund.  All companies associated with the use or manufacture of more than one 
kg of formaldehyde were identified from the Danish Product Register, and thus a total 
of 2,041 employees were identified as having their longest work experience working in 
one of 265 companies, at least 10 years before diagnosis, involved in the use or 
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manufacture of formaldehyde.  Workers were classified as probably exposed to low 
levels of formaldehyde (blue collar workers), as exposed to formaldehyde in the 
absence of wood-dust (blue collar workers), co-exposed to formaldehyde and wood-
dust, and unknown in relation to formaldehyde exposure.  Standardised Proportional 
Incidence Ratios (SPIRs) were calculated for those exposed to formaldehyde at least 10 
years prior to diagnosis.  (The SPIR is a measure of the proportion of cases of a defined 
cancer in the formaldehyde-associated companies relative to the proportion of cases of 
the same type of cancer among all employees in Denmark, adjusted for age and calendar 
time [172]).  The SPIR for nasopharyngeal cancer was 1.3 (0.3 to 3.2, 4 deaths), for 
nasal cancer was 2.3 (1.3 to 4.0, 13 deaths) and for lung cancer was 1.0 (0.9 to 1.1, 410 
deaths).  For the group of workers classified as exposed to formaldehyde in the absence 
of wood-dust the SPIR for nasal cancer was 3.0 (1.4 to 5.7, 9 deaths) and for lung 
cancer was 1.0 (0.9 to 1.1, 250 deaths). 
The most recent report of the cohort of 363,823 men enrolled in the American Cancer 
Society’s Cancer Prevention Study [173] updated earlier reports on the cohort [213, 
214].  The subcohort was a cross-sectional cohort that was assembled in 1982 and 
followed-up for six years until 1988.  Three hundred and eighty seven subjects reported 
exposure to formaldehyde and 305 reported exposure to both wood dust and 
formaldehyde.  Relative risks were estimated by incidence density ratios, relative to 
participants who did not report either employment in a wood occupation or regular 
exposure to wood dust, and were calculated using maximum likelihood with an 
adjustment for age and smoking status.  The relative risk of lung cancer for men 
exposed to formaldehyde in the absence of a wood-related occupation was 0.93 (0.73 to 
1.18, 104 deaths), and for those who had been in a wood-related occupation, the relative 
risk was 2.63 (1.25 to 5.51, 7 deaths). 
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The cohort of all Finnish men born between the years 1906 and 1945 and in 
employment during 1970 was followed up through the Finnish cancer registry for cases 
of cancer of the nose (n = 292), nasopharynx (n = 149), and lung (n = 30.137) during the 
period 1971 to 1995 [174].  The subjects’ occupations, as recorded in the population 
census in 1970, were converted to estimates of exposure to wood dust, formaldehyde, 
asbestos and silica dust though the Finnish job-exposure matrix.  Cumulative exposure 
was calculated based on the prevalence, average level, and estimated duration of 
exposure.  The relative risk estimate for the cumulative exposure category were 
obtained by Poisson regression, with adjustment for smoking, socioeconomic status, and 
exposure to asbestos and/or silica dust.  Workers exposed to formaldehyde had a RR of 
1.18 (1.12 to 1.25) for lung cancer.  There was no indication that cumulative exposure 
to formaldehyde would increase the risk of nasopharyngeal cancer.  The authors thought 
that the slight excess risk for lung cancer might be due to residual confounding from 
smoking. 
 
 
 
